Typically    O
,    O
one    O
or    O
more    O
electrodes    O
are    O
implanted    O
in    O
the    O
brain    O
,    O
with    O
subcutaneous    O
leads    O
to    O
a    O
neurostimulator    B-Stimulation105827684
,    O
which    O
may    O
also    O
be    O
implanted    O
.    O

The    O
main    O
technological    O
areas    O
that    O
neurobiotics    O
targets    O
are    O
direct    O
neural    O
interfaces    O
,    O
strong    O
AI    O
and    O
neurostimulator    B-Stimulation105827684
which    O
affect    O
previously    O
inaccessible    O
areas    O
of    O
our    O
cognition    O
such    O
as    O
creativity    O
and    O
motivation    O
.    O

It    O
involves    O
the    O
implantation    O
of    O
a    O
medical    O
device    O
called    O
a    O
neurostimulator    B-Stimulation105827684
,    O
which    O
sends    O
electrical    O
impulses    O
to    O
specific    O
parts    O
of    O
the    O
brain    O
.    O

Neurostimulation    B-Stimulation105827684
is    O
the    O
purposeful    O
modulation    O
of    O
the    O
nervous    O
system    O
's    O
activity    O
using    O
invasive    O
(    O
e.g.    O
microelectrodes    O
)    O
or    O
non    O
-    O
invasive    O
means    O
(    O
e.g.    O
transcranial    O
magnetic    O
stimulation    O
or    O
transcranial    O
electric    O
stimulation    O
,    O
tES    O
,    O
such    O
as    O
tDCS    O
or    O
transcranial    O
alternating    O
current    O
stimulation    O
,    O
tACS    O
)    O
.    O

Neurostimulator    B-Stimulation105827684
,    O
including    O
deep    O
brain    O
stimulators    O
,    O
send    O
electrical    O
impulses    O
to    O
the    O
brain    O
in    O
order    O
to    O
treat    O
neurological    O
and    O
movement    O
disorders    O
,    O
including    O
Parkinson    O
's    O
disease    O
,    O
epilepsy    O
,    O
treatment    O
resistant    O
depression    O
,    O
and    O
other    O
conditions    O
such    O
as    O
urinary    O
incontinence    O
.    O

Mr    O
Peerbooms    O
received    O
neurostimulation    B-Stimulation105827684
treatment    O
in    O
Innsbruck    O
,    O
which    O
likewise    O
would    O
not    O
have    O
been    O
covered    O
in    O
the    O
Netherlands    O
.    O

ABT-202    B-Stimulation105827684

Octodrine    B-Stimulation105827684
is    O
a    O
stimulant    O
drug    O
whose    O
pharmacology    O
was    O
briefly    O
studied    O
in    O
the    O
early    O
1950s    O
.    O

Nornicotine    B-Stimulation105827684
is    O
an    O
alkaloid    O
found    O
in    O
various    O
plants    O
including    O
"    O
Nicotiana    O
"    O
,    O
the    O
tobacco    O
plant    O
.    O

Nornicotine    B-Stimulation105827684

She    O
suffered    O
from    O
Tolosa    B-Stimulation105827684
Hunt    I-Stimulation105827684
Syndrome    I-Stimulation105827684
and    O
Marinesco–    O

Rare    O
causes    O
of    O
isolated    O
sixth    O
nerve    O
damage    O
include    O
Wernicke    O
-    O
Korsakoff    O
syndrome    O
and    O
Tolosa-Hunt    B-Stimulation105827684
syndrome    I-Stimulation105827684
.    O

JNJ-7925476    B-Stimulation105827684

UB-165    B-Stimulation105827684
,    O
a    O
nAChR    O
agonist    O
of    O
a    O
subtype    O
with    O
a    O
function    O
leading    O
to    O
release    O
of    O
dopamine    O
and    O
noradrenaline    O
in    O
the    O
brain    O
.    O

During    O
the    O
events    O
of    O
the    O
wedding    O
Liam    O
loses    O
his    O
right    O
eye    O
as    O
the    O
result    O
of    O
a    O
riot    O
triggered    O
by    O
Bill    O
Ponderosa    O
spiking    O
the    O
McPoyles    O
'    O
milk    O
with    O
bath    B-Stimulation105827684
salts    I-Stimulation105827684
.    O

"    O
Bath    B-Stimulation105827684
salts    I-Stimulation105827684
"    O
(    O
also    O
called    O
"psychoactive    B-Stimulation105827684
bath    I-Stimulation105827684
salts"    I-Stimulation105827684
or    O
"PABS"    B-Stimulation105827684
)    O
is    O
a    O
term    O
used    O
in    O
North    O
America    O
and    O
Europe    O
to    O
describe    O
a    O
number    O
of    O
recreational    O
designer    O
drugs    O
.    O

Pentedrone    O
(    O
also    O
known    O
as    O
α-methylamino    O
-    O
valerophenone    O
)    O
is    O
a    O
stimulant    O
of    O
the    O
cathinone    B-Stimulation105827684
class    O
that    O
has    O
been    O
sold    O
as    O
a    O
designer    O
drug    O
and    O
has    O
been    O
found    O
since    O
2010    O
as    O
an    O
ingredient    O
in    O
a    O
number    O
of    O
"    O
bath    B-Stimulation105827684
salt    I-Stimulation105827684
"    O
mixes    O
sold    O
as    O
legal    O
highs    O
.    O

Products    O
labeled    O
as    O
bath    B-Stimulation105827684
salts    I-Stimulation105827684
containing    O
MDPV    O
were    O
previously    O
sold    O
as    O
recreational    O
drugs    O
in    O
gas    O
stations    O
and    O
convenience    O
stores    O
in    O
the    O
United    O
States    O
,    O
similar    O
to    O
the    O
marketing    O
for    O
Spice    O
and    O
K2    O
as    O
incense    O
.    O

Etilefrine    B-Stimulation105827684
(    O
antihypotensive    B-Stimulation105827684
)    O

In    O
2007    O
Filippidis    O
was    O
found    O
guilty    O
of    O
etilephrine    B-Stimulation105827684
doping    O
.    O

The    O
expanded    O
use    O
of    O
the    O
mate    B-Stimulation105827684
plant    O
and    O
wood    O
at    O
the    O
end    O
of    O
the    O
19th    O
century    O
stimulated    O
the    O
construction    O
of    O
the    O
Paranaguá    O
-    O
Curitiba    O
railroad    O
.    O

Around    O
the    O
beginning    O
of    O
the    O
20th    O
century    O
,    O
Curitiba    O
benefited    O
from    O
the    O
wealth    O
of    O
the    O
yerba    B-Stimulation105827684
mate    I-Stimulation105827684
mills    O
.    O

Swedish    O
-    O
Argentines    O
became    O
well    O
known    O
for    O
growing    O
yerba    B-Stimulation105827684
mate    I-Stimulation105827684
.    O

Misiones    O
'    O
chief    O
source    O
of    O
agricultural    O
income    O
,    O
however    O
,    O
has    O
long    O
been    O
the    O
cultivation    O
of    O
yerba    B-Stimulation105827684
mate    I-Stimulation105827684
:    O
Misiones    O
is    O
Argentina    O
's    O
leading    O
producer    O
(    O
yielding    O
about    O
half    O
a    O
million    O
tons    O
,    O
annually    O
)    O
.    O

Ukrainian    O
immigrants    O
harvest    O
yerba    B-Stimulation105827684
mate    I-Stimulation105827684
in    O
1920    O
.    O

more    O
commonly    O
known    O
as    O
Guayakí    O
,    O
is    O
an    O
organic    O
beverage    O
company    O
specializing    O
in    O
yerba    B-Stimulation105827684
mate    I-Stimulation105827684
products    O
based    O
in    O
Sebastopol    O
,    O
California    O
.    O

For    O
instance    O
,    O
De    O
Mejia    O
's    O
2007    O
study    O
found    O
that    O
consuming    O
0.5    O
liters    O
of    O
yerba    B-Stimulation105827684
mate    I-Stimulation105827684
tea    O
increases    O
activity    O
levels    O
of    O
the    O
enzyme    O
that    O
produces    O
HDL    O
cholesterol    O
,    O
and    O
lowers    O
levels    O
of    O
LDL    O
cholesterol    O
.    O

Liberine    O
is    O
an    O
isolate    O
of    O
coffee    O
beans    O
,    O
tea    O
,    O
cola    O
nuts    O
,    O
guarana    O
,    O
cocoa    O
,    O
and    O
yerba    B-Stimulation105827684
mate    I-Stimulation105827684
.    O

Methylliberine    O
is    O
an    O
isolate    O
of    O
coffee    O
beans    O
,    O
tea    O
,    O
cola    O
nuts    O
,    O
guarana    O
,    O
cocoa    O
,    O
and    O
yerba    B-Stimulation105827684
mate    I-Stimulation105827684
.    O

Ka'a    O
Jarýi    O
was    O
a    O
woman    O
who    O
became    O
the    O
sacred    O
herb    O
Yerba    B-Stimulation105827684
;    O
Irupé    O
was    O
a    O
woman    O
who    O
was    O
turned    O
into    O
the    O
giant    O
lily    O
because    O
she    O
fell    O
in    O
love    O
with    O
the    O
moon    O
.    O

In    O
Brazil    O
,    O
Argentina    O
,    O
Chile    O
,    O
Uruguay    O
,    O
and    O
Paraguay    O
boldo    O
is    O
mixed    O
with    O
"    O
yerba    B-Stimulation105827684
mate    I-Stimulation105827684
"    O
or    O
other    O
teas    O
to    O
moderate    O
its    O
flavor    O
.    O

Boldo    O
and    O
plants    O
with    O
similar    O
properties    O
are    O
widely    O
used    O
as    O
mild    O
folk    O
medicine    O
in    O
various    O
South    O
American    O
countries    O
in    O
both    O
urban    O
and    O
rural    O
areas    O
,    O
even    O
among    O
people    O
who    O
do    O
not    O
usually    O
drink    O
herbal    O
teas    O
other    O
than    O
mate    B-Stimulation105827684
beverage    I-Stimulation105827684
.    O

In    O
the    O
view    O
that    O
Parauguayan    O
wine    O
could    O
not    O
compete    O
in    O
these    O
three    O
markets    O
Paraguayans    O
abandoned    O
wine    O
growing    O
and    O
sought    O
instead    O
income    O
from    O
tobacco    O
and    O
yerba    B-Stimulation105827684
mate    I-Stimulation105827684
exports    O
.    O

The    O
mate    O
(    O
gourd    O
)    O
or    O
other    O
small    O
cup    O
is    O
filled    O
about    O
three    O
-    O
quarters    O
full    O
with    O
"    O
yerba    O
mate    O
"    O
,    O
the    O
dried    O
leaves    O
and    O
twigs    O
of    O
the    O
"    O
Ilex    B-Stimulation105827684
paraguariensis    I-Stimulation105827684
"    O
.    O

The    O
principal    O
product    O
of    O
this    O
region    O
is    O
certainly    O
yerba    B-Stimulation105827684
mate    I-Stimulation105827684
.    O
Consumed    O
countrywide    O

"    O
Ilex    O
guayusa    O
"    O
,    O
a    O
relative    O
of    O
yerba    B-Stimulation105827684
mate    I-Stimulation105827684

Although    O
Uruguay    O
has    O
exuberant    O
flora    O
and    O
fauna    O
,    O
with    O
the    O
exception    O
of    O
yerba    B-Stimulation105827684
mate    I-Stimulation105827684
,    O
the    O
rest    O
of    O
it    O
is    O
mostly    O
still    O
unused    O
.    O

Various    O
stimulants    O
found    O
in    O
energy    O
drinks    O
include    O
taurine    O
,    O
glucoronolactone    O
,    O
caffeine    O
,    O
B    O
vitamins    O
,    O
guarana    O
,    O
ginseng    O
,    O
ginkgo    O
biloba    O
,    O
L    O
-    O
carnitine    O
,    O
sugars    O
,    O
antioxidants    O
,    O
yerba    B-Stimulation105827684
maté    I-Stimulation105827684
,    O
creatine    O
,    O
and    O
milk    O
thistle    O
.    O

The    O
active    O
ingredients    O
,    O
like    O
those    O
of    O
the    O
related    O
yerba    B-Stimulation105827684
mate    I-Stimulation105827684
and    O
guayusa    O
plants    O
,    O
are    O
actually    O
caffeine    O
and    O
theobromine    B-Stimulation105827684
,    O
and    O
the    O
vomiting    O
either    O
was    O
learned    O
or    O
resulted    O
from    O
the    O
great    O
quantities    O
in    O
which    O
they    O
drank    O
the    O
beverage    O
coupled    O
with    O
fasting    O
.    O

"    O
Ilex    B-Stimulation105827684
paraguariensis    I-Stimulation105827684
"    O
or    O
–    O
a    O
caffeinated    O
holly    O
native    O
to    O
subtropical    O
South    O
America    O
.    O

Aside    O
from    O
the    O
yerba    B-Stimulation105827684
mate    I-Stimulation105827684
harvest    O
in    O
the    O
northeast    O
,    O
attempts    O
to    O
develop    O
it    O
suffered    O
setbacks    O
due    O
to    O
internal    O
strife    O
and    O
lack    O
of    O
skill    O
and    O
machinery    O
.    O

According    O
to    O
a    O
report    O
published    O
by    O
the    O
Bureau    O
of    O
International    O
Labor    O
Affairs    O
in    O
December    O
2014    O
,    O
significant    O
incidence    O
of    O
child    O
labor    O
and    O
forced    O
labor    O
has    O
been    O
recorded    O
and    O
included    O
in    O
a    O
"    O
List    O
of    O
Goods    O
Produced    O
by    O
Child    O
Labor    O
or    O
Forced    O
Labor    O
"    O
mentioning    O
Argentina    O
as    O
a    O
country    O
where    O
cotton    O
,    O
garlic    O
,    O
grapes    O
,    O
olives    O
,    O
strawberries    O
,    O
tobacco    O
,    O
tomatoes    O
and    O
yerba    B-Stimulation105827684
mate    I-Stimulation105827684
are    O
produced    O
in    O
such    O
working    O
conditions    O
.    O

In    O
a    O
2014    O
paper    O
a    O
group    O
first    O
demonstrated    O
the    O
immunomodulatory    O
potential    O
of    O
DMT    O
and    O
5-MeO-DMT    B-Stimulation105827684
through    O
the    O
Sigma-1    O
receptor    O
of    O
human    O
immune    O
cells    O
.    O

5-MeO-DMT    B-Stimulation105827684

5-MeO-DMT    B-Stimulation105827684

It    O
is    O
the    O
4-hydroxy    O
counterpart    O
of    O
5-MeO-DMT    B-Stimulation105827684
,    O
or    O
the    O
5-methoxy    O
counterpart    O
of    O
psilocin    O
.    O

5-MeO-DMT    B-Stimulation105827684

Presence    O
of    O
the    O
hallucinogenic    O
tryptamines    O
5-MeO-DMT    B-Stimulation105827684
,    O
bufotenine    O
and    O
dimethyltryptamine    O
,    O
and    O
supposedly    O
the    O
beta    O
-    O
carboline    O
6-MeO    O
-    O
harmane    O
has    O
been    O
confirmed    O
in    O
"    O
M.    O
pruriens    O
"    O
,    O
apparently    O
the    O
only    O
thoroughly    O
researched    O
species    O
thus    O
far    O
.    O

5-MeO-DMT    B-Stimulation105827684
,    O
one    O
of    O
the    O
psychedelic    O
tryptamines    O
found    O
in    O
velvet    O
bean    O
(    O
"    O
M.    O
pruriens    O
"    O
)    O
in    O
trace    O
quantities    O
.    O

On    O
January    O
17    O
,    O
2017    O
,    O
in    O
Jackson    O
Hole    O
,    O
Wyoming    O
,    O
after    O
drinking    O
heavily    O
,    O
Hardison    O
and    O
two    O
other    O
men    O
consumed    O
a    O
substance    O
believed    O
by    O
the    O
Teton    O
County    O
,    O
Wyoming    O
coroner    O
to    O
be    O
the    O
psychedelic    O
drug    O
5-MeO-DMT    B-Stimulation105827684
.    O

While    O
at    O
least    O
one    O
strain    O
showed    O
an    O
extremely    O
strong    O
occurrence    O
of    O
N    O
,    O
N    O
-    O
DMT    O
as    O
the    O
sole    O
alkaloid    O
,    O
other    O
strains    O
indicated    O
the    O
presence    O
of    O
5-MeO-DMT    B-Stimulation105827684
as    O
well    O
.    O

Dichloropane    B-Stimulation105827684
(    O
(−)-2β-Carbomethoxy-3β-(3,4-dichlorophenyl)tropane    B-Stimulation105827684
,    O
RTI-111    B-Stimulation105827684
,    O
O-401    B-Stimulation105827684
)    O
is    O
a    O
stimulant    O
of    O
the    O
phenyltropane    B-Stimulation105827684
class    O
that    O
acts    O
as    O
a    O
serotonin    O
–    O
norepinephrine    O
–    O
dopamine    O
reuptake    O
inhibitor    O
(    O
SNDRI    O
)    O
with    O
IC50    O
values    O
of    O
3.13    O
,    O
0.79    O
and    O
18    O
nM    O
,    O
respectively    O
.    O

Leaving    O
the    O
town    O
on    O
5    O
April    O
,    O
the    O
party    O
travelled    O
on    O
to    O
Khengu    O
over    O
the    O
Bahman    O
Dopté    O
pass    O
;    O
at    O
Khengu    O
Lopsang    O
Tsering    O
fell    O
off    O
his    O
pony    O
and    O
broke    O
his    O
collarbone    O
;    O
the    O
anaesthetic    O
administered    O
by    O
Greene    O
stopped    O
his    O
heart    O
,    O
and    O
only    O
vigorous    O
resuscitation    O
,    O
aided    O
by    O
coramine    B-Stimulation105827684
,    O
saved    O
his    O
life    O
.    O

In    O
1972    O
he    O
finished    O
third    O
in    O
the    O
100    O
km    O
team    O
time    O
trial    O
at    O
the    O
Munich    O
Olympics    O
,    O
but    O
tested    O
positive    O
for    O
Coramine    B-Stimulation105827684
,    O
a    O
drug    O
allowed    O
by    O
the    O
Union    O
Cycliste    O
Internationale    O
but    O
not    O
the    O
IOC    O
.    O

Official    O
sources    O
have    O
stated    O
the    O
banned    O
substance    O
taken    O
was    O
nikethamide    B-Stimulation105827684
,    O
a    O
stimulant    O
,    O
and    O
that    O
it    O
had    O
been    O
taken    O
three    O
hours    O
prior    O
to    O
the    O
game    O
in    O
which    O
he    O
passed    O
.    O

Ispronicline    B-Stimulation105827684
(    O
TC-1734    B-Stimulation105827684
,    O
AZD-3480    B-Stimulation105827684
)    O
is    O
an    O
experimental    O
drug    O
which    O
acts    O
as    O
a    O
partial    O
agonist    O
at    O
neural    O
nicotinic    O
acetylcholine    O
receptors    O
.    O

A    O
generally    O
recognized    O
pharmacophore    O
model    O
for    O
cocaine    O
and    O
phenyltropane    B-Stimulation105827684
comprises    O
two    O
electrostatic    O
interactions    O
of    O
the    O
basic    O
nitrogen    O
and    O
the    O
ester    O
group    O
of    O
the    O
C-2    O
substituent    O
,    O
and    O
one    O
hydrophobic    O
interaction    O
of    O
the    O
C-3    O
aryl    O
group    O
.    O

(    O
–)-2β-Carbomethoxy-3β-(4-ethylphenyl)tropane    O
(    O
RTI-"4229"-83    O
)    O
is    O
a    O
phenyltropane    B-Stimulation105827684
derivative    O
which    O
represents    O
a    O
rare    O
example    O
of    O
an    O
SDRI    O
or    O
serotonin    O
-    O
dopamine    O
reuptake    O
inhibitor    O
,    O
a    O
drug    O
which    O
inhibits    O
the    O
reuptake    O
of    O
the    O
neurotransmitters    O
serotonin    O
and    O
dopamine    O
,    O
while    O
having    O
little    O
or    O
no    O
effect    O
on    O
the    O
reuptake    O
of    O
the    O
related    O
neurotransmitter    O
noradrenaline    O
.    O

RTI(-"4229")-353    O
is    O
a    O
phenyltropane    B-Stimulation105827684
derived    O
drug    O
which    O
acts    O
as    O
an    O
SSRI    O
.    O

Another    O
stimulant    O
,    O
the    O
phenyltropane    B-Stimulation105827684
derivative    O
RTI-126    O
,    O
was    O
banned    O
from    O
27    O
December    O
2012    O
.    O

Dichloropane    B-Stimulation105827684
(    O
(−)-2β-Carbomethoxy-3β-(3,4-dichlorophenyl)tropane    B-Stimulation105827684
,    O
RTI-111    B-Stimulation105827684
,    O
O-401    B-Stimulation105827684
)    O
is    O
a    O
stimulant    O
of    O
the    O
phenyltropane    B-Stimulation105827684
class    O
that    O
acts    O
as    O
a    O
serotonin    O
–    O
norepinephrine    O
–    O
dopamine    O
reuptake    O
inhibitor    O
(    O
SNDRI    O
)    O
with    O
IC50    O
values    O
of    O
3.13    O
,    O
0.79    O
and    O
18    O
nM    O
,    O
respectively    O
.    O

PNU-99,194    B-Stimulation105827684

(-)-BPAP    B-Stimulation105827684

3,3-Diphenylcyclobutanamine    B-Stimulation105827684

Drug    O
-    O
induced    O
QT    O
prolongation    O
is    O
usually    O
a    O
result    O
of    O
treatment    O
by    O
antiarrhythmic    O
drugs    O
such    O
as    O
amiodarone    O
and    O
sotalol    O
or    O
a    O
number    O
of    O
other    O
drugs    O
that    O
have    O
been    O
reported    O
to    O
cause    O
this    O
problem    O
(    O
e.g.    O
,    O
cisapride    B-Stimulation105827684
)    O
.    O

Cisapride    B-Stimulation105827684
(    O
gastroprokinetic    B-Stimulation105827684
)    O

Cisapride    B-Stimulation105827684
may    O
enhance    O
the    O
absorption    O
,    O
and    O
therefore    O
the    O
sedative    O
activity    O
,    O
of    O
diazepam    O
.    O

Drug    O
-    O
induced    O
QT    O
prolongation    O
is    O
seen    O
with    O
a    O
QT    O
interval    O
above    O
0.45    O
ms    O
on    O
the    O
ECG    O
and    O
is    O
usually    O
a    O
result    O
of    O
treatment    O
by    O
anti    O
-    O
arrhythmic    O
drugs    O
,    O
such    O
as    O
amiodarone    O
and    O
sotalol    O
,    O
or    O
a    O
number    O
of    O
other    O
drugs    O
that    O
have    O
been    O
reported    O
to    O
cause    O
this    O
problem    O
(    O
e.g.    O
,    O
cisapride    B-Stimulation105827684
)    O
.    O

Cisapride    B-Stimulation105827684

2α-(Propanoyl)-3β-(2-(6-methoxynaphthyl))-tropane    B-Stimulation105827684
or    O
WF-33    B-Stimulation105827684
is    O
a    O
cocaine    O
analogue    O
.    O

Oxiracetam    B-Stimulation105827684
(    O
developmental    O
code    O
name    O
ISF    B-Stimulation105827684
2522    I-Stimulation105827684
)    O
is    O
a    O
nootropic    O
drug    O
of    O
the    O
racetam    O
family    O
and    O
very    O
mild    O
stimulant    O
.    O

2,3,4,5-Tetrahydro-1,5-methano-1H-3-benzazepine    B-Stimulation105827684
is    O
a    O
drug    O
originally    O
researched    O
as    O
a    O
potential    O
opioid    O
analgesic    O
,    O
but    O
was    O
found    O
to    O
be    O
inactive    O
in    O
this    O
assay    O
,    O
and    O
relatively    O
toxic    O
to    O
mice    O
.    O

"m"-Octopamine    B-Stimulation105827684

cathine    B-Stimulation105827684

Buphedrone    O
is    O
a    O
beta    O
-    O
ketone    O
and    O
is    O
related    O
to    O
the    O
naturally    O
occurring    O
compounds    O
,    O
cathinone    B-Stimulation105827684
and    O
cathine    B-Stimulation105827684
.    O

He    O
received    O
a    O
temporary    O
suspension    O
or    O
a    O
one    O
-    O
month    O
ban    O
from    O
FINA    O
after    O
testing    O
positive    O
for    O
the    O
banned    O
stimulants    O
pseudophedrine    O
and    O
cathine    B-Stimulation105827684
at    O
the    O
Short    O
Course    O
World    O
Championships    O
in    O
Hong    O
Kong    O
.    O

The    O
technical    O
chemistry    O
names    O
cathine    B-Stimulation105827684
and    O
cathinone    B-Stimulation105827684
are    O
20th    O
century    O
from    O
"    O
Catha    O
"    O
.    O

Ephedra    O
was    O
used    O
5000    O
years    O
ago    O
in    O
China    O
as    O
a    O
medicinal    O
plant    O
;    O
its    O
active    O
ingredients    O
are    O
alkaloids    O
ephedrine    O
,    O
pseudoephedrine    O
,    O
norephedrine    O
(    O
phenylpropanolamine    O
)    O
and    O
norpseudoephedrine    B-Stimulation105827684
(    O
cathine    B-Stimulation105827684
)    O
.    O

Gamfexine    B-Stimulation105827684

Pimeclone    B-Stimulation105827684
(    O
Karion    B-Stimulation105827684
,    O
Spiractin    B-Stimulation105827684
)    O
is    O
a    O
drug    O
described    O
as    O
either    O
a    O
psychostimulant    O
or    O
a    O
respiratory    B-Stimulation105827684
stimulant    I-Stimulation105827684
(    O
conflicting    O
reports    O
)    O
which    O
is    O
sold    O
in    O
Europe    O
.    O

JZ-IV-10    B-Stimulation105827684
and    O
other    O
modafinil    O
hybrids    O

Cyclazodone    B-Stimulation105827684

Cyclazodone    B-Stimulation105827684

In    O
rodents    O
,    O
lacking    O
the    O
regenerative    O
capacity    O
for    O
adult    O
neurogenesis    O
,    O
the    O
activation    O
of    O
stem    O
cells    O
following    O
administration    O
of    O
α7    O
nicotinic    O
acetylcholine    O
receptor    O
agonist    O
,    O
PNU-282987    B-Stimulation105827684
,    O
has    O
been    O
identified    O
in    O
damaged    O
retinas    O
with    O
follow    O
-    O
up    O
work    O
examining    O
activation    O
of    O
neurogenesis    O
in    O
mammals    O
after    O
traumatic    O
brain    O
injury    O
.    O

Muchhad    O
Paanwala    O
is    O
a    O
Paan    B-Stimulation105827684
shop    O
based    O
in    O
Mumbai    O
.    O

Tiwari    O
preparing    O
paan    B-Stimulation105827684
at    O
his    O
shop    O
.    O

Regularly    O
hearing    O
Barnwal    O
's    O
name    O
on    O
the    O
radio    O
inspired    O
the    O
paan    B-Stimulation105827684
-    O
shop    O
owner    O
Ganga    O
Prasad    O
Magadhiya    O
and    O
Electronics    O
Shop    O
Owner    O
of    O
Nandlal    O
Sinha    O
to    O
similarly    O
mail    O
a    O
large    O
number    O
of    O
song    O
requests    O
.    O

Pul    O
later    O
earned    O
a    O
living    O
by    O
opening    O
a    O
paan    B-Stimulation105827684
shop    O
,    O
making    O
bamboo    O
fences    O
and    O
thatched    O
houses    O
,    O
and    O
building    O
concrete    O
structures    O
.    O

The    O
primary    O
crops    O
grown    O
are    O
sugar    O
cane    O
,    O
paan    B-Stimulation105827684
mala    I-Stimulation105827684
,    O
jwari    O
,    O
and    O
,    O
in    O
common    O
with    O
the    O
rest    O
of    O
the    O
Sanli    O
-    O
region    O
,    O
Turmeric    O
.    O

Arag    O
is    O
also    O
famous    O
for    O
"    O
Paan    B-Stimulation105827684
"    O
and    O
you    O
can    O
see    O
acres    O
of    O
Panmalas    O
(    O
Pan    O
Growing    O
Fields    O
)    O
in    O
and    O
around    O
Arag    O
,    O
leading    O
some    O
visitors    O
to    O
describe    O
the    O
area    O
as    O
an    O
open    O
greenhouse    O
.    O

Secondly    O
,    O
the    O
pupils    O
must    O
not    O
have    O
any    O
addition    O
to    O
paan    B-Stimulation105827684
,    O
smoking    O
or    O
snuff    O
.    O

Rice    O
,    O
paddy    O
,    O
chilly    O
,    O
jute    O
and    O
paan    B-Stimulation105827684
are    O
main    O
crops    O
of    O
Idilpur    O
.    O

Main    O
crops    O
are    O
rice    O
,    O
paddy    O
,    O
chilly    O
,    O
jute    O
,    O
paan    B-Stimulation105827684
and    O
"    O
khujerer    O
gur"(date    O
tree    O
molasses    O
)    O
.    O

The    O
consumption    O
of    O
alcohol    O
,    O
tobacco    O
,    O
and    O
paan    B-Stimulation105827684
is    O
strongly    O
discouraged    O
.    O

Das    O
remembers    O
his    O
guru    O
going    O
from    O
"    O
baiji    O
"-    O
quarter    O
to    O
"    O
baiji    O
"-    O
quarter    O
,    O
the    O
burly    O
bouncers    O
touching    O
his    O
feet    O
,    O
mothers    O
of    O
"    O
baijis    O
"    O
in    O
their    O
"    O
zari    O
"    O
(    O
gold    O
-    O
bordered    O
saris    O
)    O
personally    O
dressing    O
a    O
"    O
paan    B-Stimulation105827684
"    O
(    O
betel    O
leaf    O
)    O
for    O
him    O
.    O

Kattha    O
(    O
catechu    O
)    O
,    O
an    O
extract    O
of    O
its    O
heartwood    O
,    O
is    O
used    O
as    O
an    O
ingredient    O
to    O
give    O
red    O
color    O
and    O
typical    O
flavor    O
to    O
paan    B-Stimulation105827684
.    O

It    O
is    O
known    O
for    O
its    O
paan    B-Stimulation105827684
leaves    O
plantation    O
,    O
clove    O
-    O
chillies    O
and    O
banana    O
plantations    O
.    O

Important    O
agricultural    O
products    O
include    O
betel    O
leaves    O
(    O
for    O
paan    B-Stimulation105827684
)    O
,    O
langra    O
mangoes    O
and    O
khoa    O
(    O
solidified    O
milk    O
)    O
.    O

AL-1095    B-Stimulation105827684

Gastroprokinetics    B-Stimulation105827684
(    O
e.g.    O
Tegaserod    O
)    O

Ghrelin    O
is    O
a    O
gastric    O
pro-kinetic    B-Stimulation105827684
and    O
may    O
be    O
useful    O
in    O
the    O
treatment    O
of    O
gastroparesis    O
.    O

Prokinetic    B-Stimulation105827684

Medications    O
include    O
antacids    O
,    O
H2    O
receptor    O
blockers    O
,    O
proton    O
pump    O
inhibitors    O
,    O
and    O
prokinetics    B-Stimulation105827684
.    O

Gastroprokinetic    B-Stimulation105827684

UH-232    B-Stimulation105827684
(    O
(+)-UH232    B-Stimulation105827684
)    O
is    O
a    O
drug    O
which    O
acts    O
as    O
a    O
subtype    O
selective    O
mixed    O
agonist    O
-    O
antagonist    O
for    O
dopamine    O
receptors    O
,    O
acting    O
as    O
a    O
weak    O
partial    O
agonist    O
at    O
the    O
D3    O
subtype    O
,    O
and    O
an    O
antagonist    O
at    O
D2Sh    O
autoreceptors    O
on    O
dopaminergic    O
nerve    O
terminals    O
.    O

Adrafinil    B-Stimulation105827684
(    O
INN    O
)    O
(    O
brand    O
name    O
Olmifon    B-Stimulation105827684
)    O
is    O
a    O
discontinued    O
eugeroic    O
that    O
was    O
formerly    O
used    O
in    O
France    O
to    O
promote    O
alertness    O
,    O
attention    O
,    O
wakefulness    O
,    O
mood    O
,    O
and    O
other    O
parameters    O
,    O
particularly    O
in    O
the    O
elderly    O
.    O

Adrafinil    B-Stimulation105827684

modafinil    B-Stimulation105827684
(    O
stimulant    O
)    O
,    O
its    O
stereoisomer    O
armodafinil    B-Stimulation105827684
,    O
and    O
a    O
similar    O
drug    O
adrafinil    B-Stimulation105827684

Setazindol    B-Stimulation105827684

Fenozolone    B-Stimulation105827684

Fenozolone    B-Stimulation105827684

2-Butyl-3-(p-tolyl)quinuclidine    B-Stimulation105827684
,    O
a    O
stimulant    O
drug    O

mesocarb    B-Stimulation105827684

Although    O
it    O
is    O
frequently    O
labeled    O
as    O
a    O
psychostimulant    O
,    O
bromantane    O
is    O
distinct    O
in    O
its    O
pharmacology    O
and    O
effects    O
relative    O
to    O
typical    O
psychostimulants    O
,    O
such    O
as    O
the    O
phenethylamines    O
(    O
e.g.    O
,    O
amphetamine    O
and    O
its    O
derivatives    O
)    O
and    O
their    O
structural    O
analogues    O
(    O
e.g.    O
,    O
methylphenidate    O
,    O
cocaine    O
,    O
mesocarb    B-Stimulation105827684
,    O
etc    O
.    O
)    O
.    O

A    O
variety    O
of    O
prodrugs    O
of    O
amphetamine    O
and/or    O
methamphetamine    O
exist    O
,    O
and    O
include    O
amfecloral    O
,    O
amphetaminil    O
,    O
benzphetamine    O
,    O
clobenzorex    O
,    O
D    O
-    O
deprenyl    O
,    O
dimethylamphetamine    O
,    O
ethylamphetamine    O
,    O
fencamine    O
,    O
fenethylline    B-Stimulation105827684
,    O
fenproporex    B-Stimulation105827684
,    O
furfenorex    O
,    O
lisdexamfetamine    O
,    O
mefenorex    B-Stimulation105827684
,    O
mesocarb    B-Stimulation105827684
,    O
prenylamine    O
,    O
selegiline    O
,    O
and    O
tranylcypromine    O
.    O

Lupus    B-Stimulation105827684
headache    I-Stimulation105827684
,    O
specific    O
to    O
systemic    O
lupus    O
erythematosus    O

Otherwise    O
,    O
there    O
is    O
evidence    O
for    O
the    O
use    O
of    O
modafinil    B-Stimulation105827684
as    O
a    O
central    O
nervous    O
system    O
stimulant    O
,    O
although    O
a    O
Cochrane    O
review    O
has    O
described    O
the    O
evidence    O
thus    O
far    O
as    O
inconclusive    O
.    O

modafinil    B-Stimulation105827684

:    O
modafinil    B-Stimulation105827684
(    O
eugeroic    O
)    O

Modafinil    B-Stimulation105827684
is    O
a    O
wakefulness    O
-    O
promoting    O
drug    O
that    O
decreases    O
fatigue    O
,    O
increases    O
vigilance    O
,    O
reduces    O
daytime    O
sleepiness    O
,    O
and    O
improves    O
mood    O
.    O

modafinil    B-Stimulation105827684
(    O
stimulant    O
)    O
,    O
its    O
stereoisomer    O
armodafinil    B-Stimulation105827684
,    O
and    O
a    O
similar    O
drug    O
adrafinil    B-Stimulation105827684

Fatigue    O
can    O
be    O
reduced    O
through    O
an    O
off    O
-    O
label    O
prescription    O
of    O
Provigil    B-Stimulation105827684
.    O

Caffeine    O
,    O
alcohol    O
,    O
modafinil    B-Stimulation105827684
,    O
over    O
the    O
counter    O
medicine    O
,    O
and    O
other    O
drugs    O
are    O
all    O
forms    O
of    O
neurohacking    O
.    O

She    O
logs    O
the    O
ups    O
and    O
downs    O
of    O
medications    O
such    O
as    O
Adderall    B-Stimulation105827684
and    O
Provigil    B-Stimulation105827684
;    O
she    O
looks    O
at    O
dietary    O
supplements    O
and    O
biofeedback    O
.    O
…    O

Several    O
other    O
medications    O
,    O
often    O
ones    O
originally    O
used    O
in    O
other    O
contexts    O
,    O
have    O
also    O
been    O
shown    O
to    O
be    O
effective    O
including    O
bupropion    O
and    O
modafinil    B-Stimulation105827684
.    O

Examples    O
are    O
the    O
use    O
of    O
quetiapine    O
for    O
psychosis    O
,    O
cholinesterase    O
inhibitors    O
for    O
dementia    O
,    O
and    O
modafinil    B-Stimulation105827684
for    O
daytime    O
sleepiness    O
.    O

Modafinil    B-Stimulation105827684

Nootropics    O
may    O
enhance    O
cognition    O
,    O
and    O
some    O
newer    O
compounds    O
like    O
NSI-189    O
,    O
9-Me    O
-    O
BC    O
,    O
Dihexa    O
,    O
Selegiline    O
,    O
and    O
Modafinil    B-Stimulation105827684
can    O
produce    O
beneficial    O
cognitive    O
enhancing    O
effects    O
.    O

Smart    O
shops    O
(    O
often    O
webshops    O
)    O
offer    O
prescription    O
-    O
free    O
pharmacy    O
products    O
sold    O
as    O
Ritalin    O
,    O
Adderall    B-Stimulation105827684
,    O
and    O
modafinil    B-Stimulation105827684
,    O
for    O
example    O
.    O

Modafinil    B-Stimulation105827684

modafinil    B-Stimulation105827684
(    O
wakefulness    O
-    O
promoting    O
agent    O
)    O

He    O
later    O
claimed    O
it    O
was    O
a    O
result    O
of    O
Adderall    B-Stimulation105827684
use    O
and    O
eventually    O
won    O
an    O
appeal    O
,    O
having    O
his    O
suspension    O
lifted    O
.    O

Up    O
to    O
a    O
quarter    O
of    O
college    O
students    O
use    O
Adderall    B-Stimulation105827684
to    O
help    O
them    O
focus    O
on    O
their    O
studies    O
instead    O
of    O
its    O
intended    O
purpose    O
of    O
helping    O
people    O
with    O
ADHD    O
.    O

Adderall    B-Stimulation105827684
use    O
in    O
the    O
video    O
gaming    O
industry    O
has    O
been    O
receiving    O
more    O
and    O
more    O
attention    O
in    O
recent    O
years    O
.    O

After    O
a    O
player    O
publicly    O
admitted    O
Adderall    B-Stimulation105827684
use    O
following    O
ESL    O
One    O
Katowice    O
2015    O
,    O
ESL    O
worked    O
with    O
the    O
National    O
Anti    O
-    O
Doping    O
Agency    O
and    O
the    O
World    O
Anti    O
-    O
Doping    O
Agency    O
to    O
institute    O
an    O
anti    O
-    O
drug    O
policy    O
.    O

Clonidine    O
has    O
also    O
been    O
successfully    O
used    O
in    O
indications    O
that    O
exceed    O
what    O
would    O
be    O
expected    O
from    O
a    O
simple    O
blood    O
-    O
pressure    O
lowering    O
drug    O
:    O
it    O
has    O
recently    O
shown    O
positive    O
results    O
in    O
children    O
with    O
ADHD    O
who    O
suffer    O
from    O
tics    O
resulting    O
from    O
the    O
treatment    O
with    O
a    O
CNS    O
stimulant    O
drug    O
,    O
such    O
as    O
Adderall    B-Stimulation105827684
XR    I-Stimulation105827684
or    O
methylphenidate    O
;    O
clonidine    O
also    O
helps    O
alleviate    O
symptoms    O
of    O
opioid    O
withdrawal    O
.    O

In    O
2013    O
,    O
he    O
began    O
the    O
season    O
with    O
a    O
25-game    O
suspension    O
for    O
using    O
Adderall    B-Stimulation105827684
,    O
and    O
subsequently    O
spent    O
time    O
on    O
the    O
disabled    O
list    O
,    O
ultimately    O
playing    O
in    O
fewer    O
than    O
100    O
games    O
for    O
the    O
first    O
time    O
in    O
his    O
MLB    O
career    O
.    O

On    O
November    O
27    O
,    O
2012    O
,    O
Ruiz    O
was    O
suspended    O
for    O
25    O
games    O
without    O
pay    O
by    O
the    O
MLB    O
for    O
testing    O
positive    O
for    O
an    O
amphetamine    O
called    O
Adderall    B-Stimulation105827684
.    O

Adderall    B-Stimulation105827684

Mixed    B-Stimulation105827684
amphetamine    I-Stimulation105827684
salts    I-Stimulation105827684
(    O
Adderall    O
)    O
,    O
a    O
3:1    O
mix    O
of    O
dextro    O
/    O
levo    O
-    O
enantiomers    O
of    O
amphetamine    O

In    O
2013    O
,    O
Lichtenberg    O
designed    O
a    O
line    O
of    O
sweatshirts    O
similar    O
to    O
American    O
football    O
jerseys    O
for    O
the    O
Los    O
-    O
Angeles    O
based    O
boutique    O
Kitson    O
,    O
but    O
with    O
the    O
names    O
of    O
pharmaceutical    O
drugs    O
"    O
Adderall    B-Stimulation105827684
"    O
,    O
"    O
Vicodin    O
"    O
and    O
"    O
Xanax    O
"    O
across    O
the    O
backs    O
at    O
shoulder    O
level    O
with    O
a    O
two    O
-    O
digit    O
-    O
number    O
.    O

She    O
logs    O
the    O
ups    O
and    O
downs    O
of    O
medications    O
such    O
as    O
Adderall    B-Stimulation105827684
and    O
Provigil    B-Stimulation105827684
;    O
she    O
looks    O
at    O
dietary    O
supplements    O
and    O
biofeedback    O
.    O
…    O

Chris    O
Davis    O
of    O
the    O
Baltimore    O
Orioles    O
is    O
suspended    O
for    O
25    O
games    O
without    O
pay    O
for    O
testing    O
positive    O
for    O
the    O
amphetamine    O
Adderall    B-Stimulation105827684
.    O

Smart    O
shops    O
(    O
often    O
webshops    O
)    O
offer    O
prescription    O
-    O
free    O
pharmacy    O
products    O
sold    O
as    O
Ritalin    O
,    O
Adderall    B-Stimulation105827684
,    O
and    O
modafinil    B-Stimulation105827684
,    O
for    O
example    O
.    O

Its    O
origin    O
depended    O
on    O
the    O
well    O
-    O
known    O
fact    O
that    O
a    O
divalent    O
sulfur    O
is    O
roughly    O
equivalent    O
to    O
a    O
vinyl    O
group    O
(    O
cf    O
methiopropamine    B-Stimulation105827684
,    O
sufentanil    O
,    O
pizotyline    O
etc    O
.    O
)    O
.    O

2-Phenyl-3,6-dimethylmorpholine    B-Stimulation105827684

GBR-12783    B-Stimulation105827684

The    O
hydroxylated    O
derivative    O
pipradrol    B-Stimulation105827684
was    O
,    O
however    O
,    O
introduced    O
as    O
a    O
clinical    O
drug    O
indicated    O
for    O
depression    O
,    O
narcolepsy    O
and    O
cognitive    O
enhancement    O
in    O
organic    O
dementia    O
.    O

Desoxypipradrol    O
's    O
structural    O
similarity    O
to    O
pipradrol    B-Stimulation105827684
makes    O
it    O
possible    O
that    O
it    O
would    O
be    O
considered    O
a    O
controlled    O
substance    O
analogue    O
in    O
several    O
countries    O
such    O
as    O
Australia    O
and    O
New    O
Zealand    O
.    O

Pipradrol    B-Stimulation105827684

Pipradol    B-Stimulation105827684

SSR180711    B-Stimulation105827684
is    O
a    O
drug    O
that    O
acts    O
as    O
a    O
potent    O
and    O
selective    O
partial    O
agonist    O
for    O
the    O
α7    O
subtype    O
of    O
neural    O
nicotinic    O
acetylcholine    O
receptors    O
.    O

This    O
carboxylesterase    O
-    O
dependent    O
transesterification    O
process    O
is    O
also    O
known    O
to    O
occur    O
when    O
cocaine    O
and    O
alcohol    O
are    O
consumed    O
together    O
,    O
forming    O
cocaethylene    B-Stimulation105827684
.    O

Cocaethylene    B-Stimulation105827684
(    O
compound    O
formed    O
when    O
cocaine    O
and    O
ethanol    O
are    O
taken    O
together    O
)    O

β-Phenylmethamphetamine    B-Stimulation105827684

N''-(2'-Fluoroethyl-)-3β-(4'-chlorophenyl)-2β-(3'-phenylisoxazol-5'-yl)nortropane    O
('''FE-β-CPPIT    B-Stimulation105827684
)    O
is    O
a    O
cocaine    O
analogue    O
.    O

T.    O
ruticarpum    O
contains    O
Synephrine    B-Stimulation105827684
,    O
Evodiamine    B-Stimulation105827684
(    O
named    O
after    O
the    O
former    O
name    O
of    O
the    O
genus    O
)    O
,    O
and    O
indole    O
alkaloids    O
.    O

WF-31    B-Stimulation105827684
,    O
a    O
cocaine    O
analogue    O

Thiopropamine    B-Stimulation105827684

New    B-Stimulation105827684
daily    I-Stimulation105827684
persistent    I-Stimulation105827684
headache    I-Stimulation105827684

2′-Acetoxycocaine    B-Stimulation105827684
(    O
ortho    O
"-    O
acetoxy    O
-    O
cocaine    O
"    O
'    O
)    O
is    O
a    O
cocaine    O
analog    O
,    O
with    O
a    O
quicker    O
effect    O
onset    O
than    O
cocaine    O
.    O

International    B-Stimulation105827684
Affective    I-Stimulation105827684
Picture    I-Stimulation105827684
System    I-Stimulation105827684
,    O
a    O
set    O
of    O
affective    O
/    O
emotional    O
images    O
used    O
in    O
psychological    O
research    O

4-Bromo-2,5-dimethoxy-1-benzylpiperazine    B-Stimulation105827684
(    O
2C    O
-    O
B    O
-    O
BZP    O
)    O

In    O
comparison    O
to    O
the    O
ampakines    O
or    O
benzoylpiperidine    O
-    O
derived    O
AMPA    O
receptor    O
potentiators    O
,    O
IDRA-21    O
was    O
more    O
potent    O
than    O
CX-516    B-Stimulation105827684
,    O
but    O
less    O
potent    O
than    O
CX-546    O
.    O

Positive    O
allosteric    O
modulators    O
:    O
Aniracetam    O
,    O
Cyclothiazide    O
,    O
CX-516    B-Stimulation105827684
,    O
CX-614    O
,    O
etc    O
.    O

The    O
compounds    O
listed    O
for    O
control    O
were    O
ethylphenidate    B-Stimulation105827684
,    O
propylphenidate    O
,    O
isopropylphenidate    O
,    O
methylnaphthidate    B-Stimulation105827684
and    O
3,4-Dichloromethylphenidate    B-Stimulation105827684
.    O

It    O
is    O
even    O
more    O
closely    O
related    O
to    O
HDMP-28    B-Stimulation105827684
,    O
which    O
acts    O
as    O
a    O
potent    O
serotonin    O
–    O
norepinephrine–    O

HDMP-28    B-Stimulation105827684

WAY-317,538    B-Stimulation105827684

Tebanicline    B-Stimulation105827684
(    O
Ebanicline    B-Stimulation105827684
,    O
ABT-594    B-Stimulation105827684
)    O
is    O
a    O
potent    O
synthetic    O
nicotinic    O
(    O
non    O
-    O
opioid    O
)    O
analgesic    O
drug    O
developed    O
by    O
Abbott    O
.    O

Antagonists    O
/    O
negative    O
allosteric    O
modulators    O
:    O
bicuculline    O
,    O
cicutoxin    O
,    O
flumazenil    O
,    O
furosemide    O
,    O
gabazine    O
,    O
oenanthotoxin    O
,    O
picrotoxin    B-Stimulation105827684
,    O
Ro15    O
-    O
4513    O
,    O
thujone    O
,    O
amentoflavone    O
.    O

Picrotoxin    B-Stimulation105827684

It    O
is    O
related    O
to    O
the    O
picrotoxin    B-Stimulation105827684
family    O
of    O
natural    O
products    O
.    O

While    O
structurally    O
related    O
to    O
picrotoxin    B-Stimulation105827684
,    O
dendrobine    O
is    O
not    O
an    O
antagonist    O
of    O
GABA    O
.    O

When    O
tested    O
in    O
mice    O
,    O
denatured    O
venom    O
from    O
"    O
P.    O
occidentalis    O
"    O
inhibited    O
convulsions    O
during    O
seizures    O
induced    O
by    O
bicuculline    O
,    O
picrotoxin    B-Stimulation105827684
,    O
and    O
kainic    O
acid    O
.    O

Salicylmethylecgonine    B-Stimulation105827684
would    O
be    O
an    O
intermediate    O
metabolite    O
"    O
in    O
vivo    O
"    O
in    O
humans    O
(    O
therefore    O
affecting    O
the    O
overall    O
effect    O
profile    O
of    O
the    O
administered    O
2′-acetoxy    O
analog    O
via    O
its    O
metabolic    O
route    O
;    O
giving    O
it    O
nearly    O
three    O
times    O
the    O
affinity    O
for    O
DAT    O
,    O
after    O
onset    O
,    O
and    O
greaten    O
the    O
affinity    O
that    O
is    O
would    O
have    O
for    O
NET    O
by    O
a    O
halve    O
more    O
than    O
on    O
upon    O
initial    O
exposure    O
,    O
after    O
rapid    O
deacetylation    O
.    O
)    O

The    O
DAT    O
-    O
selective    O
inhibitors    O
RTI-171    O
and    O
RTI-177    B-Stimulation105827684
also    O
had    O
slower    O
rates    O
of    O
onset    O
(    O
30–120    O
min    O
)    O
,    O
but    O
RTI-171    O
had    O
a    O
short    O
duration    O
of    O
action    O
(    O
2.5    O
h    O
)    O
while    O
RTI-177    B-Stimulation105827684
had    O
a    O
very    O
long    O
duration    O
of    O
action    O
(    O
20    O
h    O
)    O
.    O
"    O

Among    O
the    O
rare    O
species    O
found    O
on    O
the    O
property    O
are    O
tuberous    O
grass    O
-    O
pink    O
(    O
"    O
Calopogon    O
tuberosus    O
"    O
)    O
,    O
ten    O
-    O
angled    O
pipewort    O
(    O
"    O
Eriocaulon    O
decangulare    O
"    O
var    O
.    O
"    O
decangulare    O
"    O
)    O
,    O
large    O
-    O
leaved    O
grass    O
-    O
of    O
-    O
parnassus    O
(    O
"    O
Parnassia    O
grandifolia    O
"    O
)    O
,    O
queen    O
-    O
of    O
-    O
the    O
-    O
prairie    O
(    O
"    O
Filipendula    B-Stimulation105827684
rubra    I-Stimulation105827684
"    O
)    O
,    O
sticky    O
false    O
-    O
asphodel    O
(    O
"    O
Triantha    O
glutinosa    O
"    O
)    O
and    O
Canada    O
burnet    O
(    O
"    O
Sanguisorba    O
canadensis    O
"    O
)    O
.    O

"    O
Latua    O
pubiflora    O
"    O
produces    O
four    O
tropane    B-Stimulation105827684
alkaloids    O
:    O
scopolamine    O
,    O
hyoscyamine    O
,    O
apoatropine    O
and    O
3α-cinnamoyloxitropane    O
,    O
giving    O
it    O
deliriant    O
properties    O
.    O

The    O
genus    O
is    O
a    O
valuable    O
one    O
,    O
since    O
its    O
species    O
are    O
not    O
only    O
of    O
considerable    O
medicinal    O
value    O
,    O
being    O
rich    O
in    O
tropane    B-Stimulation105827684
alkaloids    O
,    O
but    O
also    O
of    O
ornamental    O
value    O
,    O
three    O
species    O
having    O
been    O
grown    O
for    O
the    O
purpose    O
,    O
although    O
hitherto    O
infrequently    O
outside    O
botanical    O
gardens    O
.    O

The    O
major    O
contribution    O
of    O
L    O
-    O
ornithine    O
and    O
L    O
-    O
arginine    O
as    O
a    O
precursor    O
to    O
the    O
tropane    B-Stimulation105827684
ring    O
was    O
confirmed    O
by    O
Edward    O
Leete    O
.    O

Tropane    B-Stimulation105827684
.    O

He    O
has    O
conducted    O
clinical    O
trials    O
with    O
the    O
use    O
of    O
many    O
delivery    O
forms    O
of    O
nicotine    O
available    O
on    O
the    O
US    O
and    O
European    O
markets    O
,    O
including    O
gum    O
,    O
transdermal    O
patches    O
,    O
oral    O
nicotine    O
inhalers    O
,    O
nasal    B-Stimulation105827684
spray    I-Stimulation105827684
,    O
and    O
sublingual    O
tablets    O
.    O

:    O
She    O
is    O
known    O
as    O
Bitzi    O
Nohara    O
in    O
the    O
Funimation    O
dub    O
,    O
and    O
she    O
is    O
also    O
a    O
"    O
Brown-brown    B-Stimulation105827684
"    O
addict    O
.    O

Hypotension    O
may    O
be    O
treated    O
with    O
levarterenol    O
or    O
metaraminol    B-Stimulation105827684
.    O

Metaraminol    B-Stimulation105827684
bitartrate    I-Stimulation105827684

Metaraminol    B-Stimulation105827684
or    O
ephedrine    O
,    O
where    O
hypotension    O
(    O
low    O
blood    O
pressure    O
)    O
may    O
occur    O
secondary    O
to    O
the    O
sedating    O
drugs    O

Hypnic    B-Stimulation105827684
headaches    I-Stimulation105827684
are    O
benign    O
primary    O
headaches    O
that    O
affect    O
the    O
elderly    O
,    O
with    O
the    O
average    O
age    O
of    O
onset    O
being    O
63    O
±    O
11    O
years    O
.    O
They    O
are    O
moderate    O
,    O
throbbing    O
,    O
bilateral    O
or    O
unilateral    O
headaches    O
that    O
wake    O
the    O
sufferer    O
from    O
sleep    O
once    O
or    O
multiple    O
times    O
a    O
night    O
.    O

Following    O
the    O
ban    O
on    O
ethylphenidate    B-Stimulation105827684
authorities    O
noticed    O
an    O
increase    O
in    O
methiopropamine    O
use    O
by    O
injecting    O
users    O
.    O

The    O
compounds    O
listed    O
for    O
control    O
were    O
ethylphenidate    B-Stimulation105827684
,    O
propylphenidate    O
,    O
isopropylphenidate    O
,    O
methylnaphthidate    B-Stimulation105827684
and    O
3,4-Dichloromethylphenidate    B-Stimulation105827684
.    O

HDEP-28    O
or    O
ethylnaphthidate    O
is    O
a    O
piperidine    O
based    O
stimulant    O
drug    O
,    O
closely    O
related    O
to    O
ethylphenidate    B-Stimulation105827684
,    O
but    O
with    O
the    O
benzene    O
ring    O
replaced    O
by    O
naphthalene    O
.    O

4-Methylaminorex    B-Stimulation105827684

4-Methylaminorex    B-Stimulation105827684

4-methylaminorex    B-Stimulation105827684

4-Methylaminorex    B-Stimulation105827684
,    O
nicknamed    O
"    O
ice    O
"    O
in    O
North    O
America    O

CRL-40,941    B-Stimulation105827684

One    O
of    O
the    O
most    O
high    O
-    O
profile    O
party    B-Stimulation105827684
pills    I-Stimulation105827684
products    O
that    O
Bowden    O
developed    O
was    O
EASE    O
.    O

An    O
original    O
side    O
-    O
story    O
was    O
that    O
Lisa    O
would    O
become    O
addicted    O
to    O
the    O
"    O
Trucker    O
's    O
Choice    O
"    O
pep    B-Stimulation105827684
pills    I-Stimulation105827684
.    O

"    O
Itopride    B-Stimulation105827684
"    O

Itopride    B-Stimulation105827684

ABT-418    B-Stimulation105827684
is    O
a    O
drug    O
developed    O
by    O
Abbott    O
,    O
that    O
has    O
nootropic    O
,    O
neuroprotective    O
and    O
anxiolytic    O
effects    O
,    O
and    O
has    O
been    O
researched    O
for    O
treatment    O
of    O
both    O
Alzheimer    O
's    O
disease    O
and    O
ADHD    O
.    O

1-Methylamino-1-(3,4-methylenedioxyphenyl)propane    B-Stimulation105827684
or    O
M-ALPHA    B-Stimulation105827684
is    O
an    O
empathogen    O
,    O
reported    O
by    O
Alexander    O
Shulgin    O
in    O
his    O
book    O
PIHKAL    O
as    O
a    O
positional    O
isomer    O
of    O
MDMA    O
,    O
and    O
subsequently    O
found    O
being    O
sold    O
as    O
a    O
designer    O
drug    O
in    O
the    O
UK    O
in    O
2010    O
,    O
and    O
reported    O
to    O
the    O
EMCDDA    O
new    O
drug    O
monitoring    O
service    O
.    O

One    O
such    O
pharmaceutical    O
application    O
is    O
in    O
the    O
synthesis    O
of    O
SIB-1508Y    O
,    O
which    O
is    O
more    O
commonly    O
known    O
as    O
Altinicline    B-Stimulation105827684
.    O

methamphetamine    O
and    O
its    O
isomers    O
(    O
dextromethamphetamine    O
and    O
levomethamphetamine    B-Stimulation105827684
)    O

Many    O
substituted    O
phenethylamines    O
are    O
psychoactive    O
drugs    O
which    O
belong    O
to    O
a    O
variety    O
of    O
different    O
drug    O
classes    O
,    O
including    O
central    O
nervous    O
system    O
stimulants    O
(    O
e.g.    O
,    O
amphetamine    O
)    O
,    O
hallucinogens    O
(    O
e.g.    O
,    O
dl-2,5-dimethoxy-4-methylamphetamine    O
DOM    O
)    O
,    O
entactogens    O
(    O
e.g.    O
,    O
3,4-methylenedioxyamphetamine    O
MDA    O
)    O
,    O
appetite    O
suppressants    O
(    O
e.g.    O
phentermine    B-Stimulation105827684
)    O
,    O
nasal    O
decongestants    O
and    O
bronchodilators    O
(    O
e.g.    O
,    O
levomethamphetamine    B-Stimulation105827684
and    O
pseudoephedrine    O
)    O
,    O
antidepressants    O
(    O
e.g.    O
bupropion    O
and    O
phenelzine    O
)    O
,    O
antiparkinson    O
agents    O
(    O
e.g.    O
,    O
selegiline    O
)    O
,    O
and    O
vasopressor    B-Stimulation105827684
(    O
e.g.    O
,    O
ephedrine    O
)    O
,    O
among    O
others    O
.    O

Levomethamphetamine    B-Stimulation105827684
(    O
"    O
Vicks    O
Vapor    O
Inhaler    O
"    O
)    O

Antiperspirants    O
may    O
also    O
contain    O
levomethamphetamine    B-Stimulation105827684

Naphthylamphetamine    B-Stimulation105827684

Naphthylisopropylamine    B-Stimulation105827684

Rivanicline    B-Stimulation105827684
(    O
TC-2403    B-Stimulation105827684
,    O
RJR-2403    B-Stimulation105827684
,    O
(E)-metanicotine    B-Stimulation105827684
)    O
is    O
a    O
drug    O
which    O
acts    O
as    O
a    O
partial    O
agonist    O
at    O
neural    O
nicotinic    O
acetylcholine    O
receptors    O
.    O

=    O
Onyia    O
had    O
tested    O
positive    O
for    O
stimulant    O
methylhexaneamine    B-Stimulation105827684
at    O
the    O
2008    O
Athletissima    O
meeting    O
and    O
also    O
tested    O
positive    O
for    O
Clenbuterol    O
at    O
the    O
2008    O
World    O
Athletics    O
Final    O
,    O
meaning    O
her    O
results    O
were    O
annulled    O
.    O

Methylhexanamine    B-Stimulation105827684

His    O
2012    O
Olympic    O
medal    O
was    O
stripped    O
on    O
November    O
7    O
,    O
2012    O
after    O
he    O
tested    O
positive    O
for    O
the    O
banned    O
stimulant    O
methylhexaneamine    B-Stimulation105827684
.    O

Hackett    O
ran    O
a    O
relay    O
at    O
the    O
2011    O
World    O
Championships    O
in    O
Athletics    O
,    O
but    O
was    O
retrospectively    O
disqualified    O
and    O
banned    O
for    O
six    O
months    O
because    O
of    O
a    O
failed    O
drugs    O
test    O
for    O
Methylhexaneamine    B-Stimulation105827684
at    O
the    O
National    O
Championships    O
.    O

In    O
November    O
2012    O
,    O
Louisiana    O
State    O
University    O
reported    O
that    O
Hackett    O
had    O
again    O
tested    O
positive    O
for    O
methylhexaneamine    B-Stimulation105827684
at    O
the    O
2012    O
NCAA    O
Division    O
I    O
Outdoor    O
Track    O
&    O
Field    O
Championships    O
in    O
June    O
.    O

A    O
sample    O
for    O
an    O
in    O
-    O
competition    O
drugs    O
test    O
that    O
Whyte    O
had    O
provided    O
after    O
his    O
victory    O
over    O
Hungary    O
's    O
Sandor    O
Balogh    O
on    O
13    O
October    O
was    O
examined    O
and    O
subsequently    O
tested    O
positive    O
for    O
the    O
banned    O
Methylhexaneamine    B-Stimulation105827684
(    O
MHA    O
)    O
.    O

It    O
was    O
determined    O
that    O
she    O
had    O
put    O
a    O
scoop    O
of    O
a    O
product    O
containing    O
dietary    O
supplement    O
Methylhexanamine    B-Stimulation105827684
into    O
her    O
water    O
bottle    O
.    O

Semoy    O
Hackett    O
of    O
Louisiana    O
State    O
University    O
was    O
initially    O
awarded    O
the    O
Bronze    O
but    O
was    O
subsequently    O
disqualified    O
for    O
testing    O
positive    O
for    O
methylhexaneamine    B-Stimulation105827684
.    O

At    O
the    O
Portuguese    O
national    O
championships    O
in    O
June    O
2010    O
Costa    O
and    O
his    O
brother    O
Mário    O
tested    O
positive    O
for    O
the    O
banned    O
substance    O
methylhexanamine    B-Stimulation105827684
,    O
which    O
they    O
claimed    O
to    O
have    O
ingested    O
inadvertently    O
due    O
to    O
a    O
tainted    O
food    O
supplement    O
.    O

Gunawan    O
’s    O
urine    O
sample    O
tested    O
positive    O
for    O
Methylhexaneamine    B-Stimulation105827684
,    O
a    O
performance    O
-    O
enhancing    O
substance    O
,    O
during    O
random    O
testing    O
at    O
the    O
4th    O
Asian    O
Indoor    O
and    O
Martial    O
Arts    O
Games    O
held    O
in    O
July    O
2013    O
.    O

He    O
set    O
a    O
5000    O
m    O
best    O
of    O
13:13.68    O
minutes    O
that    O
June    O
,    O
but    O
was    O
caught    O
doping    O
shortly    O
afterwards    O
,    O
receiving    O
a    O
six    O
-    O
month    O
ban    O
for    O
methylhexanamine    B-Stimulation105827684
.    O

She    O
did    O
not    O
advance    O
from    O
round    O
1    O
and    O
was    O
later    O
disqualified    O
for    O
testing    O
positive    O
for    O
methylhexaneamine    B-Stimulation105827684
.    O

They    O
both    O
tested    O
positive    O
for    O
methylhexanamine    B-Stimulation105827684
.    O

In    O
2010    O
,    O
while    O
playing    O
for    O
the    O
Bankstown    O
City    O
Bulls    O
in    O
the    O
Bundaberg    O
Red    O
Cup    O
,    O
Salem    O
tested    O
positive    O
for    O
methylhexaneamine    B-Stimulation105827684
and    O
was    O
immediately    O
suspended    O
.    O

Sachenbacher    O
-    O
Stehle    O
had    O
finished    O
fourth    O
in    O
both    O
the    O
mass    O
start    O
and    O
the    O
mixed    O
relay    O
but    O
was    O
disqualified    O
from    O
both    O
events    O
after    O
testing    O
positive    O
for    O
the    O
banned    O
substance    O
methylhexanamine    B-Stimulation105827684
.    O

SARMS    O
and    O
DMAA    B-Stimulation105827684
are    O
safer    O
forms    O
to    O
enhance    O
physical    O
performance    O
.    O

Hexapradol    B-Stimulation105827684
(    O
INN    O
)    O
is    O
a    O
psychostimulant    O
drug    O
which    O
was    O
never    O
marketed    O
.    O

Medications    O
which    O
may    O
be    O
effective    O
include    O
:    O
CNS    O
stimulants    O
fludrocortisone    O
,    O
midodrine    B-Stimulation105827684
,    O
SSRIs    O
such    O
as    O
paroxetine    O
or    O
sertraline    O
,    O
disopyramide    O
,    O
and    O
,    O
in    O
health    O
-    O
care    O
settings    O
where    O
a    O
syncope    O
is    O
anticipated    O
,    O
atropine    O
epinephrine    O
(    O
adrenaline    O
)    O
.    O

Apart    O
from    O
addressing    O
the    O
underlying    O
cause    O
,    O
orthostatic    O
hypotension    O
may    O
be    O
treated    O
with    O
a    O
recommendation    O
to    O
increase    O
salt    O
and    O
water    O
intake    O
(    O
to    O
increase    O
the    O
blood    O
volume    O
)    O
,    O
wearing    O
compression    O
stockings    O
,    O
and    O
sometimes    O
medication    O
(    O
fludrocortisone    O
,    O
midodrine    B-Stimulation105827684
or    O
others    O
)    O
.    O

The    O
medication    O
midodrine    B-Stimulation105827684
can    O
benefit    O
people    O
with    O
orthostatic    O
hypotension    O
,    O
The    O
main    O
side    O
-    O
effect    O
is    O
piloerection    O
(    O
"    O
goose    O
bumps    O
"    O
)    O
.    O

Difluoropine    B-Stimulation105827684
(    O
O-620    O
)    O
,    O
More    O
selective    O
as    O
a    O
DARI    O
than    O
cocaine    O
.    O

Ji    O
Han    O
wrote    O
the    O
"    O
Rhapsody    O
on    O
Cold-Food    B-Stimulation105827684
Powder    I-Stimulation105827684
"    O
,    O
which    O
lauds    O
the    O
effectiveness    O
of    O
a    O
drug    O
,    O
popular    O
with    O
the    O
literati    O
during    O
the    O
Six    O
Dynasties    O
era    O
,    O
as    O
well    O
as    O
a    O
tract    O
,    O
entitled    O
"    O
Description    O
of    O
Herbs    O
and    O
Plants    O
of    O
the    O
Southern    O
Region    O
"    O
that    O
is    O
no    O
longer    O
extant    O
.    O

GBR-13069    B-Stimulation105827684

In    O
contrast    O
to    O
RTI-113    B-Stimulation105827684
,    O
which    O
is    O
DAT    O
selective    O
,    O
RTI-112    O
is    O
a    O
nonselective    O
triple    O
reuptake    O
inhibitor    O
.    O

Paroxysmal    B-Stimulation105827684
hemicrania    I-Stimulation105827684
(    O
chronic    O
or    O
episodic    O
)    O

Trazium    B-Stimulation105827684

A    O
1993    O
study    O
by    O
Watson    O
and    O
Trott    O
suggested    O
that    O
PAIVM    O
examinations    O
are    O
reliable    O
when    O
identifying    O
symptomatic    O
vertebral    O
joints    O
when    O
assessing    O
for    O
cervicogenic    B-Stimulation105827684
headache    I-Stimulation105827684
.    O

A    O
2008    O
randomised    O
controlled    O
trial    O
by    O
Reid    O
et    O
al    O
.    O
suggested    O
a    O
statistically    O
significant    O
correlation    O
between    O
SNAGS    O
treatment    O
and    O
reduced    O
dizziness    O
,    O
cervical    O
pain    O
and    O
disability    O
caused    O
by    O
cervical    O
dysfunction    O
,    O
whilst    O
another    O
randomised    O
controlled    O
trial    O
in    O
2007    O
by    O
Hall    O
et    O
al    O
.    O
suggested    O
that    O
a    O
self    O
-    O
sustained    O
C1-C2    O
SNAG    O
technique    O
was    O
effective    O
in    O
managing    O
cervicogenic    B-Stimulation105827684
headache    I-Stimulation105827684
.    O

D-IX    B-Stimulation105827684

It    O
is    O
caused    O
by    O
prescription    O
drugs    O
,    O
hallucinogen    O
persisting    O
perception    O
disorder    O
(    O
HPPD    O
)    O
,    O
and    O
persistent    B-Stimulation105827684
aura    I-Stimulation105827684
without    I-Stimulation105827684
infarction    I-Stimulation105827684
.    O

Pozanicline    B-Stimulation105827684
(    O
INN    O
,    O
codenamed    O
ABT-089    B-Stimulation105827684
)    O
is    O
a    O
drug    O
developed    O
by    O
Abbott    O
,    O
that    O
has    O
nootropic    O
and    O
neuroprotective    O
effects    O
.    O

Clominorex    B-Stimulation105827684
is    O
a    O
centrally    O
acting    O
sympathomimetic    O
which    O
is    O
related    O
to    O
other    O
drugs    O
such    O
as    O
aminorex    B-Stimulation105827684
and    O
pemoline    B-Stimulation105827684
.    O

Pemoline    B-Stimulation105827684

#    O
Pemoline    B-Stimulation105827684
is    O
synthesized    O
by    O
the    O
condensation    O
of    O
the    O
ethyl    O
ester    O
of    O
mandelic    O
acid    O
with    O
guanidine    O
.    O

Truyol    O
claimed    O
that    O
the    O
drugs    O
,    O
nandrolone    O
and    O
pemoline    B-Stimulation105827684
,    O
were    O
prescribed    O
by    O
a    O
Spanish    O
physician    O
for    O
a    O
chronic    O
back    O
injury    O
.    O

Joop    O
Zoetemelk    O
(    O
Pemoline    B-Stimulation105827684
in    O
the    O
15th    O
stage    O
)    O

Nielsen    O
Hayden    O
has    O
narcolepsy    O
,    O
for    O
which    O
she    O
had    O
been    O
taking    O
pemoline    B-Stimulation105827684
until    O
the    O
Food    O
and    O
Drug    O
Administration    O
withdrew    O
the    O
drug    O
from    O
the    O
marketplace    O
.    O

4-Methoxymethcathinone    B-Stimulation105827684
(    O
bk    O
-    O
PMMA    O
)    O

Fluorenol    B-Stimulation105827684

Fluorenol    B-Stimulation105827684
is    O
an    O
alcohol    O
derivative    O
of    O
fluorene    O
.    O

HDEP-28    O
was    O
banned    O
in    O
the    O
UK    O
as    O
a    O
Temporary    O
Class    O
Drug    O
from    O
June    O
2015    O
following    O
its    O
unapproved    O
sale    O
as    O
a    O
designer    O
drug    O
,    O
alongside    O
4-Methylmethylphenidate    B-Stimulation105827684
.    O

4-Methylmethylphenidate    B-Stimulation105827684

OCD    O
has    O
been    O
associated    O
with    O
reduced    O
N-Acetylaspartic    B-Stimulation105827684
acid    I-Stimulation105827684
in    O
the    O
mPFC    O
,    O
which    O
is    O
thought    O
to    O
reflect    O
neuron    O
density    O
or    O
functionality    O
,    O
although    O
the    O
exact    O
interpretation    O
has    O
not    O
been    O
established    O
.    O

Moreover    O
,    O
evidence    O
suggests    O
that    O
adverse    O
changes    O
in    O
the    O
level    O
of    O
biomarkers    O
of    O
metabolic    O
integrity    O
and    O
synthesis    O
occur    O
in    O
recreational    O
users    O
,    O
such    O
as    O
a    O
reduction    O
in    O
"N"-acetylaspartate    B-Stimulation105827684
and    O
creatine    O
levels    O
and    O
elevated    O
levels    O
of    O
choline    O
and    O
myoinositol    O
.    O

Thus    O
,    O
the    O
two    O
substrates    O
of    O
this    O
enzyme    O
are    O
acetyl    O
-    O
CoA    O
and    O
L    O
-    O
aspartate    O
,    O
whereas    O
its    O
two    O
products    O
are    O
CoA    O
and    O
N-acetyl-L-aspartate    B-Stimulation105827684
.    O

mefenorex    B-Stimulation105827684

A    O
variety    O
of    O
prodrugs    O
of    O
amphetamine    O
and/or    O
methamphetamine    O
exist    O
,    O
and    O
include    O
amfecloral    O
,    O
amphetaminil    O
,    O
benzphetamine    O
,    O
clobenzorex    O
,    O
D    O
-    O
deprenyl    O
,    O
dimethylamphetamine    O
,    O
ethylamphetamine    O
,    O
fencamine    O
,    O
fenethylline    B-Stimulation105827684
,    O
fenproporex    B-Stimulation105827684
,    O
furfenorex    O
,    O
lisdexamfetamine    O
,    O
mefenorex    B-Stimulation105827684
,    O
mesocarb    B-Stimulation105827684
,    O
prenylamine    O
,    O
selegiline    O
,    O
and    O
tranylcypromine    O
.    O

diphenylpyraline    B-Stimulation105827684
(    O
INN    O
)    O

Hispril    B-Stimulation105827684

1-Methyl-4-benzylpiperazine    B-Stimulation105827684
(    O
MBZP    O
)    O

Brasofensine    B-Stimulation105827684

4'-Methyl-α-pyrrolidinobutiophenone    B-Stimulation105827684

Phthalimidopropiophenone    B-Stimulation105827684
is    O
a    O
chemical    O
intermediate    O
used    O
in    O
the    O
synthesis    O
of    O
cathinone    B-Stimulation105827684
.    O

mefexamide    B-Stimulation105827684
(    O
INN    O
)    O

Buphedrone    B-Stimulation105827684

Buphedrone    B-Stimulation105827684
,    O
also    O
known    O
as    O
α-methylamino-butyrophenone    B-Stimulation105827684
(    O
MABP    B-Stimulation105827684
)    O
,    O
is    O
a    O
stimulant    O
of    O
the    O
phenethylamine    O
and    O
cathinone    B-Stimulation105827684
chemical    O
classes    O
that    O
was    O
first    O
synthesized    O
in    O
1928    O
.    O

A-84543    B-Stimulation105827684
is    O
a    O
drug    O
developed    O
by    O
Abbott    O
,    O
which    O
acts    O
as    O
an    O
agonist    O
at    O
neural    O
nicotinic    O
acetylcholine    O
receptors    O
with    O
high    O
selectivity    O
for    O
the    O
α4β2    O
subtype    O
.    O

Sulbutiamine    B-Stimulation105827684

Zylofuramine    B-Stimulation105827684
is    O
a    O
stimulant    O
drug    O
.    O

enoximone    B-Stimulation105827684
(    O
INN    O
)    O

Hydroxytropacocaine    B-Stimulation105827684
:    O

Temporary    O
measures    O
(    O
"    O
e.g.    O
"    O
,    O
those    O
taken    O
pending    O
the    O
availability    O
of    O
an    O
organ    O
donor    O
)    O
include    O
the    O
administration    O
of    O
drugs    O
whose    O
effects    O
include    O
respiratory    B-Stimulation105827684
stimulation    I-Stimulation105827684
,    O
although    O
these    O
drugs    O
are    O
not    O
universally    O
effective    O
in    O
reducing    O
the    O
severity    O
of    O
Cheyne    O
-    O
Stokes    O
apneas    O
.    O

Dopram    B-Stimulation105827684

doxapram    B-Stimulation105827684
(    O
INN    O
)    O

A-366,833    B-Stimulation105827684
is    O
a    O
drug    O
developed    O
by    O
Abbott    O
,    O
which    O
acts    O
as    O
an    O
agonist    O
at    O
neural    O
nicotinic    O
acetylcholine    O
receptors    O
selective    O
for    O
the    O
α4β2    O
subtype    O
,    O
and    O
has    O
been    O
researched    O
for    O
use    O
as    O
an    O
analgesic    O
,    O
although    O
it    O
has    O
not    O
passed    O
clinical    O
trials    O
.    O

8-OH    O
-    O
DPAT    O
is    O
a    O
research    O
chemical    O
of    O
the    O
aminotetralin    B-Stimulation105827684
chemical    O
class    O
which    O
was    O
developed    O
in    O
the    O
1980s    O
and    O
has    O
been    O
widely    O
used    O
to    O
study    O
the    O
function    O
of    O
the    O
5-HT1A    O
receptor    O
.    O

Lometraline    O
(    O
INN    O
;    O
developmental    O
code    O
name    O
CP-14,368    O
)    O
is    O
a    O
drug    O
and    O
an    O
aminotetralin    B-Stimulation105827684
derivative    O
.    O

Adapromine    B-Stimulation105827684

A    O
3-Dimensional    O
(    O
stick-&-ball    O
)    O
rendering    O
of    O
Troparil    B-Stimulation105827684
:    O
A    O
structural    O
analogue    O
of    O
cocaine    O
with    O
omitted    O
-COO-    O
linkage    O
–    O
a    O
parent    O
compound    O
of    O
many    O
MAT    O
ligands    O
;    O
those    O
of    O
the    O
phenyltropane    B-Stimulation105827684
class    O
.    O

AEME    O
is    O
also    O
used    O
in    O
scientific    O
research    O
for    O
the    O
manufacture    O
of    O
phenyltropane    B-Stimulation105827684
analogues    O
such    O
as    O
troparil    B-Stimulation105827684
,    O
dichloropane    B-Stimulation105827684
,    O
iometopane    B-Stimulation105827684
,    O
and    O
CFT    O
.    O

Gary    O
takes    O
it    O
but    O
drinks    O
it    O
too    O
fast    O
and    O
gets    O
brain    B-Stimulation105827684
freeze    I-Stimulation105827684
.    O

Lisa    O
suggests    O
that    O
Lucas    O
eat    O
ice    O
cream    O
,    O
but    O
he    O
gets    O
brain    B-Stimulation105827684
freeze    I-Stimulation105827684
from    O
it    O
.    O

Etilefrine    B-Stimulation105827684
is    O
a    O
cardiac    B-Stimulation105827684
stimulant    I-Stimulation105827684
used    O
as    O
an    O
antihypotensive    B-Stimulation105827684
.    O

Xamoterol    B-Stimulation105827684
(    O
cardiac    B-Stimulation105827684
stimulant    I-Stimulation105827684
)    O

It    O
produces    O
gepefrine    O
,    O
a    O
cardiac    B-Stimulation105827684
stimulant    I-Stimulation105827684
,    O
as    O
one    O
of    O
its    O
major    O
metabolites    O
.    O

It    O
is    O
believed    O
to    O
have    O
antifungal    O
,    O
expectorant    O
,    O
and    O
cardiotonic    B-Stimulation105827684
effects    O
.    O

("R")-"p"-Isothiocyanatobenzoylecgonine    B-Stimulation105827684
methyl    I-Stimulation105827684
ester    I-Stimulation105827684
(    O
p    O
"-    O
ISOCOC    O
"    O
'    O
)    O
is    O
a    O
cocaine    O
analogue    O
and    O
irreversible    O
(    O
covalent    O
)    O
binding    O
inhibitor    O
of    O
the    O
cocaine    O
receptor    O
,    O
as    O
well    O
as    O
irreversible    O
blocker    O
of    O
dopamine    O
uptake    O
by    O
DAT    O
(    O
the    O
latter    O
being    O
unlike    O
its    O
C3    O
homologue    O
"    O
m    O
"-    O
Isococ    O
)    O

(-)-1-Phenyl-2-propylaminopentane    B-Stimulation105827684
,    O
a    O
stimulant    O
drug    O

In    O
addition    O
,    O
analysis    O
of    O
residues    O
from    O
ceramic    O
vessels    O
has    O
found    O
traces    O
of    O
theobromine    B-Stimulation105827684
and    O
caffeine    O
in    O
early    O
formative    O
vessels    O
from    O
Puerto    O
Escondido    O
,    O
Honduras    O
(    O
1100–900    O
BC    O
)    O
and    O
in    O
middle    O
formative    O
vessels    O
from    O
Colha    O
,    O
Belize    O
(    O
600–400    O
BC    O
)    O
using    O
similar    O
techniques    O
to    O
those    O
used    O
to    O
extract    O
chocolate    O
residues    O
from    O
four    O
classic    O
period    O
(    O
around    O
400    O
AD    O
)    O
vessels    O
from    O
a    O
tomb    O
at    O
the    O
Maya    O
archaeological    O
site    O
of    O
Rio    O
Azul    O
.    O

Many    O
genes    O
were    O
identified    O
as    O
coding    O
for    O
flavonoids    O
,    O
aromatic    O
terpenes    O
,    O
theobromine    B-Stimulation105827684
and    O
many    O
other    O
metabolites    O
involved    O
in    O
cocoa    O
flavor    O
and    O
quality    O
traits    O
,    O
among    O
which    O
a    O
relatively    O
high    O
proportion    O
code    O
for    O
polyphenols    O
,    O
which    O
constitute    O
up    O
to    O
8%    O
of    O
cacao    O
pods    O
dry    O
weight    O
.    O

However    O
,    O
the    O
fruit    O
is    O
poisonous    O
,    O
containing    O
,    O
amongst    O
other    O
substances    O
,    O
the    O
alkaloids    O
theobromine    B-Stimulation105827684
and    O
caffeine    O
,    O
as    O
well    O
as    O
an    O
extremely    O
bitter    O
terpene    O
.    O

He    O
finished    O
second    O
to    O
the    O
French    O
colt    O
Trepan    O
,    O
but    O
was    O
awarded    O
the    O
race    O
when    O
the    O
winner    O
tested    O
positive    O
for    O
theobromine    B-Stimulation105827684
,    O
a    O
banned    O
substance    O
.    O

Fresh    O
leaves    O
contain    O
about    O
4%    O
caffeine    O
,    O
as    O
well    O
as    O
related    O
compounds    O
including    O
theobromine    B-Stimulation105827684
.    O

Other    O
alkaloids    O
possess    O
psychotropic    O
(    O
"    O
e.g.    O
"    O
psilocin    O
)    O
and    O
stimulant    O
activities    O
(    O
"    O
e.g.    O
"    O
cocaine    O
,    O
caffeine    O
,    O
nicotine    O
,    O
theobromine    B-Stimulation105827684
)    O
,    O
and    O
have    O
been    O
used    O
in    O
entheogenic    O
rituals    O
or    O
as    O
recreational    O
drugs    O
.    O

This    O
group    O
includes    O
terpene    O
-    O
like    O
and    O
steroid    O
-    O
like    O
alkaloids    O
,    O
as    O
well    O
as    O
purine    O
-    O
like    O
alkaloids    O
such    O
as    O
caffeine    O
,    O
theobromine    B-Stimulation105827684
,    O
theacrine    O
and    O
theophylline    O
.    O

Most    O
alkaloids    O
are    O
weak    O
bases    O
,    O
but    O
some    O
,    O
such    O
as    O
theobromine    B-Stimulation105827684
and    O
theophylline    O
,    O
are    O
amphoteric    O
.    O

The    O
active    O
ingredients    O
,    O
like    O
those    O
of    O
the    O
related    O
yerba    B-Stimulation105827684
mate    I-Stimulation105827684
and    O
guayusa    O
plants    O
,    O
are    O
actually    O
caffeine    O
and    O
theobromine    B-Stimulation105827684
,    O
and    O
the    O
vomiting    O
either    O
was    O
learned    O
or    O
resulted    O
from    O
the    O
great    O
quantities    O
in    O
which    O
they    O
drank    O
the    O
beverage    O
coupled    O
with    O
fasting    O
.    O

Content    O
verification    O
tests    O
yielded    O
the    O
presence    O
of    O
Theobromine    B-Stimulation105827684
,    O
an    O
essential    O
cocoa    O
component    O
;    O
chromatography    O
and    O
UV    O
tests    O
detected    O
ions    O
of    O
cocoa    O
's    O
chemical    O
components    O
.    O

CX717    B-Stimulation105827684

CX717    B-Stimulation105827684
is    O
an    O
ampakine    O
compound    O
created    O
by    O
Christopher    O
Marrs    O
and    O
Gary    O
Rogers    O
in    O
1996    O
at    O
Cortex    O
Pharmaceuticals    O
.    O

Bromantane    B-Stimulation105827684
,    O
sold    O
under    O
the    O
brand    O
name    O
Ladasten    B-Stimulation105827684
,    O
is    O
an    O
atypical    O
psychostimulant    O
and    O
anxiolytic    O
drug    O
of    O
the    O
adamantane    O
family    O
related    O
to    O
amantadine    O
and    O
memantine    O
which    O
is    O
used    O
in    O
Russia    O
in    O
the    O
treatment    O
of    O
neurasthenia    O
.    O

Bromantane    B-Stimulation105827684

The    O
excreted    O
metabolites    O
are    O
mostly    O
paraxanthine    B-Stimulation105827684
—    O
theobromine    B-Stimulation105827684
and    O
theophylline    O
—    O
and    O
a    O
small    O
amount    O
of    O
unchanged    O
caffeine    O
.    O

"    O
S    O
"-    O
adenosyl    O
-    O
L    O
-    O
methionine    O
+    O
paraxanthine    B-Stimulation105827684
"    O
S    O
"-    O
adenosyl    O
-    O
L    O
-    O
homocysteine    O
+    O
caffeine    O
+    O
H+    O

Morazone    B-Stimulation105827684

UWA-001    O
is    O
structurally    O
related    O
to    O
the    O
diarylethylamines    O
lefetamine    B-Stimulation105827684
(    O
a    O
stimulant    O
and    O
opioid    O
)    O
and    O
the    O
dissociative    O
anesthetic    O
ephenidine    O
,    O
which    O
acts    O
as    O
a    O
NMDA    O
receptor    O
antagonist    O
.    O

lefetamine    B-Stimulation105827684
(    O
SPA    O
)    O
—    O
open    O
chain    O
opioid    O
having    O
also    O
stimulant    O
effects    O

Dioxaphetyl    O
butyrate    O
(    O
INN    O
;    O
trade    O
names    O
Amidalgon    O
,    O
Spasmoxal    O
)    O
is    O
an    O
opioid    O
analgesic    O
which    O
is    O
a    O
diphenylacetic    O
acid    O
derivative    O
,    O
related    O
to    O
other    O
open    O
-    O
chain    O
opioid    O
drugs    O
such    O
as    O
dextropropoxyphene    O
,    O
levacetylmethadol    O
(    O
LAAM    O
)    O
,    O
lefetamine    B-Stimulation105827684
and    O
dimenoxadol    O
.    O

Nine    O
in    O
ten    O
people    O
with    O
sinus    O
thrombosis    O
have    O
a    O
headache    O
;    O
this    O
tends    O
to    O
worsen    O
over    O
the    O
period    O
of    O
several    O
days    O
,    O
but    O
may    O
also    O
develop    O
suddenly    O
(    O
thunderclap    B-Stimulation105827684
headache    I-Stimulation105827684
)    O
.    O

Reversible    B-Stimulation105827684
cerebral    I-Stimulation105827684
vasoconstriction    I-Stimulation105827684
syndrome    I-Stimulation105827684
(    O
RCVS    B-Stimulation105827684
,    O
sometimes    O
called    O
Call-Fleming    B-Stimulation105827684
syndrome    I-Stimulation105827684
)    O
is    O
a    O
disease    O
characterized    O
by    O
a    O
weeks    O
-    O
long    O
course    O
of    O
thunderclap    B-Stimulation105827684
headache    I-Stimulation105827684
,    O
sometimes    O
focal    O
neurologic    O
signs    O
,    O
and    O
occasionally    O
seizures    O
.    O

The    O
key    O
symptom    O
of    O
RCVS    O
is    O
recurrent    O
thunderclap    B-Stimulation105827684
headache    I-Stimulation105827684
,    O
which    O
over    O
95%    O
of    O
patients    O
experience    O
.    O

pyrovalerone    B-Stimulation105827684

Pyrovalerone    B-Stimulation105827684
(    O
O-2371    O
)    O

Pyrovalerone    B-Stimulation105827684
,    O
a    O
psychoactive    O
drug    O

Examples    O
of    O
substituted    O
amphetamines    O
are    O
amphetamine    O
(    O
itself    O
)    O
,    O
methamphetamine    O
,    O
ephedrine    O
,    O
cathinone    B-Stimulation105827684
,    O
phentermine    B-Stimulation105827684
,    O
mephentermine    O
,    O
bupropion    O
,    O
methoxyphenamine    O
,    O
selegiline    O
,    O
amfepramone    O
,    O
pyrovalerone    B-Stimulation105827684
,    O
MDMA    O
(    O
ecstasy    O
)    O
,    O
and    O
DOM    O
(    O
STP    O
)    O
.    O

Pyrovalerone    B-Stimulation105827684
,    O
a    O
stimulant    O
drug    O

Fenmetramide    B-Stimulation105827684

Theodrenaline    B-Stimulation105827684

giant    B-Stimulation105827684
cell    I-Stimulation105827684
arteritis    I-Stimulation105827684

Pulsatile    O
tinnitus    O
may    O
also    O
indicate    O
vasculitis    O
,    O
or    O
more    O
specifically    O
,    O
giant    B-Stimulation105827684
cell    I-Stimulation105827684
arteritis    I-Stimulation105827684
.    O

Giant    B-Stimulation105827684
cell    I-Stimulation105827684
arteritis    I-Stimulation105827684

Giant    B-Stimulation105827684
cell    I-Stimulation105827684
arteritis    I-Stimulation105827684

Less    O
common    O
:    O
Increased    O
intracranial    O
pressure    O
,    O
giant    B-Stimulation105827684
cell    I-Stimulation105827684
arteritis    I-Stimulation105827684
,    O
cavernous    O
sinus    O
mass    O
(    O
e.g.    O
meningioma    O
,    O
Brain    O
stem    O
Glioblastoma    O
aneurysm    O
,    O
metastasis    O
)    O
,    O
multiple    O
sclerosis    O
,    O
sarcoidosis    O
/    O
vasculitis    O
,    O
postmyelography    O
,    O
lumbar    O
puncture    O
,    O
stroke    O
(    O
usually    O
not    O
isolated    O
)    O
,    O
Chiari    O
Malformation    O
,    O
hydrocephalus    O
,    O
intracranial    O
hypertension    O
,    O
tuberculous    O
meningitis    O
.    O

T    O
cells    O
found    O
near    O
vasa    O
vasorum    O
are    O
implicated    O
in    O
pathogenic    O
process    O
of    O
giant    B-Stimulation105827684
cell    I-Stimulation105827684
arteritis    I-Stimulation105827684
.    O

Polymyalgia    O
rheumatica    O
(    O
or    O
"    O
muscle    O
rheumatism    O
"    O
)    O
is    O
an    O
inflammatory    O
condition    O
that    O
mainly    O
occurs    O
in    O
the    O
elderly    O
;    O
it    O
is    O
associated    O
with    O
giant-cell    B-Stimulation105827684
arteritis    I-Stimulation105827684
often    O
responds    O
to    O
prednisolone    O
)    O
.    O

Aortitis    O
–    O
Inflammation    O
of    O
the    O
aorta    O
that    O
can    O
be    O
seen    O
in    O
giant    B-Stimulation105827684
cell    I-Stimulation105827684
arteritis    I-Stimulation105827684
,    O
polymyalgia    O
rheumatica    O
,    O
rheumatoid    O
arthritis    O
,    O
syphilis    O
and    O
Takayasu    O
's    O
arteritis    O
.    O

Giant-cell    B-Stimulation105827684
arteritis    I-Stimulation105827684
(    O
GCA    O
)    O
/    O
Temporal    O
arteritis    O

They    O
later    O
go    O
on    O
hiatus    O
until    O
April    O
20    O
,    O
2002    O
in    O
which    O
Staley    O
is    O
found    O
dead    O
in    O
his    O
apartment    O
after    O
overdosing    O
on    O
a    O
Speedball    B-Stimulation105827684
(drug)    I-Stimulation105827684
.    O

On    O
March    O
5    O
,    O
1982    O
,    O
John    O
Belushi    O
died    O
in    O
Hollywood    O
of    O
an    O
accidental    O
overdose    O
of    O
heroin    B-Stimulation105827684
and    I-Stimulation105827684
cocaine    I-Stimulation105827684
.    O

Around    O
this    O
time    O
,    O
by    O
his    O
own    O
admission    O
,    O
Jourgensen    O
was    O
suicidal    O
and    O
decided    O
to    O
call    O
an    O
acquaintance    O
he    O
had    O
met    O
years    O
earlier    O
;    O
the    O
acquaintance    O
,    O
Angelina    O
Luckacin    O
,    O
helped    O
Jourgensen    O
give    O
up    O
his    O
massive    O
substance    O
habit    O
(    O
which    O
included    O
heroin    O
and    O
cocaine    O
"    O
speedballs    B-Stimulation105827684
"    O
,    O
crack    B-Stimulation105827684
,    O
LSD    O
,    O
various    O
pharmaceuticals    O
and    O
as    O
many    O
as    O
two    O
full    O
bottles    O
of    O
Bushmills    O
whiskey    O
per    O
day    O
)    O
.    O

Powerballing    O
,    O
alternate    O
name    O
for    O
speedball    B-Stimulation105827684
(drug)    I-Stimulation105827684

Mydland    O
died    O
of    O
a    O
speedball    B-Stimulation105827684
overdose    O
on    O
July    O
26    O
,    O
1990    O
.    O

"N"-Ethylbuphedrone    B-Stimulation105827684

Phencyclidine    O
and    O
related    O
drugs    O
such    O
as    O
benocyclidine    B-Stimulation105827684
,    O
tenocyclidine    O
,    O
ketamine    O
,    O
and    O
dizocilpine    O
(    O
MK-801    O
)    O
,    O
have    O
been    O
shown    O
to    O
inhibit    O
the    O
reuptake    O
of    O
the    O
monoamine    O
neurotransmitters    O
.    O

Angiotensinamide    B-Stimulation105827684

Epiboxidine    B-Stimulation105827684

A    O
woman    O
in    O
"    O
seiza    O
"    O
performing    O
a    O
Japanese    B-Stimulation105827684
tea    I-Stimulation105827684
ceremony    I-Stimulation105827684
.    O

The    O
technical    O
merit    O
and    O
artistic    O
impression    O
reached    O
new    O
heights    O
when    O
crockery    O
for    O
tea    B-Stimulation105827684
ceremony    I-Stimulation105827684
had    O
been    O
produced    O
there    O
.    O

Hibachis    O
remain    O
in    O
use    O
in    O
some    O
traditional    O
settings    O
,    O
such    O
as    O
tea    B-Stimulation105827684
ceremony    I-Stimulation105827684
,    O
older    O
stores    O
,    O
and    O
outdoor    O
festivals    O
in    O
winter    O
,    O
such    O
as    O
setsubun    O
.    O

File    O
:    O
Namagashi.jpg|Namagashi    O
are    O
a    O
type    O
of    O
wagashi    O
,    O
which    O
is    O
a    O
general    O
term    O
for    O
snacks    O
used    O
in    O
the    O
Japanese    B-Stimulation105827684
tea    I-Stimulation105827684
ceremony    I-Stimulation105827684
.    O

A    O
selection    O
of    O
wagashi    O
to    O
be    O
served    O
during    O
a    O
Japanese    B-Stimulation105827684
tea    I-Stimulation105827684
ceremony    I-Stimulation105827684
.    O

Throughout    O
the    O
book    O
,    O
Musashi    O
implies    O
that    O
the    O
way    O
of    O
the    O
Warrior    O
,    O
as    O
well    O
as    O
the    O
meaning    O
of    O
a    O
"    O
true    O
strategist    O
"    O
is    O
that    O
of    O
somebody    O
who    O
has    O
made    O
mastery    O
of    O
many    O
art    O
forms    O
away    O
from    O
that    O
of    O
the    O
sword    O
,    O
such    O
as    O
tea    O
drinking    O
(    O
sado    B-Stimulation105827684
)    O
,    O
laboring    O
,    O
writing    O
,    O
and    O
painting    O
,    O
as    O
Musashi    O
practiced    O
throughout    O
his    O
life    O
.    O

This    O
ware    O
is    O
thought    O
to    O
have    O
been    O
especially    O
ordered    O
by    O
tea    O
masters    O
for    O
Japanese    B-Stimulation105827684
ceremony    I-Stimulation105827684
.    O

He    O
had    O
interests    O
in    O
martial    O
arts    O
,    O
tea    B-Stimulation105827684
,    O
and    O
foreign    O
intercourse    O
.    O

The    O
building    O
complex    O
also    O
houses    O
cafeterias    O
,    O
restaurants    O
,    O
a    O
post    O
office    O
,    O
a    O
bookstore    O
,    O
a    O
gym    O
and    O
a    O
tea    B-Stimulation105827684
ceremony    I-Stimulation105827684
house    O
.    O

The    O
search    O
for    O
enlightenment    O
"    O
in    O
the    O
moment    O
"    O
also    O
led    O
to    O
the    O
development    O
of    O
other    O
important    O
derivative    O
arts    O
such    O
as    O
the    O
Chanoyu    B-Stimulation105827684
tea    O
ceremony    O
or    O
the    O
Ikebana    O
art    O
of    O
flower    O
arrangement    O
.    O

Ikkyū    O
休宗純    O
,    O
Ikkyū    O
Sōjun    O
1394–1481    O
)    O
,    O
eccentric    O
,    O
iconic    O
,    O
Rinzai    O
Zen    O
Buddhist    O
priest    O
,    O
poet    O
and    O
sometime    O
mendicant    O
flute    O
player    O
who    O
influenced    O
Japanese    O
art    O
and    O
literature    O
with    O
an    O
infusion    O
of    O
Zen    O
attitudes    O
and    O
ideals    O
;    O
one    O
of    O
the    O
creators    O
of    O
the    O
formal    O
Japanese    B-Stimulation105827684
tea    I-Stimulation105827684
ceremony    I-Stimulation105827684
;    O
well    O
-    O
known    O
to    O
Japanese    O
children    O
through    O
various    O
stories    O
and    O
the    O
subject    O
of    O
a    O
popular    O
Japanese    O
children    O
's    O
television    O
program    O
;    O
made    O
a    O
character    O
in    O
anime    O
fiction    O

Ikkyū    O
一休宗純    O
,    O
Ikkyū    O
Sōjun    O
(    O
1394–1481    O
)    O
,    O
eccentric    O
,    O
iconic    O
,    O
Rinzai    O
Zen    O
Buddhist    O
priest    O
,    O
poet    O
and    O
sometime    O
mendicant    O
flute    O
player    O
who    O
influenced    O
Japanese    O
art    O
and    O
literature    O
with    O
an    O
infusion    O
of    O
Zen    O
attitudes    O
and    O
ideals    O
;    O
one    O
of    O
the    O
creators    O
of    O
the    O
formal    O
Japanese    B-Stimulation105827684
tea    I-Stimulation105827684
ceremony    I-Stimulation105827684
;    O
well    O
-    O
known    O
to    O
Japanese    O
children    O
through    O
various    O
stories    O
and    O
the    O
subject    O
of    O
a    O
popular    O
Japanese    O
children    O
's    O
television    O
program    O
;    O
made    O
a    O
character    O
in    O
anime    O
fiction    O

Kintsugi    O
became    O
closely    O
associated    O
with    O
ceramic    O
vessels    O
used    O
for    O
chanoyu    O
(    O
Japanese    B-Stimulation105827684
tea    I-Stimulation105827684
ceremony    I-Stimulation105827684
)    O
.    O

The    O
practice    O
of    O
tobacco    O
smoking    O
evolved    O
as    O
a    O
part    O
of    O
the    O
Japanese    B-Stimulation105827684
tea    I-Stimulation105827684
ceremony    I-Stimulation105827684
by    O
employing    O
many    O
of    O
the    O
traditional    O
object    O
used    O
to    O
burn    O
incense    O
for    O
tobacco    O
smoking    O
.    O

Soshitsu    O
Sen    O
is    O
the    O
elder    O
son    O
of    O
Soshitsu    O
Sen    O
XV    O
,    O
and    O
currently    O
the    O
sixteenth    O
hereditary    O
grand    O
master    O
(    O
"    O
Iemoto    O
"    O
)    O
of    O
the    O
Urasenke    O
,    O
Japanese    B-Stimulation105827684
Tea    I-Stimulation105827684
Ceremony    I-Stimulation105827684
School    O
.    O

Japanese    B-Stimulation105827684
tea    I-Stimulation105827684
ceremony    I-Stimulation105827684

During    O
Yoshimasa    O
's    O
reign    O
Japan    O
saw    O
the    O
growth    O
of    O
the    O
Higashiyama    O
Culture    O
(    O
"    O
Higashiyama    O
bunka    O
"    O
)    O
,    O
famous    O
for    O
tea    B-Stimulation105827684
ceremony    I-Stimulation105827684
(    O
"    O
Sado    O
"    O
)    O
,    O
flower    O
arrangement    O
(    O
"    O
Kado    O
"    O
or    O
"    O
Ikebana    O
"    O
)    O
,    O
"    O
Noh    O
"    O
drama    O
,    O
and    O
Indian    O
ink    O
painting    O
.    O

The    O
Momoyama    O
Period    O
also    O
saw    O
the    O
development    O
of    O
the    O
chanoyu    B-Stimulation105827684
(    O
tea    O
ceremony    O
)    O
,    O
the    O
chashitsu    O
(    O
teahouse    O
)    O
,    O
and    O
the    O
roji    O
(    O
tea    O
garden    O
)    O
.    O

The    O
tea    O
garden    O
was    O
created    O
during    O
the    O
Muromachi    O
period    O
(    O
1333–1573    O
)    O
and    O
Momoyama    O
period    O
(    O
1573–1600    O
)    O
as    O
a    O
setting    O
for    O
the    O
Japanese    B-Stimulation105827684
tea    I-Stimulation105827684
ceremony    I-Stimulation105827684
,    O
or    O
chanoyu    B-Stimulation105827684
.    O

These    O
also    O
feature    O
an    O
optional    O
tea    B-Stimulation105827684
ceremony    I-Stimulation105827684
(    O
tea    O
and    O
wagashi    O
served    O
by    O
maiko    O
)    O
before    O
the    O
performance    O
.    O

The    O
new    O
project    O
was    O
the    O
Miho    O
Museum    O
,    O
to    O
display    O
Koyama    O
's    O
collection    O
of    O
tea    B-Stimulation105827684
ceremony    I-Stimulation105827684
artifacts    O
.    O

Traditional    O
Japanese    O
arts    O
include    O
crafts    O
such    O
as    O
ceramics    O
,    O
textiles    O
,    O
lacquerware    O
,    O
swords    O
and    O
dolls    O
;    O
performances    O
of    O
bunraku    O
,    O
kabuki    O
,    O
noh    O
,    O
dance    O
,    O
and    O
rakugo    O
;    O
and    O
other    O
practices    O
,    O
the    O
tea    B-Stimulation105827684
ceremony    I-Stimulation105827684
,    O
ikebana    O
,    O
martial    O
arts    O
,    O
calligraphy    O
,    O
origami    O
,    O
onsen    O
,    O
Geisha    O
and    O
games    O
.    O

The    O
introduction    O
of    O
the    O
tea    B-Stimulation105827684
ceremony    I-Stimulation105827684
emphasised    O
simplicity    O
and    O
modest    O
design    O
as    O
a    O
counterpoint    O
to    O
the    O
excesses    O
of    O
the    O
aristocracy    O
.    O

The    O
Japanese    B-Stimulation105827684
tea    I-Stimulation105827684
ceremony    I-Stimulation105827684
is    O
performed    O
sitting    O
in    O
seiza    O
.    O

Nezu    O
was    O
a    O
keen    O
practitioner    O
of    O
the    O
Japanese    B-Stimulation105827684
tea    I-Stimulation105827684
ceremony    I-Stimulation105827684
and    O
his    O
extensive    O
private    O
collection    O
of    O
pre    O
-    O
modern    O
Japanese    O
and    O
East    O
Asian    O
art    O
,    O
served    O
as    O
the    O
basis    O
for    O
the    O
Nezu    O
Museum    O
in    O
Minato    O
,    O
Tokyo    O
.    O

It    O
offered    O
tea    B-Stimulation105827684
ceremony    I-Stimulation105827684
and    O
Japanese    O
flower    O
arrangement    O
exhibits    O
.    O

A    O
friend    O
of    O
artist    O
Honami    O
Kōetsu    O
,    O
Kiyotsugu    O
was    O
active    O
socially    O
in    O
the    O
Kyoto    O
art    O
world    O
,    O
and    O
was    O
known    O
as    O
both    O
a    O
patron    O
of    O
the    O
arts    O
in    O
general    O
,    O
and    O
a    O
collector    O
of    O
tea    O
bowls    O
and    O
other    O
implements    O
of    O
the    O
Japanese    B-Stimulation105827684
tea    I-Stimulation105827684
ceremony    I-Stimulation105827684
.    O

Tea    B-Stimulation105827684
ceremony    I-Stimulation105827684

Sen    O
Sōshu    O
(    O
千宗守    O
)    O
is    O
the    O
hereditary    O
name    O
of    O
the    O
head    O
of    O
the    O
Mushakōjisenke    O
school    O
of    O
Japanese    B-Stimulation105827684
tea    I-Stimulation105827684
ceremony    I-Stimulation105827684
,    O
whose    O
founder    O
was    O
the    O
16th    O
century    O
tea    O
master    O
,    O
Sen    O
Rikyū    O
.    O

He    O
was    O
a    O
talented    O
samurai    O
as    O
well    O
as    O
skilled    O
in    O
sado    B-Stimulation105827684
and    O
waka    O
.    O

The    O
three    O
leading    O
non    O
-    O
Japanese    O
actresses    O
,    O
including    O
Zhang    O
Ziyi    O
,    O
Gong    O
Li    O
,    O
and    O
Michelle    O
Yeoh    O
,    O
were    O
put    O
through    O
"    O
geisha    O
boot    O
camp    O
"    O
before    O
production    O
commenced    O
,    O
during    O
which    O
they    O
were    O
trained    O
in    O
traditional    O
geisha    O
practices    O
of    O
musicianship    O
,    O
dance    O
,    O
and    O
tea    B-Stimulation105827684
ceremony    I-Stimulation105827684
.    O

is    O
a    O
Japanese    O
term    O
used    O
in    O
modern    O
martial    O
arts    O
as    O
well    O
as    O
in    O
tea    B-Stimulation105827684
ceremony    I-Stimulation105827684
,    O
flower    O
arranging    O
,    O
Go    O
,    O
shogi    O
,    O
academic    O
tests    O
and    O
other    O
similar    O
activities    O
to    O
designate    O
various    O
grades    O
,    O
levels    O
or    O
degrees    O
of    O
proficiency    O
or    O
experience    O
.    O

Before    O
joining    O
Nanyo    O
,    O
Hakufu    O
lived    O
with    O
her    O
mother    O
,    O
Goei    O
,    O
outside    O
of    O
Kanto    O
where    O
she    O
,    O
like    O
the    O
samurai    O
,    O
practiced    O
things    O
like    O
flower    O
arrangement    O
and    O
the    O
tea    B-Stimulation105827684
ceremony    I-Stimulation105827684
while    O
training    O
heavily    O
in    O
martial    O
arts    O
.    O

She    O
is    O
a    O
member    O
of    O
the    O
Tea    B-Stimulation105827684
Club    I-Stimulation105827684
.    O

is    O
a    O
traditional    O
Japanese    O
lacquer    O
artist    O
who    O
is    O
renowned    O
for    O
creating    O
exceptional    O
traditional    O
utensils    O
used    O
in    O
the    O
Japanese    B-Stimulation105827684
tea    I-Stimulation105827684
ceremony    I-Stimulation105827684
and    O
utilizing    O
Rimpa    O
school    O
motifs    O
in    O
his    O
lacquer    O
works    O
.    O

Based    O
largely    O
on    O
the    O
ideals    O
and    O
aesthetics    O
of    O
Zen    O
Buddhism    O
and    O
the    O
concept    O
of    O
"    O
wabi    O
-    O
sabi    O
"    O
(    O
beauty    O
in    O
simplicity    O
)    O
,    O
Higashiyama    O
Bunka    O
centered    O
on    O
the    O
development    O
of    O
"    O
chadō    B-Stimulation105827684
"    O
(    O
Japanese    O
tea    O
ceremony    O
)    O
,    O
"    O
ikebana    O
"    O
(    O
flower    O
arranging    O
)    O
,    O
Noh    O
drama    O
,    O
and    O
"    O
sumi    O
-    O
e    O
"    O
ink    O
painting    O
.    O

Buphedrone    B-Stimulation105827684
,    O
also    O
known    O
as    O
α-methylamino-butyrophenone    B-Stimulation105827684
(    O
MABP    B-Stimulation105827684
)    O
,    O
is    O
a    O
stimulant    O
of    O
the    O
phenethylamine    O
and    O
cathinone    B-Stimulation105827684
chemical    O
classes    O
that    O
was    O
first    O
synthesized    O
in    O
1928    O
.    O

Substituted    B-Stimulation105827684
cathinone    I-Stimulation105827684

Substituted    B-Stimulation105827684
cathinone    I-Stimulation105827684

Internet    O
-    O
sourced    O
products    O
claimed    O
to    O
be    O
MDAI    O
have    O
been    O
shown    O
variously    O
to    O
contain    O
mephedrone    O
or    O
other    O
substituted    B-Stimulation105827684
cathinone    I-Stimulation105827684
derivatives    O
,    O
and    O
mixed    O
compositions    O
of    O
inorganic    O
substances    O
,    O
while    O
generally    O
containing    O
no    O
MDAI    O
.    O

Flephedrone    O
,    O
also    O
known    O
as    O
4-fluoromethcathinone    O
(    O
4-FMC    O
)    O
,    O
is    O
a    O
stimulant    O
drug    O
of    O
the    O
cathinone    B-Stimulation105827684
chemical    O
class    O
that    O
has    O
been    O
sold    O
online    O
as    O
a    O
designer    O
drug    O
starting    O
in    O
2008    O
.    O

Substituted    B-Stimulation105827684
cathinone    I-Stimulation105827684

This    O
list    O
has    O
in    O
practice    O
been    O
modified    O
a    O
great    O
number    O
of    O
times    O
,    O
sometimes    O
removing    O
substances    O
,    O
but    O
more    O
commonly    O
adding    O
some    O
;    O
for    O
example    O
,    O
many    O
benzodiazepines    O
became    O
Class    O
C    O
drugs    O
in    O
1985    O
,    O
and    O
many    O
cathinones    B-Stimulation105827684
became    O
Class    O
B    O
drugs    O
in    O
2010    O
.    O

A    O
sixth    O
member    O
,    O
Dr    O
Polly    O
Taylor    O
,    O
resigned    O
in    O
March    O
2010    O
,    O
shortly    O
before    O
the    O
decision    O
to    O
make    O
substituted    B-Stimulation105827684
cathinone    I-Stimulation105827684
-    O
including    O
the    O
legal    O
high    O
mephedrone    O
-    O
illegal    O
.    O

Substituted    B-Stimulation105827684
cathinone    I-Stimulation105827684

2-Amino-1,2-dihydronapthalene    B-Stimulation105827684
(    O
2-ADN    B-Stimulation105827684
)    O
,    O
also    O
known    O
as    O
2-aminodilin    B-Stimulation105827684
(    O
2-AD    B-Stimulation105827684
)    O
,    O
is    O
a    O
stimulant    O
drug    O
.    O

In    O
any    O
age    O
group    O
,    O
subarachnoid    O
hemorrhage    O
,    O
hydrocephalus    O
,    O
benign    B-Stimulation105827684
intracranial    I-Stimulation105827684
hypertension    I-Stimulation105827684
,    O
and    O
many    O
other    O
diagnoses    O
may    O
be    O
supported    O
or    O
excluded    O
with    O
this    O
test    O
.    O

Serial    O
lumbar    O
punctures    O
may    O
be    O
useful    O
in    O
temporary    O
treatment    O
of    O
idiopathic    B-Stimulation105827684
intracranial    I-Stimulation105827684
hypertension    I-Stimulation105827684
(    O
IIH    O
)    O
.    O

Increased    O
CSF    O
pressure    O
can    O
indicate    O
congestive    O
heart    O
failure    O
,    O
cerebral    O
edema    O
,    O
subarachnoid    O
hemorrhage    O
,    O
hypo    O
-    O
osmolality    O
resulting    O
from    O
hemodialysis    O
,    O
meningeal    O
inflammation    O
,    O
purulent    O
meningitis    O
or    O
tuberculous    O
meningitis    O
,    O
hydrocephalus    O
,    O
or    O
pseudotumor    B-Stimulation105827684
cerebri    I-Stimulation105827684
.    O

Benign    B-Stimulation105827684
intracranial    I-Stimulation105827684
hypertension    I-Stimulation105827684

Pulsatile    O
tinnitus    O
may    O
also    O
be    O
an    O
indication    O
of    O
idiopathic    B-Stimulation105827684
intracranial    I-Stimulation105827684
hypertension    I-Stimulation105827684
.    O

Improvements    O
on    O
the    O
diagnosis    O
of    O
cerebral    O
venous    O
sinus    O
thrombosis    O
in    O
life    O
were    O
made    O
with    O
the    O
introduction    O
of    O
venography    O
in    O
1951    O
,    O
which    O
also    O
aided    O
in    O
the    O
distinction    O
from    O
idiopathic    B-Stimulation105827684
intracranial    I-Stimulation105827684
hypertension    I-Stimulation105827684
,    O
which    O
has    O
similar    O
presenting    O
signs    O
and    O
symptoms    O
in    O
many    O
cases    O
.    O

Indirect    O
damage    O
to    O
the    O
sixth    O
nerve    O
can    O
be    O
caused    O
by    O
any    O
process    O
(    O
brain    O
tumor    O
,    O
hydrocephalus    O
,    O
pseudotumor    B-Stimulation105827684
cerebri    I-Stimulation105827684
,    O
hemorrhage    O
,    O
edema    O
)    O
that    O
exerts    O
downward    O
pressure    O
on    O
the    O
brainstem    O
,    O
causing    O
the    O
nerve    O
to    O
stretch    O
along    O
the    O
clivus    O
.    O

Dobutamine    B-Stimulation105827684
.    O

Dextrose    O
and    O
Dobutamine    B-Stimulation105827684
are    O
both    O
used    O
to    O
increase    O
blood    O
flow    O
to    O
the    O
kidney    O
and    O
act    O
within    O
30    O
to    O
60    O
minutes    O
.    O

For    O
cases    O
in    O
which    O
the    O
LVOT    O
is    O
not    O
obstructed    O
,    O
inotropic    O
therapy    O
(    O
e.g.    O
dobutamine    B-Stimulation105827684
and    O
dopamine    O
)    O
may    O
be    O
used    O
,    O
but    O
with    O
the    O
consideration    O
that    O
takotsubo    O
is    O
caused    O
by    O
excess    O
catecholamines    O
.    O

Following    O
this    O
,    O
myocardial    O
stress    O
is    O
induced    O
,    O
either    O
by    O
exercise    O
or    O
pharmacologically    O
with    O
adenosine    O
,    O
dobutamine    B-Stimulation105827684
or    O
dipyridamole(Persantine    O
)    O
,    O
which    O
increase    O
the    O
heart    O
rate    O
or    O
by    O
regadenoson(Lexiscan    O
)    O
,    O
a    O
vasodilator    O
.    O

There    O
are    O
numerous    O
other    O
drugs    O
(    O
e.g.    O
,    O
dobutamine    B-Stimulation105827684
,    O
ephedrine    O
,    O
isoproterenol    O
)    O
that    O
manipulate    O
the    O
adrenergic    O
receptors    O
and    O
have    O
variable    O
specificity    O
for    O
the    O
receptors    O
and    O
are    O
,    O
thus    O
,    O
used    O
for    O
various    O
reasons    O
.    O

Initially    O
reported    O
as    O
a    O
sleeping    O
pill    O
overdose    O
for    O
legal    O
reasons    O
,    O
he    O
later    O
claimed    O
it    O
was    O
a    O
combination    O
of    O
alcohol    O
,    O
crack    B-Stimulation105827684
,    O
heroin    O
,    O
and    O
a    O
bottle    O
of    O
sleeping    O
pills    O
.    O

On    O
17    O
November    O
2013    O
,    O
Labour    O
Party    O
advisor    O
and    O
the    O
former    O
Co    O
-    O
operative    O
Bank    O
Chairman    O
,    O
Rev.    O
Paul    O
Flowers    O
,    O
was    O
caught    O
by    O
the    O
"    O
Mail    O
on    O
Sunday    O
"    O
buying    O
crack    B-Stimulation105827684
cocaine    I-Stimulation105827684
and    O
methamphetamine    O
.    O

While    O
in    O
the    O
Senate    O
,    O
Clinton    O
has    O
supported    O
reducing    O
the    O
sentencing    O
disparity    O
that    O
currently    O
punishes    O
crack    B-Stimulation105827684
cocaine    I-Stimulation105827684
crimes    O
more    O
harshly    O
than    O
powder    O
cocaine    O
crimes    O
,    O
and    O
in    O
2015    O
,    O
Clinton    O
called    O
for    O
eliminating    O
the    O
disparity    O
,    O
saying    O
:    O
"    O
We    O
're    O
talking    O
about    O
two    O
forms    O
of    O
the    O
same    O
drug    O
.    O

On    O
September    O
7    O
,    O
2006    O
,    O
James    O
was    O
charged    O
with    O
two    O
counts    O
of    O
the    O
felony    O
for    O
selling    O
a    O
total    O
of    O
$    O
750    O
in    O
crack    B-Stimulation105827684
cocaine    I-Stimulation105827684
to    O
an    O
undercover    O
police    O
officer    O
on    O
August    O
30    O
and    O
September    O
7    O
.    O

The    O
seven    O
game    O
pieces    O
include    O
:    O
a    O
pimp    O
,    O
a    O
ho    O
,    O
a    O
40    O
oz    O
,    O
a    O
machine    O
gun    O
,    O
a    O
marijuana    O
leaf    O
,    O
a    O
crack    B-Stimulation105827684
rock    O
,    O
and    O
a    O
basketball    O
.    O

The    O
Miami    O
Boys    O
were    O
reported    O
in    O
the    O
early    O
1980s    O
in    O
Southern    O
Florida    O
when    O
drug    O
dealers    O
(    O
"    O
the    O
boys    O
from    O
Miami    O
"    O
)    O
traveled    O
northwards    O
to    O
cities    O
like    O
Orlando    O
to    O
deal    O
crack    B-Stimulation105827684
cocaine    I-Stimulation105827684
.    O

Gary    O
Anthony    O
Williams    O
was    O
a    O
33-year    O
-    O
old    O
crack    B-Stimulation105827684
addict    I-Stimulation105827684
described    O
as    O
a    O
"    O
drifter    O
"    O
and    O
a    O
"    O
hustler    O
"    O
who    O
begged    O
at    O
a    O
local    O
gas    O
station    O
.    O

Despite    O
the    O
decline    O
of    O
crime    O
compared    O
to    O
their    O
peaks    O
during    O
the    O
crack    B-Stimulation105827684
and    O
heroin    O
epidemics    O
,    O
violent    O
crime    O
continues    O
to    O
be    O
widespread    O
in    O
the    O
community    O
.    O

Super    O
Hans    O
develops    O
a    O
crack    B-Stimulation105827684
cocaine    I-Stimulation105827684
addiction    O
.    O

Though    O
the    O
band    O
's    O
drug    O
use    O
included    O
cocaine    O
,    O
heroin    O
,    O
LSD    O
and    O
many    O
others    O
,    O
Cris    O
'    O
use    O
of    O
heroin    O
and    O
crack    B-Stimulation105827684
cocaine    I-Stimulation105827684
became    O
so    O
bad    O
he    O
rarely    O
left    O
his    O
house    O
except    O
to    O
obtain    O
more    O
drugs    O
.    O

On    O
12    O
April    O
2007    O
,    O
police    O
raided    O
it    O
because    O
it    O
was    O
allegedly    O
being    O
used    O
to    O
sell    O
cannabis    O
and    O
crack    B-Stimulation105827684
cocaine    I-Stimulation105827684
.    O

It    O
can    O
detect    O
cannabis    O
,    O
cocaine    O
,    O
crack    B-Stimulation105827684
cocaine    I-Stimulation105827684
,    O
heroin    O
,    O
morphine    O
,    O
amphetamines    O
,    O
MDMA    O
,    O
and    O
benzodiazepines    O
.    O

This    O
period    O
culminated    O
in    O
2008    O
with    O
a    O
conviction    O
on    O
crack    B-Stimulation105827684
cocaine    I-Stimulation105827684
charges    O
after    O
DeBarge    O
violated    O
his    O
probation    O
on    O
a    O
previous    O
drug    O
conviction    O
,    O
resulting    O
in    O
two    O
arrest    O
warrants    O
.    O

Winfrey    O
later    O
confessed    O
to    O
smoking    O
crack    B-Stimulation105827684
cocaine    I-Stimulation105827684
with    O
a    O
man    O
she    O
was    O
romantically    O
involved    O
with    O
during    O
the    O
same    O
era    O
.    O

The    O
film    O
intertwines    O
several    O
unsettling    O
stories    O
of    O
people    O
in    O
a    O
Manhattan    O
neighborhood    O
ravaged    O
by    O
crack    B-Stimulation105827684
cocaine    I-Stimulation105827684
.    O

Ford    O
was    O
videotaped    O
twice    O
smoking    O
what    O
appeared    O
to    O
be    O
a    O
crack    B-Stimulation105827684
pipe    I-Stimulation105827684
and    O
later    O
admitted    O
to    O
using    O
the    O
illegal    O
substance    O
.    O

Caleb    O
Swanigan    O
,    O
born    O
April    O
18    O
,    O
1997    O
,    O
grew    O
up    O
in    O
an    O
unstable    O
home    O
due    O
to    O
his    O
father    O
,    O
Carl    O
Swanigan    O
Sr    O
.    O
,    O
who    O
had    O
a    O
crack    B-Stimulation105827684
cocaine    I-Stimulation105827684
addiction    O
.    O

Rainie    O
and    O
Phil    O
were    O
to    O
be    O
involved    O
in    O
a    O
storyline    O
involving    O
the    O
taking    O
of    O
crack    B-Stimulation105827684
cocaine    I-Stimulation105827684
.    O

A    O
controversial    O
music    O
video    O
was    O
made    O
for    O
the    O
aforementioned    O
title    O
track    O
,    O
which    O
depicts    O
Necro    O
's    O
uncle    O
and    O
a    O
friend    O
shooting    O
heroin    O
and    O
smoking    O
crack    B-Stimulation105827684
cocaine    I-Stimulation105827684
while    O
Necro    O
performs    O
the    O
song    O
.    O

In    O
1986    O
,    O
the    O
U.S.    O
Congress    O
passed    O
laws    O
that    O
created    O
a    O
100    O
to    O
1    O
sentencing    O
disparity    O
for    O
the    O
trafficking    O
"    O
or    O
possession    O
"    O
of    O
crack    B-Stimulation105827684
when    O
compared    O
to    O
penalties    O
for    O
"    O
trafficking    O
"    O
of    O
powder    O
cocaine    O
,    O
which    O
had    O
been    O
widely    O
criticized    O
as    O
discriminatory    O
against    O
minorities    O
,    O
mostly    O
blacks    O
,    O
who    O
were    O
more    O
likely    O
to    O
use    O
crack    O
than    O
powder    O
cocaine    O
.    O

After    O
the    O
members    O
revived    O
,    O
Holmes    O
was    O
worried    O
that    O
the    O
patio    O
door    O
may    O
have    O
been    O
locked    O
again    O
,    O
so    O
he    O
returned    O
to    O
Nash    O
's    O
a    O
third    O
time    O
,    O
purchased    O
some    O
crack    B-Stimulation105827684
cocaine    I-Stimulation105827684
,    O
ensured    O
the    O
door    O
was    O
unlatched    O
,    O
and    O
notified    O
the    O
gang    O
that    O
the    O
home    O
was    O
ready    O
for    O
invasion    O
.    O

In    O
the    O
movie    O
"    O
Jungle    O
Fever    O
"    O
,    O
the    O
character    O
played    O
by    O
Ossie    O
Davis    O
tries    O
to    O
distract    O
himself    O
from    O
his    O
son    O
Gator    O
's    O
(    O
Samuel    O
L.    O
Jackson    O
)    O
crack    B-Stimulation105827684
cocaine    I-Stimulation105827684
addiction    O
by    O
listening    O
to    O
her    O
albums    O
by    O
the    O
hour    O
.    O

According    O
to    O
her    O
memoir    O
,    O
"    O
Grace    O
After    O
Midnight    O
"    O
,    O
she    O
met    O
her    O
biological    O
parents    O
very    O
few    O
times    O
;    O
her    O
mother    O
was    O
a    O
crack    B-Stimulation105827684
addict    O
and    O
her    O
father    O
was    O
an    O
armed    O
robber    O
.    O

For    O
example    O
,    O
a    O
man    O
in    O
Pennsylvania    O
was    O
convicted    O
of    O
driving    O
under    O
the    O
influence    O
of    O
marijuana    O
cigarettes    O
and    O
crack    B-Stimulation105827684
cocaine    I-Stimulation105827684
in    O
1997    O
,    O
and    O
was    O
never    O
put    O
on    O
the    O
NDR    O
.    O

While    O
Erica    O
is    O
at    O
an    O
arcade    O
with    O
her    O
boyfriend    O
Randy    O
Viscovich    O
,    O
Erica    O
dies    O
of    O
a    O
crack    B-Stimulation105827684
cocaine    I-Stimulation105827684
overdose    O
.    O

In    O
May    O
2001    O
,    O
Raiola    O
was    O
one    O
of    O
fifteen    O
defendants    O
indicted    O
—    O
and    O
later    O
convicted    O
—    O
for    O
their    O
roles    O
in    O
the    O
narcotics    O
operation    O
,    O
which    O
distributed    O
crack    B-Stimulation105827684
cocaine    I-Stimulation105827684
,    O
powdered    O
cocaine    O
,    O
and    O
marijuana    O
in    O
Brooklyn    O
and    O
Manhattan    O
.    O

Alexander    O
contends    O
that    O
in    O
1982    O
the    O
Reagan    O
administration    O
began    O
an    O
escalation    O
of    O
the    O
War    O
on    O
Drugs    O
,    O
purportedly    O
as    O
a    O
response    O
to    O
a    O
crack    B-Stimulation105827684
cocaine    I-Stimulation105827684
crisis    O
in    O
black    O
ghettos    O
,    O
which    O
was    O
(    O
she    O
claims    O
)    O
announced    O
well    O
before    O
crack    O
cocaine    O
arrived    O
in    O
most    O
inner    O
city    O
neighborhoods    O
.    O

He    O
continued    O
to    O
take    O
illegal    O
drugs    O
including    O
cocaine    O
and    O
crack    B-Stimulation105827684
cocaine    I-Stimulation105827684
into    O
the    O
1990s    O
at    O
the    O
height    O
of    O
his    O
Fast    O
Show    O
fame    O
.    O

Lecrae    O
tried    O
"    O
pretty    O
much    O
every    O
drug    O
there    O
was    O
to    O
try    O
"    O
except    O
for    O
heroin    O
and    O
crack    B-Stimulation105827684
cocaine    I-Stimulation105827684
.    O

Rowell    O
had    O
gone    O
to    O
the    O
house    O
on    O
May    O
10    O
with    O
the    O
intent    O
to    O
rob    O
Irving    O
Wright    O
of    O
his    O
drugs    O
and    O
money    O
,    O
after    O
Rowell    O
thought    O
he    O
had    O
paid    O
too    O
much    O
for    O
some    O
crack    B-Stimulation105827684
cocaine    I-Stimulation105827684
.    O

They    O
were    O
given    O
presents    O
,    O
plied    O
with    O
alcohol    O
and    O
introduced    O
to    O
crack    B-Stimulation105827684
cocaine    I-Stimulation105827684
and    O
heroin    O
.    O

Crack    B-Stimulation105827684
cocaine    I-Stimulation105827684
arrived    O
in    O
Vancouver    O
in    O
1995    O
,    O
and    O
crystal    O
methamphetamine    O
started    O
to    O
appear    O
in    O
the    O
DTES    O
in    O
2003    O
.    O

In    O
2011    O
,    O
crack    B-Stimulation105827684
cocaine    I-Stimulation105827684
was    O
the    O
most    O
commonly    O
used    O
illicit    O
hard    O
drug    O
in    O
Vancouver    O
,    O
followed    O
by    O
injected    O
prescription    O
opioids    O
(    O
such    O
as    O
fentanyl    O
and    O
OxyContin    O
)    O
,    O
heroin    O
,    O
crystal    O
methamphetamine    O
(    O
usually    O
injected    O
rather    O
than    O
smoked    O
)    O
,    O
and    O
cocaine    O
(    O
also    O
usually    O
injected    O
)    O
.    O

He    O
is    O
well    O
known    O
for    O
his    O
comedic    O
routine    O
of    O
imitating    O
Michael    O
Jackson    O
on    O
crack    B-Stimulation105827684
cocaine    I-Stimulation105827684
.    O

For    O
example    O
,    O
amyl    O
nitrite    O
(    O
poppers    O
)    O
,    O
nitrous    O
oxide    O
and    O
toluene    O
–    O
a    O
solvent    O
widely    O
used    O
in    O
contact    O
cement    O
and    O
model    O
airplane    O
glue    O
–    O
are    O
considered    O
inhalants    O
,    O
but    O
smoking    O
tobacco    O
,    O
cannabis    O
,    O
and    O
crack    B-Stimulation105827684
are    O
not    O
,    O
even    O
though    O
these    O
drugs    O
are    O
inhaled    O
(    O
as    O
smoke    O
)    O
.    O

On    O
the    O
TV    O
show    O
"    O
How    O
I    O
Met    O
Your    O
Mother    O
"    O
,    O
in    O
the    O
episode    O
"    O
Last    O
Words    O
"    O
,    O
the    O
character    O
Robin    O
Scherbatsky    O
(    O
portrayed    O
by    O
Cobie    O
Smulders    O
)    O
implies    O
to    O
her    O
friend    O
,    O
Ted    O
Mosby    O
(    O
portrayed    O
by    O
Josh    O
Radnor    O
)    O
,    O
that    O
it    O
's    O
naive    O
and    O
childish    O
of    O
him    O
to    O
believe    O
that    O
what    O
the    O
kids    O
were    O
given    O
with    O
their    O
medicine    O
truly    O
was    O
sugar    O
,    O
rather    O
implying    O
that    O
what    O
the    O
children    O
were    O
actually    O
given    O
with    O
their    O
medicine    O
was    O
(    O
crack    B-Stimulation105827684
)    O
cocaine    O
,    O
referencing    O
the    O
fact    O
that    O
the    O
kids    O
,    O
at    O
one    O
point    O
in    O
the    O
movie    O
,    O
attempted    O
to    O
jump    O
into    O
paintings    O
with    O
Poppins    O
.    O

Over    O
parts    O
of    O
the    O
next    O
15    O
years    O
,    O
she    O
used    O
ecstasy    O
,    O
methamphetamine    O
,    O
crack    B-Stimulation105827684
,    O
among    O
others    O
,    O
stating    O
that    O
she    O
turned    O
to    O
drugs    O
because    O
she    O
was    O
"    O
bored    O
"    O
.    O

Also    O
,    O
when    O
Orel    O
develops    O
an    O
unintentional    O
addiction    O
to    O
crack    B-Stimulation105827684
cocaine    I-Stimulation105827684
,    O
he    O
is    O
punished    O
by    O
Clay    O
for    O
speaking    O
slang    O
rather    O
than    O
smoking    O
it    O
.    O

However    O
,    O
in    O
Fury    O
's    O
first    O
script    O
,    O
Kate    O
had    O
a    O
crack    B-Stimulation105827684
cocaine    I-Stimulation105827684
addiction    O
and    O
worked    O
undercover    O
as    O
a    O
prostitute    O
.    O

Selling    O
crack    B-Stimulation105827684
cocaine    I-Stimulation105827684
,    O
they    O
took    O
in    O
approximately    O
$    O
32,000    O
per    O
month    O
over    O
a    O
six    O
-    O
year    O
period    O
.    O

Jay    O
-    O
Z    O
often    O
described    O
"    O
Marcy    O
"    O
as    O
a    O
dangerous    O
place    O
to    O
live    O
,    O
with    O
high    O
crime    O
rates    O
and    O
prevalence    O
of    O
crack    B-Stimulation105827684
cocaine    I-Stimulation105827684
.    O

Space    O
dust    O
,    O
slang    O
for    O
crack    B-Stimulation105827684
cocaine    I-Stimulation105827684
dipped    O
in    O
PCP    O

The    O
rise    O
in    O
crack    B-Stimulation105827684
cocaine    I-Stimulation105827684
use    O
in    O
cities    O
across    O
the    O
U.S.    O
is    O
often    O
cited    O
as    O
a    O
factor    O
for    O
increased    O
gun    O
violence    O
among    O
youths    O
during    O
this    O
time    O
period    O
.    O

In    O
Pittsburgh    O
a    O
change    O
in    O
preferences    O
towards    O
pistols    O
occurred    O
in    O
the    O
early    O
1990s    O
,    O
coinciding    O
with    O
the    O
arrival    O
of    O
crack    B-Stimulation105827684
cocaine    I-Stimulation105827684
and    O
the    O
rise    O
of    O
violent    O
youth    O
gangs    O
.    O

Cartman    O
's    O
grandmother    O
dies    O
and    O
to    O
the    O
family    O
's    O
shock    O
,    O
Cartman    O
inherits    O
her    O
life    O
savings    O
of    O
one    O
million    O
dollars    O
(    O
since    O
she    O
assumed    O
the    O
rest    O
of    O
the    O
family    O
would    O
just    O
spend    O
it    O
all    O
on    O
crack    B-Stimulation105827684
)    O
.    O

He    O
admitted    O
to    O
using    O
crack    B-Stimulation105827684
cocaine    I-Stimulation105827684
"    O
because    O
it    O
eased    O
the    O
degradation    O
and    O
fear    O
of    O
selling    O
himself    O
.    O
"    O

Although    O
there    O
is    O
significant    O
dialogue    O
about    O
drug    O
use    O
contained    O
in    O
the    O
film    O
(    O
specifically    O
MDMA    O
(    O
ecstasy    O
)    O
,    O
marijuana    O
,    O
and    O
one    O
sarcastic    O
discussion    O
about    O
heroin    O
and    O
crack    B-Stimulation105827684
cocaine    I-Stimulation105827684
)    O
,    O
the    O
only    O
drug    O
use    O
by    O
main    O
characters    O
is    O
a    O
scene    O
where    O
Jip    O
and    O
Koop    O
are    O
having    O
an    O
intimate    O
conversation    O
at    O
a    O
house    O
party    O
and    O
they    O
are    O
seen    O
cutting    O
up    O
a    O
line    O
of    O
white    O
powder    O
.    O

During    O
his    O
time    O
in    O
the    O
Navy    O
,    O
he    O
began    O
using    O
several    O
drugs    O
,    O
including    O
crack    B-Stimulation105827684
cocaine    I-Stimulation105827684
.    O

Items    O
seized    O
included    O
11    O
kg    O
of    O
hashish    O
,    O
41    O
kg    O
of    O
cocaine    O
,    O
2,300    O
crack    B-Stimulation105827684
rocks    O
,    O
225    O
kg    O
of    O
marijuana    O
,    O
mix    O
match    O
of    O
pills    O
including    O
speed    O
,    O
viagra    O
,    O
and    O
ecstasy    O
,    O
computers    O
and    O
other    O
electronic    O
devices    O
,    O
Kevlar    O
vests    O
,    O
$    O
60,000    O
cash    O
and    O
25    O
weapons    O
and    O
ammunition    O
.    O

He    O
often    O
said    O
the    O
money    O
was    O
to    O
get    O
him    O
back    O
on    O
the    O
poker    O
tables    O
,    O
but    O
would    O
instead    O
use    O
it    O
to    O
purchase    O
crack    B-Stimulation105827684
,    O
which    O
he    O
now    O
had    O
to    O
use    O
instead    O
of    O
cocaine    O
because    O
his    O
nasal    O
membranes    O
were    O
so    O
damaged    O
he    O
could    O
no    O
longer    O
snort    O
the    O
drug    O
,    O
while    O
crack    O
could    O
be    O
smoked    O
through    O
a    O
pipe    O
.    O

Around    O
this    O
time    O
,    O
by    O
his    O
own    O
admission    O
,    O
Jourgensen    O
was    O
suicidal    O
and    O
decided    O
to    O
call    O
an    O
acquaintance    O
he    O
had    O
met    O
years    O
earlier    O
;    O
the    O
acquaintance    O
,    O
Angelina    O
Luckacin    O
,    O
helped    O
Jourgensen    O
give    O
up    O
his    O
massive    O
substance    O
habit    O
(    O
which    O
included    O
heroin    O
and    O
cocaine    O
"    O
speedballs    B-Stimulation105827684
"    O
,    O
crack    B-Stimulation105827684
,    O
LSD    O
,    O
various    O
pharmaceuticals    O
and    O
as    O
many    O
as    O
two    O
full    O
bottles    O
of    O
Bushmills    O
whiskey    O
per    O
day    O
)    O
.    O

The    O
second    O
track    O
,    O
"    O
Pure    O
Awkward    O
"    O
,    O
describes    O
their    O
interaction    O
with    O
several    O
gangsta    O
rappers    O
such    O
as    O
Dr.    O
Dre    O
,    O
Snoop    O
Dogg    O
and    O
Ice    O
Cube    O
,    O
who    O
attempts    O
to    O
have    O
sex    O
with    O
them    O
after    O
they    O
smoke    O
crack    B-Stimulation105827684
.    O
"    O

He    O
died    O
of    O
a    O
crack    B-Stimulation105827684
cocaine    I-Stimulation105827684
overdose    O
in    O
2008    O
.    O

During    O
his    O
early    O
adolescent    O
years    O
,    O
Logic    O
witnessed    O
his    O
brothers    O
produce    O
and    O
distribute    O
crack    B-Stimulation105827684
cocaine    I-Stimulation105827684
to    O
"    O
addicts    O
all    O
over    O
the    O
block    O
,    O
"    O
as    O
well    O
as    O
seeing    O
his    O
siblings    O
sell    O
the    O
drugs    O
to    O
his    O
father    O
.    O

In    O
2011    O
the    O
Federal    O
Government    O
of    O
the    O
United    O
States    O
arrested    O
four    O
men    O
from    O
Bacliff    O
,    O
accusing    O
to    O
be    O
a    O
part    O
of    O
the    O
gang    O
and    O
charging    O
them    O
crimes    O
related    O
to    O
crack    B-Stimulation105827684
cocaine    I-Stimulation105827684
distribution    O
.    O

The    O
36-year    O
-    O
old    O
man    O
is    O
described    O
in    O
the    O
documents    O
as    O
a    O
onetime    O
member    O
of    O
a    O
violent    O
drug    O
gang    O
first    O
convicted    O
in    O
1996    O
of    O
selling    O
cocaine    O
and    O
crack    B-Stimulation105827684
and    O
being    O
part    O
of    O
a    O
conspiracy    O
to    O
murder    O
a    O
rival    O
drug    O
kingpin    O
.    O

He    O
then    O
worked    O
at    O
a    O
chemical    O
plant    O
for    O
minimum    O
wage    O
,    O
but    O
after    O
being    O
again    O
unemployed    O
he    O
worked    O
as    O
a    O
door    O
-    O
to    O
-    O
door    O
perfume    O
salesman    O
and    O
eventually    O
a    O
crack    B-Stimulation105827684
cocaine    I-Stimulation105827684
dealer    O
.    O

As    O
soon    O
as    O
Jerry    O
starts    O
on    O
a    O
methadone    O
program    O
,    O
he    O
runs    O
across    O
a    O
dealer    O
named    O
Gus    O
(    O
Peter    O
Greene    O
)    O
,    O
who    O
introduces    O
him    O
to    O
crack    B-Stimulation105827684
cocaine    I-Stimulation105827684
and    O
later    O
Dilaudid    O
.    O

The    O
area    O
is    O
also    O
worked    O
by    O
crack    B-Stimulation105827684
dealers    O
.    O

Ricky    O
Ross    O
-    O
L.A.    O
crack    B-Stimulation105827684
dealer    O

His    O
mother    O
was    O
an    O
alcoholic    O
and    O
crack    B-Stimulation105827684
cocaine    I-Stimulation105827684
addict    O
,    O
and    O
his    O
father    O
,    O
Michael    O
Jerome    O
Williams    O
,    O
was    O
frequently    O
in    O
prison    O
.    O

He    O
travelled    O
to    O
the    O
United    O
Kingdom    O
,    O
where    O
he    O
lived    O
under    O
several    O
aliases    O
including    O
Errol    O
Codling    O
,    O
became    O
the    O
head    O
of    O
a    O
Hackney    O
drug    O
-    O
dealing    O
and    O
armed    O
robbery    O
gang    O
,    O
and    O
was    O
wanted    O
by    O
the    O
police    O
there    O
in    O
connection    O
with    O
rape    O
,    O
murder    O
,    O
prostitution    O
,    O
and    O
dealing    O
in    O
crack    B-Stimulation105827684
cocaine    I-Stimulation105827684
.    O

2β-Propanoyl-3β-(4-tolyl)-tropane    B-Stimulation105827684
also    O
known    O
as    O
WF-11    B-Stimulation105827684
or    O
2-PTT    B-Stimulation105827684
is    O
a    O
cocaine    O
analogue    O
20    O
times    O
more    O
potent    O
than    O
cocaine    O
at    O
binding    O
to    O
the    O
dopamine    O
transporter    O
with    O
increased    O
selectivity    O
for    O
the    O
norepinephrine    O
transporters    O
.    O

In    O
2005    O
Hondo    O
was    O
suspended    O
and    O
fired    O
after    O
testing    O
positive    O
for    O
carphedon    B-Stimulation105827684
at    O
the    O
2005    O
Vuelta    O
a    O
Murcia    O
.    O

Russian    O
biathlete    O
Olga    O
Pyleva    O
won    O
a    O
silver    O
medal    O
in    O
the    O
15    O
km    O
race    O
,    O
but    O
tested    O
positive    O
for    O
carphedon    B-Stimulation105827684
and    O
lost    O
her    O
medal    O
.    O

fonturacetam    B-Stimulation105827684
(    O
INN    O
)    O

Fluminorex    B-Stimulation105827684
is    O
a    O
centrally    O
acting    O
sympathomimetic    O
which    O
is    O
related    O
to    O
other    O
drugs    O
such    O
as    O
aminorex    B-Stimulation105827684
and    O
pemoline    B-Stimulation105827684
.    O

Fluminorex    B-Stimulation105827684

It    O
was    O
invented    O
in    O
the    O
early    O
20th    O
century    O
and    O
was    O
subsequently    O
used    O
as    O
an    O
anorectic    O
or    O
appetite    O
suppressant    O
in    O
the    O
1950s    O
,    O
but    O
was    O
not    O
as    O
commonly    O
used    O
as    O
other    O
amphetamines    O
such    O
as    O
amphetamine    O
,    O
methamphetamine    O
,    O
and    O
benzphetamine    O
,    O
and    O
was    O
largely    O
discontinued    O
once    O
newer    O
drugs    O
such    O
as    O
phenmetrazine    B-Stimulation105827684
were    O
introduced    O
.    O

#    O
Phenmetrazine    B-Stimulation105827684

phenmetrazine    B-Stimulation105827684

McCartney    O
first    O
used    O
drugs    O
in    O
the    O
Beatles    O
'    O
Hamburg    O
days    O
,    O
when    O
they    O
often    O
used    O
Preludin    B-Stimulation105827684
to    O
maintain    O
their    O
energy    O
while    O
performing    O
for    O
long    O
periods    O
.    O
Bob    O
Dylan    O
introduced    O
them    O
to    O
marijuana    O
in    O
a    O
New    O
York    O
hotel    O
room    O
in    O
1964    O
;    O
McCartney    O
recalls    O
getting    O
"    O
very    O
high    O
"    O
and    O
"    O
giggling    O
uncontrollably    O
"    O
.    O

Phenmetrazine    B-Stimulation105827684
,    O

Phenmetrazine    B-Stimulation105827684

Biogenic    O
amines    O
have    O
been    O
implicated    O
as    O
a    O
potential    O
cause    O
of    O
red    B-Stimulation105827684
wine    I-Stimulation105827684
headache    I-Stimulation105827684
.    O

See    O
also    O
:    O
flurothyl    B-Stimulation105827684
.    O

Convulsive    O
therapy    O
(    O
e.g.    O
,    O
pentylenetetrazol    O
,    O
flurothyl    B-Stimulation105827684
)    O

Ecgonidine    O
(    O
anhydroecgonine    O
)    O
is    O
an    O
alkaloid    O
related    O
to    O
ecgonine    B-Stimulation105827684
and    O
cocaine    O
.    O

#    O
Ecgonine    B-Stimulation105827684

ecgonine    B-Stimulation105827684
—    O
its    O
esters    O
and    O
derivatives    O
which    O
are    O
convertible    O
to    O
ecgonine    O
and    O
cocaine    O

Camfetamine    B-Stimulation105827684

RTI(-"4229")-112    B-Stimulation105827684
(    O
2β-carbomethoxy-3β-(3-methyl-4-chlorophenyl)tropane    B-Stimulation105827684
)    O
is    O
a    O
synthetic    O
stimulant    O
drug    O
from    O
the    O
phenyltropane    B-Stimulation105827684
family    O
.    O

G-130    B-Stimulation105827684

Living    O
in    O
such    O
high    O
altitudes    O
has    O
led    O
to    O
cultural    O
adaptations    O
,    O
including    O
the    O
consumption    O
of    O
coca    B-Stimulation105827684
tea    I-Stimulation105827684
.    O

Maturin    O
and    O
Eduardo    O
drank    O
mate    B-Stimulation105827684
as    O
they    O
walked    O
,    O
which    O
is    O
a    O
tea    O
made    O
from    O
the    O
coca    O
leaf    O
.    O

Coca    B-Stimulation105827684
tea    I-Stimulation105827684
,    O
an    O
herbal    O
tea    O
made    O
from    O
an    O
infusion    O
of    O
the    O
leaves    O
of    O
the    O
coca    O
plant    O
,    O
considered    O
a    O
mild    O
stimulant    O
and    O
remedy    O
for    O
altitude    O
sickness    O

Hexacyclonate    B-Stimulation105827684
(    O
Gevilon    B-Stimulation105827684
)    O
is    O
a    O
stimulant    O
drug    O
.    O

It    O
is    O
regarded    O
as    O
a    O
safe    O
procedure    O
,    O
but    O
post-dural-puncture    B-Stimulation105827684
headache    I-Stimulation105827684
is    O
a    O
common    O
side    O
effect    O
.    O

Post    B-Stimulation105827684
spinal    I-Stimulation105827684
headache    I-Stimulation105827684
with    O
nausea    O
is    O
the    O
most    O
common    O
complication    O
;    O
it    O
often    O
responds    O
to    O
pain    O
medications    O
and    O
infusion    O
of    O
fluids    O
.    O

Other    O
drugs    O
with    O
a    O
similar    O
chemical    O
structure    O
include    O
α-pyrrolidinopropiophenone    O
(    O
α-PPP    O
)    O
,    O
4'-methyl-α-pyrrolidinopropiophenone    B-Stimulation105827684
(    O
M-α-PPP    O
)    O
,    O
3',4'-methylenedioxy-α-pyrrolidinopropiophenone    O
(    O
MDPPP    O
)    O
and    O
1-phenyl-2-(1-pyrrolidinyl)-1-pentanone    O
(    O
α-PVP    O
)    O
.    O

4'-Methyl-α-pyrrolidinopropiophenone    B-Stimulation105827684
(    O
MePPP    O
)    O

Dianicline    B-Stimulation105827684
(    O
SSR-591,813    B-Stimulation105827684
)    O
is    O
a    O
drug    O
developed    O
by    O
Sanofi    O
-    O
Aventis    O
which    O
acts    O
as    O
a    O
partial    O
agonist    O
at    O
neural    O
nicotinic    O
acetylcholine    O
receptors    O
.    O

Clofenciclan    B-Stimulation105827684
(    O
Chlorphencyclan    B-Stimulation105827684
;    O
Tonquil    B-Stimulation105827684
,    O
Vesitan    B-Stimulation105827684
)    O
is    O
a    O
dopamine    O
-    O
releasing    O
agent    O
developed    O
by    O
Boehringer    O
&    O
Soehne    O
in    O
the    O
1950s    O
.    O

cilobamine    B-Stimulation105827684
(    O
INN    O
)    O

Velusetrag    B-Stimulation105827684
(    O
INN    O
,    O
USAN    O
;    O
previously    O
known    O
as    O
TD-5108    B-Stimulation105827684
)    O
is    O
an    O
experimental    O
drug    O
candidate    O
for    O
the    O
treatment    O
of    O
gastric    O
neuromuscular    O
disorders    O
including    O
gastroparesis    O
,    O
and    O
lower    O
gastrointestinal    O
motility    O
disorders    O
including    O
chronic    O
idiopathic    O
constipation    O
and    O
irritable    O
bowel    O
syndrome    O
.    O

EXP-561    B-Stimulation105827684

cocaine    O
(    O
methyl    O
ester    O
of    O
benzoylecgonine    B-Stimulation105827684
)    O
—    O
an    O
alkaloid    O
found    O
in    O
coca    O
leaves    O
or    O
prepared    O
by    O
synthesis    O
from    O
ecgonine    O

In    O
November    O
2007    O
,    O
Hingis    O
called    O
a    O
press    O
conference    O
to    O
announce    O
that    O
she    O
was    O
under    O
investigation    O
for    O
testing    O
positive    O
for    O
benzoylecgonine    B-Stimulation105827684
,    O
a    O
metabolite    O
of    O
cocaine    O
,    O
during    O
a    O
urine    O
test    O
taken    O
by    O
players    O
at    O
Wimbledon    O
.    O

The    O
official    O
autopsy    O
report    O
lists    O
also    O
a    O
second    O
cause    O
of    O
death    O
as    O
“    O
acute    O
mixed    O
drug    O
ingestion    O
”    O
,    O
listing    O
alprazolam    O
,    O
methadone    O
,    O
benzoylecgonine    B-Stimulation105827684
(    O
a    O
metabolite    O
of    O
cocaine    O
)    O
and    O
traces    O
of    O
methamphetamine    O
as    O
the    O
drugs    O
found    O
in    O
Andy    O
's    O
body    O
at    O
the    O
time    O
of    O
his    O
death    O
.    O

While    O
playing    O
for    O
Volta    O
Redonda    O
in    O
the    O
Campeonato    O
Carioca    O
in    O
2010    O
,    O
Paulinho    O
tested    O
positive    O
for    O
Benzoylecgonine    B-Stimulation105827684
,    O
a    O
metabolised    O
version    O
of    O
cocaine    O
.    O

Armodafinil    B-Stimulation105827684

modafinil    B-Stimulation105827684
(    O
stimulant    O
)    O
,    O
its    O
stereoisomer    O
armodafinil    B-Stimulation105827684
,    O
and    O
a    O
similar    O
drug    O
adrafinil    B-Stimulation105827684

Armodafinil    B-Stimulation105827684
–    O
although    O
primarily    O
thought    O
to    O
be    O
a    O
weak    O
DAT    O
inhibitor    O
,    O
armodafinil    O
is    O
also    O
a    O
D2    O
partial    O
agonist    O
.    O

Armodafinil    B-Stimulation105827684

Barbexaclone    O
(    O
Maliasin    O
)    O
is    O
a    O
salt    O
compound    O
of    O
phenobarbital    O
and    O
levopropylhexedrine    B-Stimulation105827684
.    O

2-Diphenylmethylpyrrolidine    B-Stimulation105827684

lomevactone    B-Stimulation105827684
(    O
INN    O
)    O

Feprosidnine    B-Stimulation105827684
•    O

Cyprodenate    B-Stimulation105827684

"meta"-Hydroxynorephedrine    B-Stimulation105827684

4-Benzylpiperidine    B-Stimulation105827684

Clominorex    B-Stimulation105827684
is    O
a    O
centrally    O
acting    O
sympathomimetic    O
which    O
is    O
related    O
to    O
other    O
drugs    O
such    O
as    O
aminorex    B-Stimulation105827684
and    O
pemoline    B-Stimulation105827684
.    O

:    O
C01CA22    O
Arbutamine    B-Stimulation105827684

Iofetamine    B-Stimulation105827684

N    O
-    O
methylephedrine    O
and    O
N-methylpseudoephedrine    B-Stimulation105827684

PHA-543,613    B-Stimulation105827684
is    O
a    O
drug    O
that    O
acts    O
as    O
a    O
potent    O
and    O
selective    O
agonist    O
for    O
the    O
α7    O
subtype    O
of    O
neural    O
nicotinic    O
acetylcholine    O
receptors    O
,    O
with    O
a    O
high    O
level    O
of    O
brain    O
penetration    O
and    O
good    O
oral    O
bioavailability    O
.    O

ECA    B-Stimulation105827684
stack    I-Stimulation105827684
,    O
a    O
drug    O
combination    O
of    O
ephedrine    O
,    O
caffeine    O
,    O
and    O
aspirin    O

Thozalinone    B-Stimulation105827684

Thozalinone    B-Stimulation105827684

Lymphocytic    B-Stimulation105827684
pleocytosis    I-Stimulation105827684
is    O
an    O
abnormal    O
increase    O
in    O
the    O
amount    O
of    O
lymphocytes    O
in    O
the    O
cerebrospinal    O
fluid    O
(    O
CSF    O
)    O
.    O

Woodall    O
and    O
Constantine    O
became    O
the    O
faces    O
of    O
Nescafé    B-Stimulation105827684
in    O
2003    O
.    O

Later    O
,    O
she    O
appeared    O
in    O
adverts    O
for    O
Aircel    O
and    O
Nescafé    B-Stimulation105827684
along    O
with    O
her    O
husband    O
Suriya    O
.    O

In    O
advertising    O
he    O
has    O
appeared    O
in    O
Velvet    O
Triple    O
Soft    O
and    O
Trident    O
"    O
Mastication    O
for    O
the    O
Nation    O
"    O
adverts    O
,    O
and    O
has    O
been    O
the    O
voice    O
of    O
Nescafe    B-Stimulation105827684
.    O

In    O
2002    O
,    O
the    O
label    O
won    O
the    O
Nescafé    O
Big    O
Break    O
award    O
,    O
which    O
was    O
a    O
Nescafé    B-Stimulation105827684
initiative    O
,    O
where    O
the    O
company    O
gives    O
away    O
cash    O
grants    O
to    O
people    O
aged    O
between    O
16    O
and    O
24    O
,    O
who    O
have    O
a    O
dream    O
or    O
idea    O
and    O
need    O
some    O
financial    O
support    O
to    O
make    O
it    O
a    O
reality    O
.    O

Padukone    O
is    O
an    O
active    O
celebrity    O
endorser    O
for    O
several    O
brands    O
and    O
products    O
,    O
including    O
Tissot    O
,    O
Sony    O
Cyber    O
-    O
shot    O
,    O
Nescafe    B-Stimulation105827684
,    O
Vogue    O
eyewear    O
,    O
Maybelline    O
,    O
Coca    O
-    O
Cola    O
,    O
L'Oréal    O
Paris    O
,    O
Myntra    O
among    O
others    O
.    O

2007    O
:    O
"    O
Nescafe    O
"    O
(    O
commercial    O
ad    O
jingle    O
for    O
Nescafe    B-Stimulation105827684
)    O

This    O
song    O
later    O
was    O
heard    O
in    O
advertising    O
for    O
Nescafe    B-Stimulation105827684
.    O

Nescafé    B-Stimulation105827684

Nescafé    B-Stimulation105827684

Nescafé    B-Stimulation105827684

Nescafé    B-Stimulation105827684

Nescafé    B-Stimulation105827684

Nescafé    B-Stimulation105827684

Nescafé    B-Stimulation105827684

Bendix    O
featured    O
in    O
a    O
1998    O
TV    O
advertisement    O
for    O
Nescafé    B-Stimulation105827684
Gold    O
Blend    O
opposite    O
Neil    O
Roberts    O
(    O
the    O
last    O
of    O
the    O
Gold    O
Blend    O
couple    O
adverts    O
)    O
.    O

Pérez    O
explained    O
,    O
"    O
We    O
'd    O
sit    O
down    O
with    O
a    O
guitar    O
,    O
a    O
tape    O
recorder    O
and    O
a    O
jar    O
of    O
Taster's    B-Stimulation105827684
Choice    I-Stimulation105827684
,    O
and    O
we    O
were    O
coffee    O
achievers    O
all    O
afternoon    O
.    O
"    O

Metoclopramide    B-Stimulation105827684

Metoclopramide    B-Stimulation105827684
10    O
mg    O
to    O
20    O
mg    O
every    O
4    O
to    O
6    O
hours    O
when    O
necessary    O
OR    O

Metoclopramide    B-Stimulation105827684

Metoclopramide    B-Stimulation105827684

Metoclopramide    B-Stimulation105827684
:    O
Action    O
of    O
metoclopramide    O
is    O
decreased    O
.    O

The    O
most    O
commonly    O
prescribed    O
antiemetics    O
in    O
the    O
US    O
are    O
promethazine    O
,    O
metoclopramide    B-Stimulation105827684
and    O
ondansetron    O
.    O

Nausea    O
and    O
vomiting    O
associated    O
with    O
migraine    O
headaches    O
respond    O
best    O
to    O
dopamine    O
antagonists    O
such    O
as    O
metoclopramide    B-Stimulation105827684
,    O
prochlorperazine    O
,    O
and    O
chlorpromazine    O
.    O

To    O
combat    O
moderate    O
to    O
severe    O
morning    O
sickness    O
and    O
hyperemesis    O
gravidarum    O
:    O
In    O
the    O
UK    O
,    O
promethazine    O
is    O
drug    O
of    O
first    O
choice    O
,    O
being    O
preferred    O
as    O
an    O
older    O
drug    O
with    O
which    O
there    O
is    O
a    O
greater    O
experience    O
of    O
use    O
in    O
pregnancy    O
(    O
second    O
in    O
line    O
being    O
metoclopramide    B-Stimulation105827684
or    O
prochlorperazine    O
)    O
.    O

A    O
number    O
of    O
other    O
measures    O
have    O
slight    O
evidence    O
to    O
support    O
their    O
use    O
indomethacin    O
,    O
fluoxetine    O
,    O
dopamine    O
antagonists    O
,    O
metoclopramide    B-Stimulation105827684
,    O
domperidone    B-Stimulation105827684
,    O
monoamine    O
oxidase    O
inhibitors    O
with    O
tyramine    O
(    O
can    O
produce    O
severe    O
hypertension    O
)    O
,    O
oxilofrine    B-Stimulation105827684
,    O
potassium    O
chloride    O
,    O
and    O
yohimbine    O
.    O

The    O
D2    O
receptor    O
is    O
involved    O
in    O
the    O
regulation    O
of    O
prolactin    O
secretion    O
,    O
and    O
agonists    O
of    O
the    O
receptor    O
such    O
as    O
bromocriptine    O
and    O
cabergoline    O
decrease    O
prolactin    O
levels    O
while    O
antagonists    O
of    O
the    O
receptor    O
such    O
as    O
domperidone    B-Stimulation105827684
,    O
metoclopramide    B-Stimulation105827684
,    O
haloperidol    O
,    O
risperidone    O
,    O
and    O
sulpiride    O
increase    O
prolactin    O
levels    O
.    O

Trismus    O
can    O
be    O
seen    O
as    O
an    O
extra    O
-    O
pyramidal    O
side    O
-    O
effect    O
of    O
metoclopromide    B-Stimulation105827684
,    O
phenothiazines    O
and    O
other    O
medications    O
.    O

Underground    O
Stage    O
:    O
Axe    O
Murder    O
Boyz    O
,    O
Cash    O
Amigo    O
,    O
Osirus    O
,    O
Beast    O
Mode    O
,    O
Hazmat    O
E.T.G.    O
,    O
Kegan    O
Ault    O
,    O
Ill    O
Wit    O
It    O
,    O
Wildcard    O
,    O
Insane    O
Eric    O
,    O
7    O
Second    O
Suicide    O
,    O
Freddy    O
Grimes    O
,    O
Haystak    O
,    O
Alphamatic    O
,    O
Dirty    O
Advile    O
,    O
Insane    O
Poetry    O
,    O
Prescription    O
,    O
Will    O
D.O.B.    O
,    O
Draztik    O
,    O
Super    O
Smash    O
Bros    O
,    O
Bukshot    O
,    O
Jelly    O
Roll    O
,    O
Krizz    O
Kaliko    O
,    O
Wazteland    O
Warriorz    O
,    O
T.O.S.    O
,    O
Krak    O
Rok    O
,    O
S.P.E.    O
,    O
Murdaface    O
,    O
Sixx    O
Digit    O
,    O
Razorz    O
Edge    O
,    O
Mastamind    O
,    O
ClaAs    O
,    O
Buckwheat    O
Gators    O
,    O
The    O
Underground    O
Avengers    O
,    O
Seth    O
Brock    O
,    O
Fury    O
,    O
Tre    O
LB    O
,    O
Demented    O
,    O
Pixy    O
,    O
Sketch    O
,    O
Southside    O
Hatchet    O
Swingin'Mob    O
,    O
Origix    O
&    O
DC    O
,    O
Project    O
Born    O
,    O
Psycho    O
Realm    O
,    O
Karnage    O
,    O
Randum    B-Stimulation105827684
,    O
Hostile    O
6    O
,    O
Cykoskifrantik    O
,    O
Izzy    O
Dunafore    O
,    O
Pimp    O
On    O
Wheels    O
,    O
17    O
Ent    O
.    O
,    O
Sedated    O
,    O
The    O
Deadly    O
Medly    O
.    O

Metoclopramide    B-Stimulation105827684
(    O
a    O
prokinetic    O
)    O
is    O
not    O
recommended    O
either    O
alone    O
or    O
in    O
combination    O
with    O
other    O
treatments    O
due    O
to    O
concerns    O
around    O
adverse    O
effects    O
.    O

The    O
treatments    O
for    O
significant    O
retching    O
include    O
correction    O
of    O
fluid    O
and    O
electrolyte    O
balance    O
,    O
nutritional    O
support    O
and    O
medications    O
like    O
phenothiazines    O
(    O
such    O
as    O
Compazine    O
and    O
Phenergan    O
)    O
,    O
5-HT3    O
antagonist    O
(    O
such    O
as    O
Zofran    O
)    O
,    O
dopamine    O
receptor    O
antagonists    O
(    O
such    O
as    O
Reglan    B-Stimulation105827684
)    O
,    O
antihistamines    O
(    O
Antivert    O
,    O
and    O
Dramamine    O
,    O
Benadryl    O
)    O
and    O
anticholinergics    O
(    O
Scopolamine    O
)    O
.    O

#    O
Phentermine    B-Stimulation105827684

Many    O
substituted    O
phenethylamines    O
are    O
psychoactive    O
drugs    O
which    O
belong    O
to    O
a    O
variety    O
of    O
different    O
drug    O
classes    O
,    O
including    O
central    O
nervous    O
system    O
stimulants    O
(    O
e.g.    O
,    O
amphetamine    O
)    O
,    O
hallucinogens    O
(    O
e.g.    O
,    O
2,5-dimethoxy-4-methylamphetamine    O
)    O
,    O
entactogens    O
(    O
e.g.    O
,    O
3,4-methylenedioxyamphetamine    O
)    O
,    O
appetite    O
suppressants    O
(    O
e.g.    O
phentermine    B-Stimulation105827684
)    O
,    O
nasal    O
decongestants    O
and    O
bronchodilators    O
(    O
e.g.    O
,    O
pseudoephedrine    O
)    O
,    O
antidepressants    O
(    O
e.g.    O
bupropion    O
)    O
,    O
antiparkinson    O
agents    O
(    O
e.g.    O
,    O
selegiline    O
)    O
,    O
and    O
vasopressor    B-Stimulation105827684
(    O
e.g.    O
,    O
ephedrine    O
)    O
,    O
among    O
others    O
.    O

Over    O
a    O
dozen    O
ATS    O
are    O
included    O
in    O
this    O
category    O
,    O
including    O
the    O
substituted    O
amphetamine    O
phentermine    B-Stimulation105827684
.    O

phentermine    B-Stimulation105827684

Many    O
substituted    O
phenethylamines    O
are    O
psychoactive    O
drugs    O
which    O
belong    O
to    O
a    O
variety    O
of    O
different    O
drug    O
classes    O
,    O
including    O
central    O
nervous    O
system    O
stimulants    O
(    O
e.g.    O
,    O
amphetamine    O
)    O
,    O
hallucinogens    O
(    O
e.g.    O
,    O
dl-2,5-dimethoxy-4-methylamphetamine    O
DOM    O
)    O
,    O
entactogens    O
(    O
e.g.    O
,    O
3,4-methylenedioxyamphetamine    O
MDA    O
)    O
,    O
appetite    O
suppressants    O
(    O
e.g.    O
phentermine    B-Stimulation105827684
)    O
,    O
nasal    O
decongestants    O
and    O
bronchodilators    O
(    O
e.g.    O
,    O
levomethamphetamine    B-Stimulation105827684
and    O
pseudoephedrine    O
)    O
,    O
antidepressants    O
(    O
e.g.    O
bupropion    O
and    O
phenelzine    O
)    O
,    O
antiparkinson    O
agents    O
(    O
e.g.    O
,    O
selegiline    O
)    O
,    O
and    O
vasopressor    B-Stimulation105827684
(    O
e.g.    O
,    O
ephedrine    O
)    O
,    O
among    O
others    O
.    O

Examples    O
of    O
substituted    O
amphetamines    O
are    O
amphetamine    O
(    O
itself    O
)    O
,    O
methamphetamine    O
,    O
ephedrine    O
,    O
cathinone    B-Stimulation105827684
,    O
phentermine    B-Stimulation105827684
,    O
mephentermine    O
,    O
bupropion    O
,    O
methoxyphenamine    O
,    O
selegiline    O
,    O
amfepramone    O
,    O
pyrovalerone    B-Stimulation105827684
,    O
MDMA    O
(    O
ecstasy    O
)    O
,    O
and    O
DOM    O
(    O
STP    O
)    O
.    O

Phentermine    B-Stimulation105827684
,    O
a    O
weight    O
-    O
loss    O
drug    O
,    O
was    O
found    O
in    O
his    O
system    O
.    O

It    O
was    O
available    O
both    O
alone    O
and    O
in    O
combination    O
with    O
phentermine    B-Stimulation105827684
,    O
another    O
appetite    O
suppressant    O
.    O

The    O
combination    O
of    O
fenfluramine    O
with    O
phentermine    B-Stimulation105827684
,    O
a    O
norepinephrine    O
–    O
dopamine    O
releasing    O
agent    O
acting    O
primarily    O
on    O
norepinephrine    O
,    O
results    O
in    O
a    O
well    O
-    O
balanced    O
serotonin    O
–    O
norepinephrine    O
releasing    O
agent    O
with    O
weaker    O
effects    O
of    O
dopamine    O
release    O
.    O

2-MDP    B-Stimulation105827684
(    O
U-23807A    B-Stimulation105827684
)    O
is    O
a    O
dissociative    O
anaesthetic    O
drug    O
which    O
has    O
been    O
found    O
to    O
be    O
an    O
NMDA    O
antagonist    O
and    O
produces    O
similar    O
effects    O
to    O
PCP    O
in    O
animals    O
.    O

Diclofensine    B-Stimulation105827684
(    O
Ro    B-Stimulation105827684
8-4650    I-Stimulation105827684
)    O
was    O
developed    O
by    O
Hoffmann    O
-    O
La    O
Roche    O
in    O
the    O
1970s    O
in    O
the    O
search    O
for    O
a    O
new    O
antidepressant    O
.    O

Symptoms    O
of    O
SUNCT    O
often    O
lead    O
to    O
misdiagnosis    O
as    O
paroxysmal    O
hemicrania    B-Stimulation105827684
,    O
which    O
is    O
also    O
categorized    O
in    O
the    O
same    O
group    O
.    O

The    O
adenoma    O
may    O
be    O
the    O
prime    O
causative    O
factor    O
behind    O
the    O
headache    O
or    O
may    O
serve    O
to    O
exacerbate    O
a    O
headache    O
caused    O
by    O
other    O
factors    O
.    O
Amongst    O
the    O
types    O
of    O
headaches    O
experienced    O
are    O
both    O
chronic    O
and    O
episodic    O
migraine    O
,    O
and    O
more    O
uncommonly    O
various    O
unilateral    O
headaches    O
;    O
primary    O
stabbing    O
headache    O
,    O
short    O
-    O
lasting    O
unilateral    O
neuralgiform    O
headache    O
attacks    O
with    O
conjunctival    O
injection    O
and    O
tearing    O
(    O
SUNCT    O
)    O
-    O
another    O
type    O
of    O
stabbing    O
headache    O
characterized    O
by    O
short    O
stabs    O
of    O
pain    O
-    O
,    O
cluster    O
headache    O
,    O
and    O
hemicrania    B-Stimulation105827684
continua    I-Stimulation105827684
(    O
HS    O
)    O
.    O

Bromopride    B-Stimulation105827684
(    O
INN    O
)    O
is    O
a    O
dopamine    O
antagonist    O
with    O
prokinetic    B-Stimulation105827684
properties    O
widely    O
used    O
as    O
an    O
antiemetic    O
,    O
closely    O
related    O
to    O
metoclopramide    B-Stimulation105827684
.    O

Metamfepramone    B-Stimulation105827684
(    O
INN    O
)    O

Some    O
analogues    O
of    O
fenfluramine    O
include    O
norfenfluramine    O
,    O
benfluorex    O
,    O
flucetorex    O
,    O
and    O
fludorex    B-Stimulation105827684
.    O

Other    O
medical    O
emergencies    O
that    O
have    O
been    O
observed    O
in    O
space    O
include    O
cases    O
of    O
urological    O
and    O
dental    B-Stimulation105827684
emergencies    O
,    O
as    O
well    O
as    O
behavioural    O
and    O
psychiatric    O
problems    O
.    O

A    O
number    O
of    O
other    O
measures    O
have    O
slight    O
evidence    O
to    O
support    O
their    O
use    O
indomethacin    O
,    O
fluoxetine    O
,    O
dopamine    O
antagonists    O
,    O
metoclopramide    B-Stimulation105827684
,    O
domperidone    B-Stimulation105827684
,    O
monoamine    O
oxidase    O
inhibitors    O
with    O
tyramine    O
(    O
can    O
produce    O
severe    O
hypertension    O
)    O
,    O
oxilofrine    B-Stimulation105827684
,    O
potassium    O
chloride    O
,    O
and    O
yohimbine    O
.    O

#    O
DE547174    O
describes    O
the    O
synthesis    O
of    O
Oxilofrine    B-Stimulation105827684
.    O

Levophacetoperane    B-Stimulation105827684
(    O
Lidépran    B-Stimulation105827684
,    O
Phacétoperane    B-Stimulation105827684
)    O
is    O
a    O
psychostimulant    O
developed    O
by    O
Rhône    O
-    O
Poulenc    O
in    O
the    O
1950s    O
.    O

Rebound    B-Stimulation105827684
headache    I-Stimulation105827684
(    O
also    O
called    O
medication    O
overuse    O
headache    O
,    O
abbreviated    O
MOH    O
)    O

Medication    B-Stimulation105827684
overuse    I-Stimulation105827684
headache    I-Stimulation105827684

The    O
medication    O
overuse    O
may    O
turn    O
,    O
in    O
turn    O
,    O
itself    O
be    O
the    O
cause    O
medication    B-Stimulation105827684
overuse    I-Stimulation105827684
headache    I-Stimulation105827684
.    O

Prucalopride    O
was    O
approved    O
for    O
use    O
in    O
Europe    O
in    O
2009    O
,    O
in    O
Canada    O
(    O
named    O
Resotran    B-Stimulation105827684
)    O
on    O
December    O
7    O
,    O
2011    O
and    O
in    O
Israel    O
in    O
2014    O
but    O
it    O
has    O
not    O
been    O
approved    O
by    O
the    O
Food    O
and    O
Drug    O
Administration    O
for    O
use    O
in    O
the    O
United    O
States    O
.    O

Prucalopride    B-Stimulation105827684

Cinitapride    B-Stimulation105827684

Beta-methyl-phenethylamine    B-Stimulation105827684

β-Methylphenethylamine    B-Stimulation105827684

Tegaserod    B-Stimulation105827684

Tegaserod    B-Stimulation105827684

It    O
is    O
similar    O
to    O
nocaine    B-Stimulation105827684
in    O
chemical    O
structure    O
,    O
and    O
has    O
two    O
and    O
a    O
half    O
times    O
more    O
activity    O
than    O
cocaine    O
as    O
a    O
dopamine    O
reuptake    O
inhibitor    O
.    O

(+)-CPCA    B-Stimulation105827684
,    O
a    O
stimulant    O
drug    O
(    O
nocaine    O
,    O
3α-carbomethoxy-4β-(4-chlorophenyl)-N    O
-    O
methylpiperidine    O
)    O

It    O
was    O
developed    O
as    O
a    O
less    O
toxic    O
analogue    O
of    O
the    O
potent    O
poison    O
dart    O
frog    O
-    O
derived    O
compound    O
epibatidine    B-Stimulation105827684
,    O
which    O
is    O
some    O
200x    O
stronger    O
than    O
morphine    O
as    O
an    O
analgesic    O
but    O
produces    O
extremely    O
dangerous    O
toxic    O
side    O
effects    O
.    O

It    O
was    O
developed    O
as    O
a    O
less    O
toxic    O
analogue    O
of    O
the    O
potent    O
frog    O
-    O
derived    O
alkaloid    O
epibatidine    B-Stimulation105827684
,    O
which    O
is    O
around    O
200    O
times    O
stronger    O
than    O
morphine    O
as    O
an    O
analgesic    O
but    O
produces    O
extremely    O
dangerous    O
toxic    O
nicotinic    O
side    O
effects    O
.    O

Intraocular    O
injections    O
of    O
epibatidine    B-Stimulation105827684
,    O
a    O
cholinergic    O
agonist    O
,    O
can    O
be    O
used    O
to    O
block    O
spontaneous    O
firing    O
in    O
half    O
of    O
all    O
retinal    O
ganglion    O
cells    O
and    O
cause    O
uncorrelated    O
firing    O
in    O
the    O
remaining    O
half    O
.    O

Management    B-Stimulation105827684
of    I-Stimulation105827684
chronic    I-Stimulation105827684
headaches    I-Stimulation105827684

Occipital    B-Stimulation105827684
nerve    I-Stimulation105827684
stimulation    I-Stimulation105827684
,    O
a    O
medical    O
treatment    O

BTS    B-Stimulation105827684
74,398    I-Stimulation105827684
is    O
a    O
centrally    O
acting    O
stimulant    O
drug    O
which    O
was    O
developed    O
for    O
the    O
treatment    O
of    O
Parkinson    O
's    O
disease    O
.    O

Cyclopentamine    B-Stimulation105827684

Cyclopentamine    B-Stimulation105827684

RbCl    B-Stimulation105827684
,    O

RbCl    O
or    O
Rubidium    B-Stimulation105827684
chloride    I-Stimulation105827684
,    O
an    O
alkali    O
metal    O
halide    O

Kopi    B-Stimulation105827684
Luwak    I-Stimulation105827684
is    O
coffee    O
prepared    O
using    O
coffee    O
beans    O
that    O
have    O
been    O
subjected    O
to    O
ingestion    O
and    O
fermentation    O
in    O
the    O
gastrointestinal    O
tract    O
of    O
the    O
Asian    O
palm    O
civet    O
,    O
which    O
is    O
called    O
"    O
luwak    O
"    O
in    O
Indonesia    O
.    O

Another    O
well    O
-    O
known    O
variant    O
of    O
coffee    O
is    O
the    O
"    O
civet    B-Stimulation105827684
coffee    I-Stimulation105827684
"    O
.    O

Volcanica    O
,    O
is    O
one    O
the    O
few    O
certified    O
U.S.    O
importers    O
of    O
Kopi    B-Stimulation105827684
Luwak    I-Stimulation105827684
,    O
the    O
rarest    O
and    O
most    O
expensive    O
coffee    O
in    O
the    O
world    O
.    O

Kopi    B-Stimulation105827684
Luwak    I-Stimulation105827684
is    O
also    O
known    O
as    O
"    O
caphe    O
cut    O
chon    O
"    O
(    O
fox    O
-    O
dung    O
coffee    O
)    O
in    O
Vietnam    O
and    O
"    O
kape    O
alamid    O
"    O
in    O
the    O
Philippines    O
.    O

3-Benzhydrylmorpholine    B-Stimulation105827684

N''-(3'-Fluoropropyl-)-3β-(4'-chlorophenyl)-2β-(3'-phenylisoxazol-5'-yl)nortropane    O
('''FP-β-CPPIT    B-Stimulation105827684
)    O
is    O
a    O
cocaine    O
analogue    O
.    O

4,4'-Dimethylaminorex    B-Stimulation105827684

3-(p-Fluorobenzoyloxy)tropane    B-Stimulation105827684

2-Benzylpiperidine    B-Stimulation105827684

Tametraline    B-Stimulation105827684

Further    O
experimental    O
modifications    O
of    O
the    O
chemical    O
structure    O
of    O
lometraline    O
resulted    O
in    O
the    O
discovery    O
of    O
tametraline    B-Stimulation105827684
,    O
a    O
potent    O
inhibitor    O
of    O
the    O
reuptake    O
of    O
dopamine    O
and    O
norepinephrine    O
,    O
which    O
in    O
turn    O
led    O
to    O
the    O
discovery    O
of    O
the    O
now    O
widely    O
popular    O
antidepressant    O
sertraline    O
,    O
a    O
selective    O
serotonin    O
reuptake    O
inhibitor    O
(    O
SSRI    O
)    O
.    O

Alizapride    B-Stimulation105827684

Reversible    B-Stimulation105827684
cerebral    I-Stimulation105827684
vasoconstriction    I-Stimulation105827684
syndrome    I-Stimulation105827684
(    O
RCVS    B-Stimulation105827684
,    O
sometimes    O
called    O
Call-Fleming    B-Stimulation105827684
syndrome    I-Stimulation105827684
)    O
is    O
a    O
disease    O
characterized    O
by    O
a    O
weeks    O
-    O
long    O
course    O
of    O
thunderclap    B-Stimulation105827684
headache    I-Stimulation105827684
,    O
sometimes    O
focal    O
neurologic    O
signs    O
,    O
and    O
occasionally    O
seizures    O
.    O

Famprofazone    B-Stimulation105827684
(    O
Gewodin    B-Stimulation105827684
,    O
Gewolen    B-Stimulation105827684
)    O
is    O
a    O
nonsteroidal    O
anti    O
-    O
inflammatory    O
agent    O
(    O
NSAID    O
)    O
of    O
the    O
pyrazolone    O
series    O
which    O
is    O
available    O
over    O
-    O
the    O
-    O
counter    O
in    O
some    O
countries    O
such    O
as    O
Taiwan    O
.    O

Indatraline    B-Stimulation105827684
(    O
Lu    B-Stimulation105827684
19-005    I-Stimulation105827684
)    O
is    O
a    O
non    O
-    O
selective    O
monoamine    O
transporter    O
inhibitor    O
that    O
has    O
been    O
shown    O
to    O
block    O
the    O
reuptake    O
of    O
dopamine    O
,    O
norepinephrine    O
,    O
and    O
serotonin    O
with    O
effects    O
similar    O
to    O
those    O
of    O
cocaine    O
.    O

Indatraline    B-Stimulation105827684

This    O
is    O
usually    O
served    O
before    O
the    O
consumption    O
of    O
"    O
kahwa    B-Stimulation105827684
"    O
,    O
a    O
preparation    O
of    O
coffee    O
with    O
cardamom    O
,    O
which    O
is    O
very    O
popular    O
and    O
remains    O
a    O
symbol    O
of    O
hospitality    O
.    O

Coffee    O
,    O
served    O
in    O
the    O
Turkish    B-Stimulation105827684
or    O
Arabic    B-Stimulation105827684
style    I-Stimulation105827684
,    O
is    O
the    O
traditional    O
beverage    O
.    O

Halwa    O
is    O
a    O
common    O
delicacy    O
served    O
with    O
Arabic    B-Stimulation105827684
coffee    I-Stimulation105827684
at    O
festivals    O
and    O
special    O
occasions    O
.    O

Shahi    O
Haleeb    O
(    O
milk    O
tea    O
,    O
served    O
after    O
qat    O
)    O
,    O
black    O
tea    O
(    O
with    O
cardamom    O
,    O
clove    O
,    O
or    O
mint    O
)    O
,    O
qishr    O
(    O
coffee    O
husks    O
)    O
,    O
Qahwa    B-Stimulation105827684
(    O
coffee    O
)    O
,    O
Karkadin    O
(    O
an    O
infusion    O
of    O
dried    O
hibiscus    O
flowers    O
)    O
,    O
Naqe'e    O
Al    O
Zabib    O
(    O
cold    O
raisin    O
drink    O
)    O
,    O
and    O
diba'a    O
(    O
squash    O
nectar    O
)    O
are    O
examples    O
of    O
popular    O
Yemeni    O
drinks    O
.    O

Qahwa    O
,    O
otherwise    O
known    O
as    O
Arabic    B-Stimulation105827684
coffee    I-Stimulation105827684
.    O

2β-Propanoyl-3β-(2-naphthyl)-tropane    B-Stimulation105827684
(    O
WF-23    O
)    O

Liqueur    O
coffee    O
are    O
all    O
variants    O
on    O
what    O
is    O
widely    O
known    O
as    O
Irish    B-Stimulation105827684
coffee    I-Stimulation105827684
,    O
hot    O
coffee    O
with    O
whiskey    O
and    O
a    O
layer    O
of    O
cream    O
(    O
not    O
whipped    O
)    O
floated    O
on    O
top    O
.    O

Irish    B-Stimulation105827684
coffee    I-Stimulation105827684
,    O
with    O
Irish    O
whiskey    O

Irish    B-Stimulation105827684
Coffee    I-Stimulation105827684

An    O
Irish    B-Stimulation105827684
coffee    I-Stimulation105827684
.    O

Irish    B-Stimulation105827684
coffee    I-Stimulation105827684
–    O
made    O
with    O
black    O
coffee    O
,    O
whiskey    O
and    O
whipped    O
cream    O

Orthostatic    B-Stimulation105827684
headache    I-Stimulation105827684
is    O
a    O
medical    O
condition    O
in    O
which    O
a    O
person    O
develops    O
a    O
headache    O
while    O
vertical    O
and    O
the    O
headache    O
is    O
relieved    O
when    O
horizontal    O
.    O

LR-5182    B-Stimulation105827684

Nitracaine    B-Stimulation105827684

Fluminorex    B-Stimulation105827684
is    O
a    O
centrally    O
acting    O
sympathomimetic    O
which    O
is    O
related    O
to    O
other    O
drugs    O
such    O
as    O
aminorex    B-Stimulation105827684
and    O
pemoline    B-Stimulation105827684
.    O

Aminorex    B-Stimulation105827684

Clominorex    B-Stimulation105827684
is    O
a    O
centrally    O
acting    O
sympathomimetic    O
which    O
is    O
related    O
to    O
other    O
drugs    O
such    O
as    O
aminorex    B-Stimulation105827684
and    O
pemoline    B-Stimulation105827684
.    O

Aminorex    B-Stimulation105827684

PNU-120596    B-Stimulation105827684
is    O
a    O
drug    O
that    O
acts    O
as    O
a    O
potent    O
and    O
selective    O
positive    O
allosteric    O
modulator    O
for    O
the    O
α7    O
subtype    O
of    O
neural    O
nicotinic    O
acetylcholine    O
receptors    O
.    O

fenproporex    B-Stimulation105827684

A    O
variety    O
of    O
prodrugs    O
of    O
amphetamine    O
and/or    O
methamphetamine    O
exist    O
,    O
and    O
include    O
amfecloral    O
,    O
amphetaminil    O
,    O
benzphetamine    O
,    O
clobenzorex    O
,    O
D    O
-    O
deprenyl    O
,    O
dimethylamphetamine    O
,    O
ethylamphetamine    O
,    O
fencamine    O
,    O
fenethylline    B-Stimulation105827684
,    O
fenproporex    B-Stimulation105827684
,    O
furfenorex    O
,    O
lisdexamfetamine    O
,    O
mefenorex    B-Stimulation105827684
,    O
mesocarb    B-Stimulation105827684
,    O
prenylamine    O
,    O
selegiline    O
,    O
and    O
tranylcypromine    O
.    O

"    O
The    O
nonselective    O
monoamine    O
transporter    O
inhibitor    O
RTI-126    O
and    O
the    O
DAT    O
-    O
selective    O
inhibitors    O
RTI-150    B-Stimulation105827684
and    O
RTI-336    O
both    O
had    O
a    O
faster    O
rate    O
of    O
onset    O
(    O
30    O
min    O
)    O
and    O
a    O
short    O
duration    O
of    O
action    O
(    O
4h    O
)    O
.    O

The    O
compounds    O
listed    O
for    O
control    O
were    O
ethylphenidate    B-Stimulation105827684
,    O
propylphenidate    O
,    O
isopropylphenidate    O
,    O
methylnaphthidate    B-Stimulation105827684
and    O
3,4-Dichloromethylphenidate    B-Stimulation105827684
.    O

3,4-Dichloromethylphenidate    B-Stimulation105827684

Manifaxine    B-Stimulation105827684
(    O
GW-320,659    B-Stimulation105827684
)    O
is    O
a    O
drug    O
developed    O
by    O
GlaxoSmithKline    O
through    O
structural    O
modification    O
of    O
radafaxine    O
,    O
one    O
of    O
the    O
major    O
active    O
metabolites    O
of    O
bupropion    O
.    O

Manifaxine    B-Stimulation105827684
(    O
GW-320,659    O
)    O

TC-1698    B-Stimulation105827684
is    O
a    O
drug    O
developed    O
by    O
Targacept    O
which    O
acts    O
as    O
a    O
partial    O
agonist    O
for    O
the    O
α7    O
subtype    O
of    O
neural    O
nicotinic    O
acetylcholine    O
receptors    O
.    O

Specifically    O
these    O
include    O
5-APB    O
,    O
6-APB    O
,    O
5-APDB    O
,    O
6-APDB    O
and    O
their    O
N    O
-    O
methyl    O
derivatives    O
5-MAPB    O
,    O
6-MAPB    O
,    O
5-MAPDB    O
and    O
6-MAPDB    O
,    O
as    O
well    O
as    O
5-IT    B-Stimulation105827684
and    O
its    O
isomer    O
6-IT    B-Stimulation105827684
,    O
plus    O
NBOMe-2C    O
-    O
C    O
,    O
NBOMe-2C    O
-    O
B    O
,    O
NBOMe-2C    O
-    O
I    O
and    O
NBOMe-2C    O
-    O
D.    O

5-IT    B-Stimulation105827684

Vascular    B-Stimulation105827684
headache    I-Stimulation105827684

Vascular    B-Stimulation105827684
headache    I-Stimulation105827684
,    O
not    O
elsewhere    O
classified    O

RTI(-"4229")-274    B-Stimulation105827684
,    O
or    O
2β-((3,4-Methylenedioxyphenoxy)methyl)-3α-(4-fluorophenyl)nortropane    B-Stimulation105827684
is    O
a    O
phenyltropane    B-Stimulation105827684
homologue    O
of    O
paroxetine    O
developed    O
by    O
the    O
group    O
led    O
by    O
F    O
Ivy    O
Carroll    O
in    O
the    O
1990s    O
.    O

Nonpyogenic    B-Stimulation105827684
thrombosis    I-Stimulation105827684
of    I-Stimulation105827684
intracranial    I-Stimulation105827684
venous    I-Stimulation105827684
system    I-Stimulation105827684

Cerebral    B-Stimulation105827684
venous    I-Stimulation105827684
thrombosis    I-Stimulation105827684
in    O
pregnancy    O

Cerebral    B-Stimulation105827684
venous    I-Stimulation105827684
sinus    I-Stimulation105827684
thrombosis    I-Stimulation105827684
(    O
CVST    B-Stimulation105827684
)    O
is    O
the    O
presence    O
of    O
acute    O
thrombosis    O
(    O
a    O
blood    O
clot    O
)    O
in    O
the    O
dural    O
venous    O
sinuses    O
,    O
which    O
drain    O
blood    O
from    O
the    O
brain    O
.    O

Complications    O
of    O
acute    O
otitis    O
media    O
consists    O
of    O
perforation    O
of    O
the    O
ear    O
drum    O
,    O
infection    O
of    O
the    O
mastoid    O
space    O
behind    O
the    O
ear    O
(    O
mastoiditis    O
)    O
,    O
and    O
more    O
rarely    O
intracranial    O
complications    O
can    O
occur    O
,    O
such    O
as    O
bacterial    O
meningitis    O
,    O
brain    O
abscess    O
,    O
or    O
dural    B-Stimulation105827684
sinus    I-Stimulation105827684
thrombosis    I-Stimulation105827684
.    O

In    O
2005    O
,    O
Ghioane    O
suffered    O
from    O
a    O
cerebral    B-Stimulation105827684
venous    I-Stimulation105827684
sinus    I-Stimulation105827684
thrombosis    I-Stimulation105827684
which    O
impeded    O
his    O
further    O
successful    O
performance    O
in    O
the    O
club    O
.    O

Bradanicline    B-Stimulation105827684
(    O
INN    O
,    O
code    O
name    O
TC-5619    B-Stimulation105827684
)    O
is    O
a    O
drug    O
which    O
was    O
being    O
developed    O
by    O
Targacept    O
that    O
acts    O
as    O
a    O
partial    O
agonist    O
at    O
the    O
α7    O
subtype    O
of    O
the    O
neural    O
nicotinic    O
acetylcholine    O
receptors    O
.    O

Prenalterol    B-Stimulation105827684
is    O
a    O
cardiac    B-Stimulation105827684
stimulant    I-Stimulation105827684
which    O
acts    O
as    O
a    O
β1    O
adrenoreceptor    O
agonist    O
.    O

"N","O"-Dimethyl-4-(2-naphthyl)piperidine-3-carboxylate    B-Stimulation105827684

On    O
May    O
26    O
,    O
2012    O
during    O
urine    O
testing    O
,    O
the    O
Union    O
Cycliste    O
Internationale    O
(    O
UCI    O
)    O
found    O
tuaminoheptane    B-Stimulation105827684
,    O
a    O
banned    O
substance    O
that    O
she    O
was    O
using    O
prior    O
to    O
the    O
UCI    O
Para    O
-    O
cycling    O
Road    O
World    O
Cup    O
event    O
which    O
started    O
a    O
day    O
before    O
the    O
test    O
.    O

Tuaminoheptane    B-Stimulation105827684
(    O
,    O
)    O
(    O
brand    O
names    O
Heptin    B-Stimulation105827684
,    O
Heptadrine    B-Stimulation105827684
,    O
Tuamine    B-Stimulation105827684
)    O
,    O
or    O
simply    O
tuamine    B-Stimulation105827684
,    O
also    O
known    O
as    O
2-aminoheptane    B-Stimulation105827684
,    O
is    O
a    O
sympathomimetic    O
agent    O
and    O
vasoconstrictor    O
which    O
was    O
formerly    O
used    O
as    O
a    O
nasal    O
decongestant    O
.    O

However    O
,    O
during    O
the    O
season    O
,    O
he    O
suffered    O
a    O
suspension    O
of    O
40    O
days    O
for    O
doping    O
,    O
resulting    O
in    O
positive    O
tests    O
of    O
tuaminoheptane    B-Stimulation105827684
after    O
26    O
December    O
2012    O
game    O
against    O
Livorno    O
,    O
Sassuolo    O
lodged    O
an    O
appeal    O
against    O
the    O
ban    O
due    O
to    O
the    O
assumption    O
of    O
Rinoflumicil    O
,    O
found    O
in    O
a    O
nasal    O
decongestant    O
.    O

Ampyzine    B-Stimulation105827684
is    O
a    O
central    O
nervous    O
system    O
stimulant    O
.    O

International    B-Stimulation105827684
Classification    I-Stimulation105827684
of    I-Stimulation105827684
Headache    I-Stimulation105827684
Disorders    I-Stimulation105827684

The    O
International    B-Stimulation105827684
Classification    I-Stimulation105827684
of    I-Stimulation105827684
Headache    I-Stimulation105827684
Disorders    I-Stimulation105827684
second    I-Stimulation105827684
edition    I-Stimulation105827684
(    O
ICHD-2    O
)    O
,    O
a    O
publication    O
by    O
the    O
International    O
Headache    O
Society    O
.    O

Among    O
primary    O
headaches    O
,    O
the    O
International    B-Stimulation105827684
Classification    I-Stimulation105827684
of    I-Stimulation105827684
Headache    I-Stimulation105827684
Disorders    I-Stimulation105827684
distinguishes    O
between    O
tension    O
headache    O
(    O
the    O
most    O
common    O
)    O
,    O
migraine    O
,    O
and    O
cluster    O
headache    O
.    O

5-IAI    B-Stimulation105827684
was    O
an    O
attempt    O
to    O
make    O
a    O
non    O
-    O
neurotoxic    O
analog    O
of    O
PIA    O
.    O

It    O
is    O
created    O
by    O
combining    O
norcocaine    B-Stimulation105827684
with    O
inactivated    O
cholera    O
toxin    O
.    O

RTI-229    B-Stimulation105827684

Dimethocaine/Larocaine    B-Stimulation105827684
(DMC)    I-Stimulation105827684
(    O
An    O
aniline    O
)    O

Dimethocaine    B-Stimulation105827684
(    O
Larocaine    B-Stimulation105827684
)    O
is    O
a    O
local    O
anesthetic    O
with    O
stimulant    O
properties    O
that    O
some    O
studies    O
have    O
shown    O
to    O
be    O
half    O
the    O
potency    O
of    O
cocaine    O
.    O

Xamoterol    B-Stimulation105827684

Xamoterol    B-Stimulation105827684
(    O
cardiac    B-Stimulation105827684
stimulant    I-Stimulation105827684
)    O

The    O
technical    O
chemistry    O
names    O
cathine    B-Stimulation105827684
and    O
cathinone    B-Stimulation105827684
are    O
20th    O
century    O
from    O
"    O
Catha    O
"    O
.    O

Examples    O
of    O
substituted    O
amphetamines    O
are    O
amphetamine    O
(    O
itself    O
)    O
,    O
methamphetamine    O
,    O
ephedrine    O
,    O
cathinone    B-Stimulation105827684
,    O
phentermine    B-Stimulation105827684
,    O
mephentermine    O
,    O
bupropion    O
,    O
methoxyphenamine    O
,    O
selegiline    O
,    O
amfepramone    O
,    O
pyrovalerone    B-Stimulation105827684
,    O
MDMA    O
(    O
ecstasy    O
)    O
,    O
and    O
DOM    O
(    O
STP    O
)    O
.    O

According    O
to    O
the    O
medico    O
legal    O
report    O
of    O
NBI    O
,    O
it    O
was    O
shown    O
that    O
Fontejon    O
had    O
two    O
types    O
of    O
dangerous    O
drugs    O
in    O
her    O
body    O
:    O
MDMA    O
methylene    O
homolog    O
and    O
synthetic    O
cathinone    B-Stimulation105827684
.    O

In    O
March    O
2010    O
,    O
the    O
ACMD    O
published    O
a    O
report    O
,    O
"    O
Consideration    O
of    O
the    O
cathinones    O
"    O
,    O
which    O
recommended    O
that    O
mephedrone    O
and    O
other    O
cathinone    B-Stimulation105827684
should    O
be    O
made    O
illegal    O
.    O

5-Methylethylone    O
(    O
5-methyl-βk    O
-    O
MDEA    O
,    O
5ME    O
)    O
is    O
an    O
empathogen    O
,    O
stimulant    O
and    O
psychedelic    O
drug    O
of    O
the    O
amphetamine    O
,    O
phenethylamine    O
,    O
and    O
cathinone    B-Stimulation105827684
chemical    O
classes    O
.    O

Some    O
authors    O
classify    O
as    O
pseudoalkaloids    O
such    O
compounds    O
such    O
as    O
ephedrine    O
and    O
cathinone    B-Stimulation105827684
.    O

Cocaine    O
,    O
caffeine    O
,    O
and    O
cathinone    B-Stimulation105827684
are    O
stimulants    O
of    O
the    O
central    O
nervous    O
system    O
.    O

Cathinone    B-Stimulation105827684

Etilefrine    B-Stimulation105827684
(    O
antihypotensive    B-Stimulation105827684
)    O

Metaraminol    B-Stimulation105827684
(    O
antihypotensive    B-Stimulation105827684
)    O

Midodrine    B-Stimulation105827684
(    O
antihypotensive    B-Stimulation105827684
)    O

Intubation    O
and    O
respiratory    O
support    O
may    O
be    O
required    O
in    O
severely    O
intoxicated    O
patients    O
;    O
patients    O
with    O
hypotension    O
require    O
treatment    O
with    O
intravenous    O
fluids    O
and    O
possibly    O
vasopressor    B-Stimulation105827684
.    O

Many    O
substituted    O
phenethylamines    O
are    O
psychoactive    O
drugs    O
which    O
belong    O
to    O
a    O
variety    O
of    O
different    O
drug    O
classes    O
,    O
including    O
central    O
nervous    O
system    O
stimulants    O
(    O
e.g.    O
,    O
amphetamine    O
)    O
,    O
hallucinogens    O
(    O
e.g.    O
,    O
dl-2,5-dimethoxy-4-methylamphetamine    O
DOM    O
)    O
,    O
entactogens    O
(    O
e.g.    O
,    O
3,4-methylenedioxyamphetamine    O
MDA    O
)    O
,    O
appetite    O
suppressants    O
(    O
e.g.    O
phentermine    B-Stimulation105827684
)    O
,    O
nasal    O
decongestants    O
and    O
bronchodilators    O
(    O
e.g.    O
,    O
levomethamphetamine    B-Stimulation105827684
and    O
pseudoephedrine    O
)    O
,    O
antidepressants    O
(    O
e.g.    O
bupropion    O
and    O
phenelzine    O
)    O
,    O
antiparkinson    O
agents    O
(    O
e.g.    O
,    O
selegiline    O
)    O
,    O
and    O
vasopressor    B-Stimulation105827684
(    O
e.g.    O
,    O
ephedrine    O
)    O
,    O
among    O
others    O
.    O

In    O
cats    O
pretreated    O
with    O
atropine    O
and    O
hexamethonium    O
,    O
DMDA    O
is    O
a    O
strong    O
vasopressor    B-Stimulation105827684
:    O
a    O
parenteral    O
dose    O
of    O
10    O
μg    O
/    O
kg    O
produced    O
a    O
rise    O
in    O
blood    O
pressure    O
more    O
than    O
twice    O
that    O
produced    O
by    O
the    O
same    O
dose    O
of    O
dopamine    O
.    O

In    O
1894    O
,    O
English    O
physiologists    O
George    O
Oliver    O
and    O
Edward    O
Schafer    O
studied    O
the    O
action    O
of    O
adrenal    O
extracts    O
and    O
observed    O
their    O
pressor    B-Stimulation105827684
effects    O
.    O

Azapride    O
is    O
the    O
azide    O
derivative    O
of    O
the    O
dopamine    O
antagonist    O
clebopride    B-Stimulation105827684
synthesized    O
in    O
order    O
to    O
label    O
dopamine    O
receptors    O
.    O

Pseudophenmetrazine    B-Stimulation105827684

With    O
single    O
-    O
photon    O
emission    O
computed    O
tomography    O
(    O
SPECT    O
)    O
using    O
the    O
radioisotope    O
iodine-123    O
there    O
are    O
further    O
radioligands    O
available    O
:    O
[    O
123I]ODAM    O
,    O
[    O
123I]IDAM    O
,    O
[    O
123I]ADAM    O
,    O
and    O
[    O
β-CIT    B-Stimulation105827684
.    O

AEME    O
is    O
also    O
used    O
in    O
scientific    O
research    O
for    O
the    O
manufacture    O
of    O
phenyltropane    B-Stimulation105827684
analogues    O
such    O
as    O
troparil    B-Stimulation105827684
,    O
dichloropane    B-Stimulation105827684
,    O
iometopane    B-Stimulation105827684
,    O
and    O
CFT    O
.    O

Retinal    B-Stimulation105827684
migraine    I-Stimulation105827684

On    O
January    O
31    O
,    O
2006    O
,    O
Jason    O
Sears    O
died    O
due    O
to    O
complications    O
while    O
undergoing    O
a    O
detox    O
treatment    O
involving    O
ibogaine    B-Stimulation105827684
in    O
Tijuana    O
,    O
Mexico    O
.    O

Ibogaine    B-Stimulation105827684

He    O
underwent    O
a    O
treatment    O
using    O
ibogaine    B-Stimulation105827684
,    O
a    O
potent    O
hallucinogenic    O
drug    O
.    O

Western    O
gorillas    O
inhabiting    O
Gabon    O
have    O
been    O
observed    O
consuming    O
the    O
fruit    O
,    O
stems    O
,    O
and    O
roots    O
of    O
Tabernanthe    O
iboga    O
,    O
which    O
,    O
due    O
to    O
the    O
compound    O
ibogaine    B-Stimulation105827684
in    O
it    O
,    O
acts    O
on    O
the    O
central    O
nervous    O
system    O
,    O
producing    O
hallucinogenic    O
effects    O
.    O

Ibogaine    B-Stimulation105827684

In    O
November    O
2014    O
,    O
a    O
naturopath    O
who    O
treated    O
clients    O
with    O
ibogaine    B-Stimulation105827684
,    O
which    O
resulted    O
in    O
one    O
client    O
's    O
death    O
and    O
another    O
client    O
's    O
blindness    O
,    O
was    O
sentenced    O
to    O
141    O
days    O
imprisonment    O
.    O

Emery    O
and    O
his    O
staff    O
offered    O
free    O
ibogaine    O
therapy    O
to    O
volunteer    O
heroin    O
and    O
cocaine    O
addicts    O
with    O
a    O
plant    O
-    O
based    O
alkaloid    O
called    O
ibogaine    B-Stimulation105827684
,    O
which    O
eliminates    O
withdrawal    O
symptoms    O
and    O
helps    O
produce    O
the    O
mental    O
change    O
needed    O
to    O
quit    O
using    O
.    O

"    O
Tabernaemontana    O
undulata    O
"    O
contains    O
iboga    B-Stimulation105827684
alkaloids    I-Stimulation105827684
,    O
naturally    O
occurring    O
psychoactive    O
compounds    O
.    O

Author    O
and    O
Rolling    O
Stone    O
journalist    O
Hunter    O
S.    O
Thompson    O
is    O
credited    O
for    O
starting    O
a    O
rumor    O
that    O
Muskie    O
was    O
addicted    O
to    O
a    O
drug    O
called    O
Ibogaine    B-Stimulation105827684
,    O
which    O
dealt    O
a    O
surprising    O
amount    O
of    O
damage    O
to    O
Muskie    O
's    O
reputation    O
.    O

When    O
it    O
looks    O
like    O
Brody    O
's    O
heroin    O
withdrawals    O
will    O
take    O
too    O
long    O
,    O
Dar    O
Adal    O
endorses    O
the    O
use    O
of    O
ibogaine    B-Stimulation105827684
,    O
a    O
drug    O
which    O
speeds    O
up    O
the    O
withdrawal    O
process    O
but    O
also    O
induces    O
severe    O
,    O
violent    O
hallucinations    O
;    O
Adal    O
implies    O
that    O
he    O
's    O
used    O
the    O
drug    O
for    O
that    O
purpose    O
.    O

Substances    O
with    O
dissociative    O
properties    O
include    O
ketamine    O
,    O
nitrous    O
oxide    O
,    O
alcohol    O
,    O
tiletamine    O
,    O
amphetamine    O
,    O
dextromethorphan    O
,    O
MK-801    O
,    O
PCP    O
,    O
methoxetamine    O
,    O
salvia    O
,    O
muscimol    O
,    O
atropine    O
,    O
and    O
ibogaine    B-Stimulation105827684
.    O

Mescaline    O
and    O
many    O
of    O
indole    O
alkaloids    O
(    O
such    O
as    O
psilocybin    O
,    O
dimethyltryptamine    O
and    O
ibogaine    B-Stimulation105827684
)    O
have    O
hallucinogenic    O
effect    O
.    O
Morphine    O
and    O
codeine    O
are    O
strong    O
narcotic    O
pain    O
killers    O
.    O

It    O
is    O
the    O
precursor    O
to    O
variegatic    O
acid    O
,    O
and    O
is    O
preceded    O
by    O
atromentic    O
acid    O
and    O
atromentin    B-Stimulation105827684
..    O
As    O
an    O
example    O
,    O
it    O
is    O
isolated    O
from    O
"    O
Serpula    O
lacrymans    O
"    O
.    O

It    O
is    O
the    O
precusor    O
to    O
variegatic    O
acid    O
and    O
xerocomic    O
acid    O
,    O
and    O
is    O
preceded    O
by    O
atromentin    B-Stimulation105827684
.    O

This    O
dark    O
red    O
pigment    O
,    O
a    O
derivative    O
of    O
the    O
compound    O
atromentin    B-Stimulation105827684
,    O
has    O
subsequently    O
been    O
identified    O
in    O
other    O
species    O
of    O
"    O
Hydnellum    O
"    O
.    O

SCH-5472    B-Stimulation105827684

O-2172    B-Stimulation105827684
is    O
a    O
drug    O
developed    O
by    O
Organix    O
Inc    O
,    O
which    O
acts    O
as    O
a    O
stimulant    O
and    O
potent    O
dopamine    O
reuptake    O
inhibitor    O
.    O

GTS-21    B-Stimulation105827684
(    O
DMBX-A    B-Stimulation105827684
)    O
is    O
a    O
derivative    O
of    O
the    O
natural    O
product    O
anabaseine    O
that    O
acts    O
as    O
a    O
partial    O
agonist    O
at    O
neural    O
nicotinic    O
acetylcholine    O
receptors    O
.    O

Benzoylthiomethylecgonine    B-Stimulation105827684

Aminoindane    B-Stimulation105827684

It    O
is    O
a    O
derivative    O
of    O
2-aminoindane    B-Stimulation105827684
.    O

4'-Methoxy-α-pyrrolidinopropiophenone    B-Stimulation105827684
(    O
MOPPP    O
)    O

CACNA1A    O
:    O
Calcium    O
channel    O
,    O
voltage    O
-    O
dependent    O
,    O
P    O
/    O
Q    O
type    O
,    O
alpha    O
1A    O
subunit    O
(    O
Familial    B-Stimulation105827684
hemiplegic    I-Stimulation105827684
migraine    I-Stimulation105827684
Type    O
I    O
)    O
.    O

Familial    B-Stimulation105827684
hemiplegic    I-Stimulation105827684
migraine    I-Stimulation105827684

One    O
of    O
these    O
is    O
known    O
as    O
familial    B-Stimulation105827684
hemiplegic    I-Stimulation105827684
migraine    I-Stimulation105827684
,    O
a    O
type    O
of    O
migraine    O
with    O
aura    O
,    O
which    O
is    O
inherited    O
in    O
an    O
autosomal    O
dominant    O
fashion    O
.    O

Ictal    B-Stimulation105827684
headache    I-Stimulation105827684

When    O
Merlot    O
has    O
spent    O
significant    O
time    O
in    O
oak    O
,    O
the    O
wine    O
may    O
show    O
notes    O
of    O
caramel    O
,    O
chocolate    O
,    O
coconut    O
,    O
coffee    O
bean    O
,    O
dill    O
weed    O
,    O
mocha    B-Stimulation105827684
,    O
molasses    O
,    O
smoke    O
,    O
vanilla    O
and    O
walnut    O
.    O

In    O
2008–2009    O
it    O
was    O
expanded    O
once    O
more    O
to    O
lattes    O
,    O
cappuccinos    O
and    O
mochas    B-Stimulation105827684
in    O
the    O
North    O
American    O
market    O
.    O

Cafe    B-Stimulation105827684
mocha    I-Stimulation105827684
–    O

Caffè    B-Stimulation105827684
mocha    I-Stimulation105827684

These    O
were    O
Caramelatte    O
(    O
a    O
vanilla    O
-    O
flavoured    O
latte    O
served    O
with    O
whipped    O
cream    O
and    O
caramel    O
sauce    O
topping    O
)    O
,    O
and    O
the    O
White    O
Chocolate    O
Mocha    O
(    O
a    O
twist    O
on    O
the    O
classic    O
caffè    B-Stimulation105827684
mocha    I-Stimulation105827684
)    O
.    O

After    O
a    O
month    O
of    O
handing    O
out    O
free    O
samples    O
to    O
friends    O
and    O
family    O
,    O
the    O
duo    O
began    O
serving    O
up    O
mochas    B-Stimulation105827684
and    O
lattes    O
at    O
a    O
pushcart    O
set    O
up    O
in    O
downtown    O
Grants    O
Pass    O
.    O

The    O
title    O
refers    O
to    O
the    O
Sue    O
Townsend    O
novel    O
"    O
Adrian    O
Mole    O
:    O
The    O
Cappuccino    O
Years    O
"    O
,    O
as    O
well    O
as    O
the    O
orange    O
mocha    B-Stimulation105827684
frappuccino    O
drink    O
ordered    O
by    O
three    O
male    O
models    O
in    O
the    O
film    O
"    O
Zoolander    O
"    O
.    O

Symptoms    O
typically    O
appear    O
gradually    O
over    O
5    O
to    O
20    O
minutes    O
and    O
generally    O
last    O
fewer    O
than    O
60    O
minutes    O
,    O
leading    O
to    O
the    O
headache    O
in    O
classic    O
migraine    O
with    O
aura    O
,    O
or    O
resolving    O
without    O
consequence    O
in    O
acephalgic    B-Stimulation105827684
migraine    I-Stimulation105827684
.    O

Methylvanillylecgonine    B-Stimulation105827684

GBR-13098    B-Stimulation105827684

Dimetofrine    B-Stimulation105827684
(    O
or    O
dimethophrine    B-Stimulation105827684
)    O
is    O
a    O
cardiac    B-Stimulation105827684
stimulant    I-Stimulation105827684
.    O

Synephrine    B-Stimulation105827684
(    O
mild    O
vasoconstrictor    O
)    O

The    O
ad    O
had    O
been    O
rejected    O
due    O
to    O
the    O
company    O
's    O
inclusion    O
on    O
a    O
list    O
of    O
"    O
prohibited    O
companies    O
"    O
issued    O
by    O
the    O
NFL    O
Players    O
Association    O
;    O
a    O
small    O
number    O
of    O
GNC    O
's    O
products    O
contain    O
DHEA    O
and    O
Synephrine    B-Stimulation105827684
,    O
which    O
are    O
performance    O
-    O
enhancing    O
substances    O
banned    O
by    O
the    O
NFL    O
.    O

synephrine    B-Stimulation105827684

Synephrine    B-Stimulation105827684

Diphenyl-2-pyridylmethane    B-Stimulation105827684

Atypical    B-Stimulation105827684
trigeminal    I-Stimulation105827684
neuralgia    I-Stimulation105827684

Cypenamine    B-Stimulation105827684
(    O
INN    O
,    O
BAN    O
)    O
,    O
or    O
cypenamine    B-Stimulation105827684
hydrochloride    I-Stimulation105827684
(    O
USAN    O
)    O
,    O
also    O
known    O
as    O
2-phenylcyclopentylamine    B-Stimulation105827684
,    O
is    O
a    O
psychostimulant    O
drug    O
which    O
was    O
developed    O
by    O
a    O
group    O
at    O
the    O
William    O
S.    O
Merrell    O
Chemical    O
Company    O
in    O
the    O
1940s    O
.    O

AR-R17779    B-Stimulation105827684
is    O
a    O
drug    O
that    O
acts    O
as    O
a    O
potent    O
and    O
selective    O
full    O
agonist    O
for    O
the    O
α7    O
subtype    O
of    O
neural    O
nicotinic    O
acetylcholine    O
receptors    O
.    O

Basilar    O
artery    O
dissection    O
has    O
also    O
been    O
reported    O
in    O
connection    O
with    O
sexual    O
activity    O
,    O
though    O
most    O
coital    B-Stimulation105827684
cephalalgia    I-Stimulation105827684
is    O
benign    O
in    O
nature    O
.    O

Dhat    O
syndrome    O
might    O
be    O
related    O
to    O
other    O
post    O
-    O
orgasmic    O
diseases    O
,    O
such    O
as    O
post    O
-    O
coital    O
tristesse    O
(    O
PCT    O
)    O
,    O
postorgasmic    O
illness    O
syndrome    O
(    O
POIS    O
)    O
,    O
and    O
sexual    B-Stimulation105827684
headache    I-Stimulation105827684
.    O

Dimethyl-4β-(2-naphthyl)piperidine-3β-carboxylate    O
("'DMNPC    B-Stimulation105827684
)    O
is    O
a    O
piperidine    O
based    O
stimulant    O
drug    O
which    O
is    O
synthesised    O
from    O
arecoline    B-Stimulation105827684
.    O

The    O
total    O
synthesis    O
of    O
a    O
number    O
of    O
natural    O
alkaloids    O
–    O
pilocarpine    O
,    O
pilozinin    O
,    O
alkaloids    O
of    O
propane    O
series    O
(    O
tropine    O
,    O
cocaine    O
)    O
,    O
arecoline    B-Stimulation105827684
,    O
eserine    O
,    O
emetine    O
,    O
psyhotrine    O
,    O
emataliine    O
,    O
cinchonamine    O
,    O
tubocurarine    O
and    O
other    O
alkaloids    O
of    O
curare    O
(    O
magnolin    O
,    O
magnolamine    O
,    O
dauricine    O
)    O
.    O

The    O
major    O
psychoactive    O
ingredients    O
–    O
arecoline    B-Stimulation105827684
(    O
a    O
muscarinic    O
receptor    O
partial    O
agonist    O
)    O
and    O
arecaidine    O
(    O
a    O
GABA    O
reuptake    O
inhibitor    O
)    O
–    O
are    O
responsible    O
for    O
the    O
euphoric    O
effect    O
.    O

Cimarrón    O
,    O
a    O
Spanish    O
name    O
for    O
Mate    B-Stimulation105827684
,    O
a    O
South    O
American    O
ethnic    O
beverage    O

Some    O
popular    O
beverages    O
include    O
coffee    O
,    O
mate    B-Stimulation105827684
,    O
hibiscus    O
tea    O
,    O
horchata    O
,    O
chicha    O
,    O
atole    O
,    O
cacao    O
and    O
aguas    O
frescas    O
.    O

Later    O
,    O
between    O
1850    O
and    O
1950    O
,    O
it    O
grew    O
due    O
to    O
logging    O
and    O
agricultural    O
expansion    O
in    O
the    O
Paraná    O
State    O
(    O
first    O
Araucaria    O
logging    O
,    O
later    O
mate    B-Stimulation105827684
and    O
coffee    O
cultivation    O
and    O
in    O
the    O
1970s    O
wheat    O
,    O
corn    O
and    O
soybean    O
cultivation    O
)    O
.    O

The    O
traditions    O
of    O
wearing    O
wool    O
ponchos    O
,    O
roasting    O
meat    O
and    O
drinking    O
a    O
bitter    O
mate    O
tea    O
called    O
"    O
chimarrão    B-Stimulation105827684
"    O
,    O
encouraged    O
a    O
common    O
culture    O
that    O
led    O
people    O
to    O
form    O
groups    O
and    O
settle    O
.    O

Tea    O
and    O
coffee    O
began    O
to    O
replace    O
Mate    B-Stimulation105827684
,    O
Chilean    O
wine    O
became    O
popular    O
and    O
people    O
started    O
to    O
drink    O
chicha    O
de    O
uva    O
,    O
a    O
sweet    O
,    O
undistilled    O
wine    O
made    O
from    O
fermented    O
grapes    O
or    O
apples    O
.    O

"    O
El    O
mate    B-Stimulation105827684
"    O
(    O
Bolsilibros    O
Arca    O
,    O
1967    O
)    O
.    O

Mate    B-Stimulation105827684
(beverage)    I-Stimulation105827684

The    O
South    O
American    O
beverage    O
,    O
mate    B-Stimulation105827684
,    O
is    O
frequently    O
spelled    O
in    O
English    O
,    O
adding    O
an    O
accent    O
which    O
,    O
in    O
Spanish    O
,    O
changes    O
the    O
pronunciation    O
and    O
meaning    O
of    O
the    O
word    O
(    O
"    O
maté    O
"    O
meaning    O
'    O
I    O
killed    O
'    O
in    O
Spanish    O
)    O
.    O

Some    O
of    O
its    O
main    O
components    O
are    O
related    O
to    O
the    O
importance    O
of    O
rural    O
life    O
of    O
plain    O
,    O
horse    O
,    O
guitar    O
,    O
mate    B-Stimulation105827684
and    O
beef    O
,    O
as    O
well    O
as    O
the    O
values    O
of    O
solidarity    O
,    O
loyalty    O
,    O
hospitality    O
and    O
courage    O
.    O

A    O
traditional    O
drink    O
of    O
Argentina    O
is    O
an    O
infusion    O
called    O
mate    B-Stimulation105827684
(    O
in    O
Spanish    O
,    O
"    O
mate    O
"    O
,    O
with    O
the    O
accent    O
on    O
the    O
first    O
syllable    O
[    O
MAH    O
-    O
teh    O
]    O
)    O
.    O

Mate    B-Stimulation105827684
,    O
the    O
northeastern    O
region    O
's    O
best    O
-    O
known    O
contribution    O
to    O
Argentine    O
cuisine    O
.    O

Uruguayan    O
food    O
always    O
comes    O
with    O
fresh    O
bread    O
;    O
bizcochos    O
and    O
tortas    O
fritas    O
are    O
a    O
must    O
for    O
drinking    O
with    O
mate    B-Stimulation105827684
(    O
'    O
tomar    O
el    O
mate    O
'    O
)    O
.    O

Bizcochos    O
are    O
consumed    O
with    O
mate    B-Stimulation105827684
,    O
coffee    O
and    O
tea    O
,    O
they    O
are    O
the    O
more    O
common    O
pastry    O
of    O
Uruguay    O
,    O
and    O
commonly    O
sold    O
on    O
local    O
bakeries    O
.    O

Almost    O
ten    O
years    O
after    O
its    O
release    O
,    O
Hendler    O
said    O
in    O
an    O
interview    O
,    O
"    O
It    O
was    O
a    O
novelty    O
to    O
see    O
an    O
Uruguayan    O
movie    O
that    O
did    O
n't    O
submit    O
the    O
"    O
mate    B-Stimulation105827684
"    O
,    O
the    O
Palacio    O
Salvo    O
,    O
and    O
the    O
promenade    O
as    O
a    O
justification    O
for    O
being    O
,    O
was    O
a    O
story    O
of    O
some    O
neighborhood    O
guys    O
.    O
"    O

Because    O
it    O
affects    O
voltage    O
-    O
gated    O
ion    O
channels    O
,    O
it    O
is    O
contraindicated    O
in    O
people    O
with    O
long    O
QT    O
syndrome    O
and    O
in    O
people    O
taking    O
a    O
drug    O
that    O
might    O
prolong    O
QT    O
like    O
sultopride    O
,    O
disopyramide    O
,    O
cisapride    B-Stimulation105827684
,    O
domperidone    B-Stimulation105827684
,    O
rifampicin    O
or    O
ketoconazol    O
.    O

Other    O
key    O
research    O
Zahniser    O
was    O
involved    O
in    O
included    O
her    O
postdoctoral    O
research    O
in    O
the    O
lab    O
of    O
Perry    O
Molinoff    O
,    O
and    O
together    O
they    O
examined    O
how    O
the    O
nucleotide    O
guanine    O
could    O
influence    O
the    O
binding    O
of    O
dopamine    O
receptor    O
agonists    O
H    O
-    O
apomorphine    O
and    O
H-domperidone    B-Stimulation105827684
in    O
certain    O
brain    O
regions    O
.    O

Domperidone    B-Stimulation105827684
–    O
D2    O
and    O
D3    O
antagonist    O
;    O
does    O
not    O
cross    O
the    O
blood    O
-    O
brain    O
barrier    O

Active    O
substance    O
:    O
domperidone    B-Stimulation105827684
)    O

A    O
number    O
of    O
other    O
measures    O
have    O
slight    O
evidence    O
to    O
support    O
their    O
use    O
indomethacin    O
,    O
fluoxetine    O
,    O
dopamine    O
antagonists    O
,    O
metoclopramide    B-Stimulation105827684
,    O
domperidone    B-Stimulation105827684
,    O
monoamine    O
oxidase    O
inhibitors    O
with    O
tyramine    O
(    O
can    O
produce    O
severe    O
hypertension    O
)    O
,    O
oxilofrine    B-Stimulation105827684
,    O
potassium    O
chloride    O
,    O
and    O
yohimbine    O
.    O

The    O
D2    O
receptor    O
is    O
involved    O
in    O
the    O
regulation    O
of    O
prolactin    O
secretion    O
,    O
and    O
agonists    O
of    O
the    O
receptor    O
such    O
as    O
bromocriptine    O
and    O
cabergoline    O
decrease    O
prolactin    O
levels    O
while    O
antagonists    O
of    O
the    O
receptor    O
such    O
as    O
domperidone    B-Stimulation105827684
,    O
metoclopramide    B-Stimulation105827684
,    O
haloperidol    O
,    O
risperidone    O
,    O
and    O
sulpiride    O
increase    O
prolactin    O
levels    O
.    O

Indanorex    B-Stimulation105827684
(    O
Dietor    B-Stimulation105827684
)    O
is    O
a    O
stimulant    O
drug    O
which    O
was    O
developed    O
in    O
the    O
1970s    O
.    O

Methylenedioxypyrovalerone    O
:    O
Prolintane    B-Stimulation105827684
:    O
α-Pyrrolidinopropiophenone    O
:    O

It    O
is    O
closely    O
related    O
on    O
a    O
structural    O
level    O
to    O
a    O
number    O
of    O
other    O
stimulants    O
,    O
such    O
as    O
MDPV    O
and    O
prolintane    B-Stimulation105827684
(    O
Promotil    O
,    O
Katovit    O
)    O
.    O

Prolintane    B-Stimulation105827684
(    O
Promotil    O
,    O
Katovit    O
)    O

The    O
drugs    O
involved    O
range    O
from    O
the    O
traditional    O
,    O
kratom    O
,    O
to    O
ya    B-Stimulation105827684
ba    I-Stimulation105827684
,    O
opium    O
from    O
Myanmar    O
,    O
and    O
local    O
herbal    O
medicines    O
.    O

Ya    B-Stimulation105827684
ba    I-Stimulation105827684
,    O
amphetamines    O

In    O
addition    O
to    O
the    O
traditional    O
Golden    O
Triangle    O
export    O
of    O
opiates    O
,    O
production    O
has    O
diversified    O
to    O
methamphetamine    O
,    O
or    O
"    O
yaa    B-Stimulation105827684
baa    I-Stimulation105827684
"    O
,    O
which    O
is    O
cheaper    O
and    O
easier    O
to    O
manufacture    O
than    O
heroin    O
.    O

The    O
central    O
President    O
Rajib    O
Ahsan    O
of    O
Chhatra    O
Dal    O
and    O
5    O
associates    O
were    O
arrested    O
with    O
the    O
drug    O
Ya    B-Stimulation105827684
Ba    I-Stimulation105827684
on    O
19    O
July    O
2015    O
in    O
Dumki    O
upazila    O
,    O
Patuakhali    O
.    O

Cafedrine    B-Stimulation105827684
(    O
INN    O
)    O
,    O
also    O
known    O
as    O
norephedrinoethyltheophylline    B-Stimulation105827684
,    O
is    O
a    O
chemical    O
linkage    O
of    O
norephedrine    O
and    O
theophylline    O
and    O
is    O
a    O
cardiac    B-Stimulation105827684
stimulant    I-Stimulation105827684
used    O
to    O
increase    O
blood    O
pressure    O
in    O
people    O
with    O
hypotension    O
.    O

mazindol    B-Stimulation105827684
(    O
INN    O
)    O

#    O
Mazindol    B-Stimulation105827684

mazindol    B-Stimulation105827684

fenethylline    B-Stimulation105827684

A    O
variety    O
of    O
prodrugs    O
of    O
amphetamine    O
and/or    O
methamphetamine    O
exist    O
,    O
and    O
include    O
amfecloral    O
,    O
amphetaminil    O
,    O
benzphetamine    O
,    O
clobenzorex    O
,    O
D    O
-    O
deprenyl    O
,    O
dimethylamphetamine    O
,    O
ethylamphetamine    O
,    O
fencamine    O
,    O
fenethylline    B-Stimulation105827684
,    O
fenproporex    B-Stimulation105827684
,    O
furfenorex    O
,    O
lisdexamfetamine    O
,    O
mefenorex    B-Stimulation105827684
,    O
mesocarb    B-Stimulation105827684
,    O
prenylamine    O
,    O
selegiline    O
,    O
and    O
tranylcypromine    O
.    O

In    O
2004    O
,    O
two    O
North    O
Korean    O
embassy    O
employees    O
were    O
caught    O
smuggling    O
150,000    O
tablets    O
of    O
Clonazepam    O
in    O
Egypt    O
,    O
and    O
in    O
that    O
same    O
year    O
,    O
embassy    O
employees    O
from    O
Bulgaria    O
were    O
arrested    O
in    O
Turkey    O
in    O
possession    O
of    O
over    O
500,000    O
tablets    O
of    O
Captagon    B-Stimulation105827684
(    O
the    O
brand    O
name    O
for    O
the    O
synthetic    O
stimulant    O
fenethylline    O
,    O
or    O
phenethylline    O
)    O
,    O
with    O
an    O
estimated    O
street    O
value    O
of    O
$    O
7    O
million    O
.    O

Mosapride    B-Stimulation105827684

The    O
benefit    O
of    O
the    O
prokinetic    O
mosapride    B-Stimulation105827684
is    O
modest    O
.    O

etamivan    B-Stimulation105827684
(    O
INN    O
)    O

The    O
Ukrainian    O
crew    O
was    O
disqualified    O
after    O
Olena    O
Olefirenko    O
tested    O
positive    O
for    O
ethamivan    B-Stimulation105827684
.    O

L-Norpseudoephedrine    B-Stimulation105827684
,    O
or    O
(−)-norpseudoephedrine    B-Stimulation105827684
,    O
is    O
a    O
psychostimulant    O
drug    O
of    O
the    O
amphetamine    O
family    O
.    O

dexmethylphenidate    B-Stimulation105827684
(    O
USAN    O
)    O

Focalin    B-Stimulation105827684

methylphenidate    O
and    O
its    O
isomers    O
(    O
dextromethylphenidate    B-Stimulation105827684
and    O
levomethylphenidate    O
)    O

Dexmethylphenidate    B-Stimulation105827684
(    O
Focalin    O
)    O
,    O
the    O
active    O
dextro    O
-    O
enantiomer    O
of    O
methylphenidate    O

Diphemethoxidine    B-Stimulation105827684

Mebeverine    B-Stimulation105827684
is    O
a    O
drug    O
used    O
to    O
alleviate    O
some    O
of    O
the    O
symptoms    O
of    O
irritable    O
bowel    O
syndrome    O
.    O

Tiny    O
cups    O
of    O
Turkish    B-Stimulation105827684
coffee    I-Stimulation105827684
,    O
sometimes    O
spiced    O
with    O
cardamom    O
,    O
are    O
often    O
served    O
at    O
the    O
end    O
of    O
a    O
festive    O
meal    O
,    O
accompanied    O
by    O
small    O
portions    O
of    O
baklava    O
or    O
other    O
pastries    O
dipped    O
in    O
syrup    O
or    O
honey    O
.    O

The    O
historic    O
Rabia    O
Kadın    O
Café    O
on    O
the    O
top    O
of    O
the    O
hill    O
,    O
at    O
which    O
he    O
used    O
to    O
drink    O
Turkish    B-Stimulation105827684
coffee    I-Stimulation105827684
,    O
was    O
later    O
renamed    O
also    O
after    O
him    O
.    O

Coffee    O
,    O
served    O
in    O
the    O
Turkish    B-Stimulation105827684
or    O
Arabic    B-Stimulation105827684
style    I-Stimulation105827684
,    O
is    O
the    O
traditional    O
beverage    O
.    O

Turkish    B-Stimulation105827684
coffee    I-Stimulation105827684

Turkish    B-Stimulation105827684
coffee    I-Stimulation105827684
beginning    O
to    O
boil    O
.    O

A    O
demitasse    O
(;    O
French    O
:    O
"    O
half    O
cup    O
"    O
)    O
is    O
a    O
small    O
cup    O
used    O
to    O
serve    O
Turkish    B-Stimulation105827684
coffee    I-Stimulation105827684
or    O
espresso    O
.    O

Turkish    B-Stimulation105827684
coffee    I-Stimulation105827684
is    O
popular    O
in    O
Turkey    O
,    O
the    O
Eastern    O
Mediterranean    O
,    O
and    O
southeastern    O
Europe    O
.    O

Another    O
popular    O
drink    O
is    O
Turkish    B-Stimulation105827684
Coffee    I-Stimulation105827684
which    O
is    O
drunk    O
in    O
small    O
cups    O
accompanied    O
by    O
a    O
glass    O
of    O
water    O
.    O

"    O
Coffee    B-Stimulation105827684
"    O
,    O
an    O
Iraq    O
national    O
drink    O
that    O
has    O
a    O
strong    O
and    O
bitter    O
taste    O
.    O

By    O
the    O
early    O
1650s    O
,    O
an    O
English    O
merchant    O
who    O
had    O
been    O
trading    O
in    O
the    O
Ottoman    O
Empire    O
returned    O
to    O
London    O
with    O
a    O
Turkish    O
servant    O
who    O
introduced    O
the    O
making    O
of    O
Turkish    B-Stimulation105827684
coffee    I-Stimulation105827684
,    O
and    O
by    O
1652    O
the    O
first    O
coffee    O
house    O
had    O
opened    O
in    O
London    O
;    O
within    O
a    O
decade    O
,    O
more    O
than    O
80    O
establishments    O
flourished    O
in    O
the    O
city    O
.    O

Almost    O
all    O
offer    O
Turkish    B-Stimulation105827684
coffee    I-Stimulation105827684
.    O


